1 hsa-mir-21 miR-21 miR-21 Acute myeloid Leukemia arabinosylcytosine (Ara-C) arabinosylcytosine (Ara-C) treatment leukemic HL60 cells Human A specific anti-miR-21 oligonucleotide (AMO-miR-21) to sensitize leukemic HL60 cells to arabinosylcytosine (Ara-C) by down-regulating miR-21.Expression of miR-21 was significantly decreased after AMO-miR-21 treatment.AMO-miR-21 significantly sensitizes HL 20670480 2 hsa-mir-212 miR-212 miR-212 Alcoholic liver disease alcohol alcohol treatment colon biopsy samples from patients with ALD and in Caco-2 cells (a human intestinal epithelial cell line) Human Ethanol increased miR-212 expression 18162065 3 hsa-mir-451 miR-451 miR-451 Glioblastoma Imatinib mesylate Imatinib mesylate treatment GBM cells Human miR-451 combined with Imatinib mesylate treatment had a cooperative effect in dispersal of GBM neurospheres;through up-regulation of miR-451 and reduces their tumorigenicity 18765229 4 hsa-mir-20a miR-20a miR-20a n/a ICI-182780 (Fulvestrant) ICI-182780 (Fulvestrant) treatment myometrium and leiomyoma smooth muscle cells Human ICI-182780 increased the expression of miR-20a and miR-21 in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 5 hsa-mir-21 miR-21 miR-21 n/a ICI-182780 (Fulvestrant) ICI-182780 (Fulvestrant) treatment myometrium and leiomyoma smooth muscle cells Human ICI-182780 increased the expression of miR-20a and miR-21 in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 6 hsa-mir-26a-1 miR-26a miR-26a n/a ICI-182780 (Fulvestrant) ICI-182780 (Fulvestrant) treatment myometrium and leiomyoma smooth muscle cells Human ICI-182780 increased the expression of miR-20a and miR-21 in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 7 hsa-mir-26a-2 miR-26a miR-26a n/a ICI-182780 (Fulvestrant) ICI-182780 (Fulvestrant) treatment myometrium and leiomyoma smooth muscle cells Human ICI-182780 increased the expression of miR-20a and miR-21 in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 8 hsa-mir-34a miR-34a miR-34a DNA-damage response UV irradiation UV irradiation exposure HeLa cells Human A direct p53 target, miR-34a, is upregulated. 19536137 9 hsa-mir-100 miR-100 miR-100 Prostate Cancer radical prostatectomy radical prostatectomy treatment frozen specimens from 49 patients Human A high level of miR-100 is related to biochemical recurrence of localized prostate cancer in patients treated with radical prostatectomy. 21255804 10 hsa-mir-101-1 miR-101 miR-101 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 11 hsa-mir-101-2 miR-101 miR-101 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 12 hsa-mir-122 miR-122a miR-122a Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 13 hsa-mir-141 miR-141 miR-141 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 14 hsa-mir-15b miR-15b miR-15b Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 15 hsa-mir-16-1 miR-16 miR-16 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 16 hsa-mir-16-2 miR-16 miR-16 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 17 hsa-mir-186 miR-186 miR-186 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 18 hsa-mir-197 miR-197 miR-197 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 19 hsa-mir-19a miR-19a miR-19a Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 20 hsa-mir-20a miR-20a miR-20a Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 21 hsa-mir-20b miR-20b miR-20b Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 22 hsa-mir-29b-1 miR-29b miR-29b Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 23 hsa-mir-29b-2 miR-29b miR-29b Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 24 hsa-mir-30b miR-30b miR-30b Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 25 hsa-mir-30e miR-30e-5p miR-30e-5p Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 26 hsa-mir-101-1 miR-101 miR-101 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 27 hsa-mir-101-2 miR-101 miR-101 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 28 hsa-mir-122 miR-122a miR-122a Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 29 hsa-mir-141 miR-141 miR-141 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 30 hsa-mir-15b miR-15b miR-15b Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 31 hsa-mir-16-1 miR-16 miR-16 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 32 hsa-mir-16-2 miR-16 miR-16 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 33 hsa-mir-186 miR-186 miR-186 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 34 hsa-mir-197 miR-197 miR-197 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 35 hsa-mir-19a miR-19a miR-19a Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 36 hsa-mir-20a miR-20a miR-20a Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 37 hsa-mir-20b miR-20b miR-20b Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 38 hsa-mir-29b-1 miR-29b miR-29b Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 39 hsa-mir-29b-2 miR-29b miR-29b Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 40 hsa-mir-30b miR-30b miR-30b Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 41 hsa-mir-30e miR-30e-5p miR-30e-5p Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human a set of microRNAs were identified as downregulated in hypoxic cells, including miR-15b, 16, 19a, 20a, 20b, 29b, 30b, 30e-5p, 101, 141, 122a, 186, 320 and 197. 18219318 42 hsa-mir-26a-1 miR-26a-1 miR-26a-1 Colorectal Cancer 5-fluorouracil and irinotecan (CPT-11) 5-fluorouracil and irinotecan (CPT-11) treatment metastatic colorectal cancer (mCRC) patients Human A significant association with tumor response and time to progression (TTP) was found for SNP rs7372209 in pri-miR26a-1 (P=0.041 and P=0.017, respectively). The genotypes CC and CT were favorable when compared with the TT variant genotype.miRNA polymorphi 20585341 43 hsa-mir-558 miR-558 miR-558 n/a X-ray 2 h post-irradiation following high doses of radiation human fibroblasts Human A transient up-regulation of miRNAs was observed after 2 h post-irradiation following high doses of radiation, including miR-558 and 662 18729083 44 hsa-mir-662 miR-662 miR-662 n/a X-ray 2 h post-irradiation following high doses of radiation human fibroblasts Human A transient up-regulation of miRNAs was observed after 2 h post-irradiation following high doses of radiation, including miR-558 and 662 18729083 45 hsa-mir-451 miR-451 miR-451 Cancer glucose glucose treatment cancer cell/glioblastoma patients Human Abundant glucose allows relatively high miR-451 expression, promoting cell growth. In low glucose, miR-451 levels decrease, slowing proliferation but enhancing migration and survival.In glioblastoma patients, elevated miR-451 is associated with shorter su 20227367 46 hsa-mir-122 miR-122a miR-122a n/a Vitamin E Vitamin E treatment n/a Human Alpha-tocopherol regulates signal transduction cascades not only at the mRNA but also at the miRNA level since miRNA 122a (involved in lipid metabolism) and miRNA 125b (involved in inflammation) are downregulated by alpha-tocopherol. 20336011 47 hsa-mir-15b miR-15b miR-15b n/a Vitamin E Vitamin E treatment n/a Human Alpha-tocopherol regulates signal transduction cascades not only at the mRNA but also at the miRNA level since miRNA 122a (involved in lipid metabolism) and miRNA 125b (involved in inflammation) are downregulated by alpha-tocopherol. 20336011 48 hsa-mir-1-1 miR-1 miR-1 Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human An acute bout of exercise increased mir-1 (P < 0.05) and mir-133a (P < 0.05) expression before, but not after, training.In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to it 20724368 49 hsa-mir-1-2 miR-1 miR-1 Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human An acute bout of exercise increased mir-1 (P < 0.05) and mir-133a (P < 0.05) expression before, but not after, training.In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to it 20724368 50 hsa-mir-133a-1 miR-133a miR-133a Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human An acute bout of exercise increased mir-1 (P < 0.05) and mir-133a (P < 0.05) expression before, but not after, training.In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to it 20724368 51 hsa-mir-133a-2 miR-133a miR-133a Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human An acute bout of exercise increased mir-1 (P < 0.05) and mir-133a (P < 0.05) expression before, but not after, training.In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to it 20724368 52 hsa-mir-21 miR-21 miR-21 Leukemia Arsenic trioxide (ATO) Arsenic trioxide (ATO) treatment K562 cells Human anti-miR-21 oligonucleotide (AMO-miR-21) significantly promoted ATO-mediated growth inhibition and apotosis without affecting the G1 phase.AMO-miR-21 sensitized leukemic K562 cells to ATO by inducing apoptosis partially due to its up-regulation of PDCD4 p 20148895 53 hsa-mir-221 miR-221 miR-221 Glioblastoma radiation radiation treatment U251 human glioblastoma cells Human Anti-miR-221/222 may enhance the radiosensitivity of U251 human glioblastoma through upregulation of p27(kip1). 19953484 54 hsa-mir-222 miR-222 miR-222 Glioblastoma radiation radiation treatment U251 human glioblastoma cells Human Anti-miR-221/222 may enhance the radiosensitivity of U251 human glioblastoma through upregulation of p27(kip1). 19953484 55 hsa-let-7f-1 let-7f let-7f Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 56 hsa-let-7f-2 let-7f let-7f Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 57 hsa-let-7g let-7g let-7g Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 58 hsa-mir-155 miR-155 miR-155 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 59 hsa-mir-181a miR-181a miR-181a Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 60 hsa-mir-221 miR-221 miR-221 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 61 hsa-mir-424 miR-424 miR-424 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 62 hsa-mir-451 miR-451 miR-451 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 63 hsa-mir-563 miR-563 miR-563 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 64 hsa-mir-98 miR-98 miR-98 Leukemia adriamycin adriamycin treatment K562 cell line and its adriamycin resistant cells-K562/A02 cell line Human As compared to K562 cells, expressions of miR-221, miR-155 and miR-451 were up-regulated by more than two fold, while expression of miR-98, miR-181a, let-7f, let-7g, miR-424 and miR-563 down-regulated by more than two fold in K562/A02 cells.miR-221, miR-1 21122348 65 hsa-mir-1-1 pri-miRNA-1-1 pri-miRNA-1-1 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human At baseline,pri-miRNA-1-1, -1-2, -133a-1, and -133a-2 expression elevated in older compared with young men. 18827171 66 hsa-mir-1-2 pri-miRNA-1-2 pri-miRNA-1-2 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human At baseline,pri-miRNA-1-1, -1-2, -133a-1, and -133a-2 expression elevated in older compared with young men.Pri-miRNA-1-2, -133a-1, and -133a-2 were reduced at 6 h after exercise only in the young men compared with baseline 18827171 67 hsa-mir-133a-1 pri-miRNA-133a-1 pri-miRNA-133a-1 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human At baseline,pri-miRNA-1-1, -1-2, -133a-1, and -133a-2 expression elevated in older compared with young men.Pri-miRNA-1-2, -133a-1, and -133a-2 were reduced at 6 h after exercise only in the young men compared with baseline 18827171 68 hsa-mir-133a-2 pri-miRNA-133a-2 pri-miRNA-133a-2 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human At baseline,pri-miRNA-1-1, -1-2, -133a-1, and -133a-2 expression elevated in older compared with young men.Pri-miRNA-1-2, -133a-1, and -133a-2 were reduced at 6 h after exercise only in the young men compared with baseline 18827171 69 hsa-mir-137 miR-137 miR-137 n/a X-ray low (0.1 Gy) and high (2.0 Gy) doses of X-ray human fibroblasts Human At early (0.5 h) and late (6 and 24 h) time points, irradiation caused qualitative and quantitative differences in the down-regulation of miRNA levels, including miR-92b, 137, 660, and 656. 18729083 70 hsa-mir-656 miR-656 miR-656 n/a X-ray low (0.1 Gy) and high (2.0 Gy) doses of X-ray human fibroblasts Human At early (0.5 h) and late (6 and 24 h) time points, irradiation caused qualitative and quantitative differences in the down-regulation of miRNA levels, including miR-92b, 137, 660, and 656. 18729083 71 hsa-mir-660 miR-660 miR-660 n/a X-ray low (0.1 Gy) and high (2.0 Gy) doses of X-ray human fibroblasts Human At early (0.5 h) and late (6 and 24 h) time points, irradiation caused qualitative and quantitative differences in the down-regulation of miRNA levels, including miR-92b, 137, 660, and 656. 18729083 72 hsa-mir-92b miR-92b miR-92b n/a X-ray low (0.1 Gy) and high (2.0 Gy) doses of X-ray human fibroblasts Human At early (0.5 h) and late (6 and 24 h) time points, irradiation caused qualitative and quantitative differences in the down-regulation of miRNA levels, including miR-92b, 137, 660, and 656. 18729083 73 hsa-let-7a-3 let-7a-3 let-7a-3 Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 74 hsa-let-7c let-7c let-7c Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 75 hsa-let-7d let-7d let-7d Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 76 hsa-mir-107 miR-107 miR-107 Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 77 hsa-mir-15a miR-15a miR-15a Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 78 hsa-mir-15b miR-15b miR-15b Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 79 hsa-mir-16-1 miR-16-1 miR-16-1 Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 80 hsa-mir-181b-1 miR-181b miR-181b Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 81 hsa-mir-181b-2 miR-181b miR-181b Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 82 hsa-mir-223 miR-223 miR-223 Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 83 hsa-mir-342 miR-342 miR-342 Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment Human ATRA causes upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated 17260024 84 hsa-mir-155 miR-155 miR-155 Pancreatic Cancer gemcitabine gemcitabine treatment human pancreatic cancer PANC-1 cells Human B-cell integration cluster (BIC) RNA RNA is strongly induced by anti-cancer drugs in PANC-1 cells and the levels of miR-155 also slightly increase. 20356498 85 hsa-mir-29a miR-29a miR-29 Hepatocellular carcinoma serum starvation and hypoxia or chemotherapeutic drugs serum starvation and hypoxia or chemotherapeutic drugs treatment HCC cells Human Both gain- and loss-of-function studies revealed that miR-29 could sensitize HCC cells to apoptosis that was triggered by either serum starvation and hypoxia or chemotherapeutic drugs, which mimicked the tumor growth environment in vivo and the clinical t 20041405 86 hsa-let-7i let-7i let-7i Breast Cancer cis-platinum cis-platinum treatment breast cancer cells Human Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of breast cancer cells to the chemotherapy drug, cis-p 19074899 87 hsa-mir-21 miR-21 miR-21 Pancreatic Cancer curcumin curcumin treatment pancreatic cancer (PC) cell lines Human CDF treatment upregulated miR-200 expression and downregulated the expression of miR-21, and the downregulation of miR-21 resulted in the induction of PTEN. These results prompt further interest in CDF as a drug modality to improve treatment outcome of pa 20388782 88 hsa-let-7d let-7d let-7d Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 89 hsa-mir-124-1 miR-124 miR-124 Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 90 hsa-mir-124-2 miR-124 miR-124 Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 91 hsa-mir-124-3 miR-124 miR-124 Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 92 hsa-mir-181a-1 miR-181a miR-181a Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 93 hsa-mir-181a-2 miR-181a miR-181a Cocaine addiction cocaine chronic cocaine n/a Human chronic cocaine suppresses miR-124 and let-7d and induces the expression of miR-181a in mesolimbic pathway. 21307844 94 hsa-mir-29b-1 miR-29b miR-29b synthesis and deposition of extracellular matrix (ECM) Chronic oxidative stress incubation at 40% oxygen for 4-5 days, using cultures incubated at 5% oxygen as controls. human trabecular meshwork cells Human Chronic oxidative stress induced a significant downregulation of miR-29b in two HTM cell lines that was associated with increased expression of several ECM genes known to be regulated by miR-29b. 19956414 95 hsa-mir-29b-2 miR-29b miR-29b synthesis and deposition of extracellular matrix (ECM) Chronic oxidative stress incubation at 40% oxygen for 4-5 days, using cultures incubated at 5% oxygen as controls. human trabecular meshwork cells Human Chronic oxidative stress induced a significant downregulation of miR-29b in two HTM cell lines that was associated with increased expression of several ECM genes known to be regulated by miR-29b. 19956414 96 hsa-mir-31 miR-31 miR-31 Lung Cancer tobacco cigarette smoke normal respiratory epithelia and lung cancer cells Human cigarette smoke condensate (CSC)significantly increased miR-31 expression and activated LOC554202 in normal respiratory epithelia and lung cancer cells 21048943 97 hsa-mir-24-1 miR-24 miR-24 Potential contribution to the pathogenesis of glaucoma Cyclic mechanical stress (CMS) Cyclic mechanical stress (CMS) treatment human trabecular meshwork (TM) cell Human CMS induced the expression of miR-24 that led to the down regulation of the subtilisin-like proprotein convertase FURIN, which is known to play a major role in the processing of TGFbeta1. Overexpression of miR-24 resulted in a significant decrease in acti 20945401 98 hsa-mir-24-2 miR-24 miR-24 Potential contribution to the pathogenesis of glaucoma Cyclic mechanical stress (CMS) Cyclic mechanical stress (CMS) treatment human trabecular meshwork (TM) cell Human CMS induced the expression of miR-24 that led to the down regulation of the subtilisin-like proprotein convertase FURIN, which is known to play a major role in the processing of TGFbeta1. Overexpression of miR-24 resulted in a significant decrease in acti 20945401 99 hsa-mir-15a miR-15a miR-15a Leukemia Arsenic trioxide (As(2)O(3), ATO) Arsenic trioxide (As(2)O(3), ATO) treatment Bcr-Abl positive leukemic K562 cells Human Combination of miR-15a/16-1 and ATO synergistically induced growth inhibition and apoptosis in K562 cells.Moreover, apoptotic synergy between miR-15a/16-1 and ATO was observed in Bcr-Abl negative leukemic cell lines and primary leukemic cells. 21056550 100 hsa-mir-16-1 miR-16-1 miR-16-1 Leukemia Arsenic trioxide (As(2)O(3), ATO) Arsenic trioxide (As(2)O(3), ATO) treatment Bcr-Abl positive leukemic K562 cells Human Combination of miR-15a/16-1 and ATO synergistically induced growth inhibition and apoptosis in K562 cells.Moreover, apoptotic synergy between miR-15a/16-1 and ATO was observed in Bcr-Abl negative leukemic cell lines and primary leukemic cells. 21056550 101 hsa-mir-1-1 miR-1 miR-1 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human Compared with baseline, miR-1 was reduced only in the young men 18827171 102 hsa-mir-1-2 miR-1 miR-1 Sarcopenia anabolic stimulus resistance exercise + ingestion of a 20-g leucine-enriched essential amino acid solution skeletal muscle of young and older men Human Compared with baseline, miR-1 was reduced only in the young men 18827171 103 hsa-mir-106b miR-106b miR-106b Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 104 hsa-mir-126 miR-126 miR-126 Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 105 hsa-mir-128-1 miR-128b miR-128b Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 106 hsa-mir-128-2 miR-128b miR-128b Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 107 hsa-mir-130a miR-130a miR-130a Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 108 hsa-mir-15b miR-15b miR-15b Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 109 hsa-mir-17 miR-17-5p miR-17-5p Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 110 hsa-mir-21 miR-21 miR-21 Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 111 hsa-mir-22 miR-22 miR-22 Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 112 hsa-mir-451 miR-451 miR-451 Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 113 hsa-mir-495 miR-495 miR-495 Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 114 hsa-let-7a-1 let-7a let-7a Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 115 hsa-let-7a-2 let-7a let-7a Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 116 hsa-let-7a-3 let-7a let-7a Lung Cancer irradiation irradiation treatment SK-MES-1 cells induced by irradiation Human Comparing with resistant patients, five miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and miRNA-128b) were significantly upregulated and seven miRNAs (miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, miRNA-17-5p and miRNA-21) were greatly d 20728239 117 hsa-mir-20a miR-20a miR-20a n/a MPA+RU-486 MPA+RU-486 treatment myometrium and leiomyoma smooth muscle cells Human Co-treatment with MPA+RU-486 resulted in a similar effect as seen with MPA-treated cells with the exception of miR-20a expression that was reduced as compared to other treatments 18182067 118 hsa-mir-146a miR-146a miR-146 islet dysfunction glucose Human islets were cultured for 24 hours in the presence of low (5.6 mM) or high glucose (20 mM).Islets were also exposed to sodium palmitate or the proinflammatory cytokines IL-1beta and IFN-gamma, since saturated free fatty acids and cytokines also cause Human islets Human Culture in high glucose resulted in increased islet contents of miR-133a and reduced contents of miR-146. 20520763 119 hsa-mir-146b miR-146b miR-146 islet dysfunction glucose Human islets were cultured for 24 hours in the presence of low (5.6 mM) or high glucose (20 mM).Islets were also exposed to sodium palmitate or the proinflammatory cytokines IL-1beta and IFN-gamma, since saturated free fatty acids and cytokines also cause Human islets Human Culture in high glucose resulted in increased islet contents of miR-133a and reduced contents of miR-146. 20520763 120 hsa-mir-133a-1 miR-133a miR-133a islet dysfunction glucose Human islets were cultured for 24 hours in the presence of low (5.6 mM) or high glucose (20 mM).Islets were also exposed to sodium palmitate or the proinflammatory cytokines IL-1beta and IFN-gamma, since saturated free fatty acids and cytokines also cause Human islets Human Culture in high glucose resulted in increased islet contents of miR-133a and reduced contents of miR-146. 20520763 121 hsa-mir-133a-2 miR-133a miR-133a islet dysfunction glucose Human islets were cultured for 24 hours in the presence of low (5.6 mM) or high glucose (20 mM).Islets were also exposed to sodium palmitate or the proinflammatory cytokines IL-1beta and IFN-gamma, since saturated free fatty acids and cytokines also cause Human islets Human Culture in high glucose resulted in increased islet contents of miR-133a and reduced contents of miR-146. 20520763 122 hsa-mir-186 miR-186* miR-186* Lung Cancer curcumin curcumin treatment human lung adenocarcinoma cells Human Curcumin had anti-cancer effects on A549/DDP multidrug-resistant human lung adenocarcinoma cells.Further studies showed that curcumin altered miRNA expression; in particular, significantly downregulated the expression of miR-186 * in A549/DDP. In addition 20627087 123 hsa-mir-140 miR-140* miR-140* Inflammatory responses of airway smooth muscle (ASM) proinflammatory stimulus airway smooth muscle (ASM) cells exposed to IL-1beta, TNF-alpha, and IFN-gamma airway smooth muscle Human decreased expression 19541842 124 hsa-mir-188 miR-188 miR-188 Inflammatory responses of airway smooth muscle (ASM) proinflammatory stimulus airway smooth muscle (ASM) cells exposed to IL-1beta, TNF-alpha, and IFN-gamma airway smooth muscle Human decreased expression 19541842 125 hsa-mir-138-1 miR-138 miR-138 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 126 hsa-mir-138-2 miR-138 miR-138 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 127 hsa-mir-196b miR-196b miR-196b Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 128 hsa-mir-7-1 miR-7 miR-7 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 129 hsa-mir-7-2 miR-7 miR-7 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 130 hsa-mir-7-3 miR-7 miR-7 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human decreased expression 20352393 131 hsa-let-7a-1 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 132 hsa-let-7a-2 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 133 hsa-let-7a-3 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 134 hsa-let-7b let-7b let-7b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 135 hsa-mir-100 miR-100 miR-100 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 136 hsa-mir-125b-1 miR-125b miR-125b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 137 hsa-mir-125b-2 miR-125b miR-125b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 138 hsa-mir-15b miR-15b miR-15b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 139 hsa-mir-222 miR-222 miR-222 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 140 hsa-mir-21 miR-21 miR-21 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 141 hsa-mir-24-1 miR-24 miR-24 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 142 hsa-mir-24-2 miR-24 miR-24 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 143 hsa-mir-638 miR-638 miR-638 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 144 hsa-let-7a-1 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 145 hsa-let-7a-2 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 146 hsa-let-7a-3 let-7a let-7a Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 147 hsa-let-7b let-7b let-7b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 148 hsa-mir-100 miR-100 miR-100 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 149 hsa-mir-125b-1 miR-125b miR-125b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 150 hsa-mir-125b-2 miR-125b miR-125b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 151 hsa-mir-222 miR-222 miR-222 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 152 hsa-mir-24-1 miR-24 miR-24 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 153 hsa-mir-24-2 miR-24 miR-24 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 154 hsa-mir-638 miR-638 miR-638 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Decreased expression 19633716 155 hsa-mir-185 miR-185 miR-185 Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Decreased expression 19237188 156 hsa-mir-331 miR-331 miR-331 Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Decreased expression 19237188 157 hsa-mir-518c miR-518c miR-518c Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human Decreased expression 19237188 158 hsa-mir-132 miR-132 miR-132 Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Decreased expression 19237188 159 hsa-mir-330 miR-330 miR-330 Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Decreased expression 19237188 160 hsa-mir-339 miR-339 miR-339 Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Decreased expression 19237188 161 hsa-mir-29c miR-29c miR-29c Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Decreased expression 19237188 162 hsa-mir-142 miR-142-5p miR-142-5p Ovarian Cancer (OVCA) topotecan topotecan treatment OVCA cell lines Human Decreased expression 19237188 163 hsa-mir-25 miR-25 miR-25 Inflammatory responses of airway smooth muscle (ASM) proinflammatory stimulus airway smooth muscle (ASM) cells exposed to IL-1beta, TNF-alpha, and IFN-gamma airway smooth muscle Human decreased expression;miR-25 has a broad role in regulating ASM phenotype by modulating expression of inflammatory mediators such as RANTES, eotaxin, and TNF-alpha; genes involved in extracellular matrix turnover; and contractile proteins, most notably myo 19541842 164 hsa-mir-182 miR-182 miR-182 Cancer susceptibility serum starvation serum starvation treatment breast epithelial cell line MCF12F Human deregulated 20564226 165 hsa-let-7g let-7g let-7g Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 166 hsa-mir-126 miR-126 miR-126 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 167 hsa-mir-196a-1 miR-196a miR-196a Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 168 hsa-mir-196a-2 miR-196a miR-196a Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 169 hsa-mir-200a miR-200a miR-200a Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 170 hsa-mir-200b miR-200b miR-200b Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 171 hsa-mir-200c miR-200c miR-200c Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 172 hsa-mir-31 miR-31 miR-31 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 173 hsa-mir-7-1 miR-7 miR-7 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 174 hsa-mir-7-2 miR-7 miR-7 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 175 hsa-mir-7-3 miR-7 miR-7 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 176 hsa-mir-98 miR-98 miR-98 Gastric Cancer hydroxycamptothecin (HCPT) hydroxycamptothecin (HCPT) treatment gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). Human deregulated 21293479 177 hsa-mir-22 miR-22 miR-22 Hepatic degenerative lesions Arsenic sodium arsenite exposure lymphoblastoid cells Human deregulated 17108120 178 hsa-mir-221 miR-221 miR-221 Hepatic degenerative lesions Arsenic sodium arsenite exposure lymphoblastoid cells Human deregulated 17108120 179 hsa-mir-222 miR-222 miR-222 Hepatic degenerative lesions Arsenic sodium arsenite exposure lymphoblastoid cells Human deregulated 17108120 180 hsa-mir-34a miR-34a miR-34a Hepatic degenerative lesions Arsenic sodium arsenite exposure lymphoblastoid cells Human deregulated 17108120 181 hsa-mir-100 hsa-miR-100 hsa-miR-100 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 182 hsa-mir-126 hsa-miR-126* hsa-miR-126* Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 183 hsa-mir-134 hsa-miR-134 hsa-miR-134 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 184 hsa-mir-141 hsa-miR-141 hsa-miR-141 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 185 hsa-mir-183 hsa-miR-183 hsa-miR-183 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 186 hsa-mir-191 hsa-miR-191 hsa-miR-191 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 187 hsa-mir-196b hsa-miR-196b hsa-miR-196b Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 188 hsa-mir-199a-1 hsa-miR-199a hsa-miR-199a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 189 hsa-mir-199a-2 hsa-miR-199a hsa-miR-199a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 190 hsa-mir-224 hsa-miR-224 hsa-miR-224 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 191 hsa-mir-23a hsa-miR-23a hsa-miR-23a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 192 hsa-mir-26a-1 hsa-miR-26a hsa-miR-26a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 193 hsa-mir-26a-2 hsa-miR-26a hsa-miR-26a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 194 hsa-mir-29a hsa-miR-29a hsa-miR-29a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 195 hsa-mir-29c hsa-miR-29c hsa-miR-29c Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 196 hsa-mir-30b hsa-miR-30b hsa-miR-30b Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 197 hsa-mir-30c-1 hsa-miR-30c hsa-miR-30c Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 198 hsa-mir-30c-2 hsa-miR-30c hsa-miR-30c Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 199 hsa-mir-326 hsa-miR-326 hsa-miR-326 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 200 hsa-mir-422b hsa-miR-422b hsa-miR-422b Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 201 hsa-mir-520a hsa-miR-520a hsa-miR-520a Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 202 hsa-mir-7-1 hsa-miR-7 hsa-miR-7 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 203 hsa-mir-7-2 hsa-miR-7 hsa-miR-7 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 204 hsa-mir-7-3 hsa-miR-7 hsa-miR-7 Chronic Myeloid Leukemia (CML) Imatinib Imatinib treatment bone marrow mononuclear cells from CML patients Human deregulated in drug-resistant samples 19723306 205 hsa-mir-30e miR-30e miR-30e n/a dexamethasone dexamethasone treatment intestinal crypt IEC-6 cells Human Dexamethasone-induced IEC-6 cells differentiation caused a 2.5-fold increase in miR-30e expression 20372961 206 hsa-mir-181a-1 miR-181a miR-181a Chronic lymphocytic Leukemia (CLL) fludarabine fludarabine treatment CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine. Human Differential expression of the miR-29a, -181a, and -221 was observed between fludarabine resistant and fludarabine sensitive patients before treatment. 20487546 207 hsa-mir-181a-2 miR-181a miR-181a Chronic lymphocytic Leukemia (CLL) fludarabine fludarabine treatment CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine. Human Differential expression of the miR-29a, -181a, and -221 was observed between fludarabine resistant and fludarabine sensitive patients before treatment. 20487546 208 hsa-mir-221 miR-221 miR-221 Chronic lymphocytic Leukemia (CLL) fludarabine fludarabine treatment CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine. Human Differential expression of the miR-29a, -181a, and -221 was observed between fludarabine resistant and fludarabine sensitive patients before treatment. 20487546 209 hsa-mir-29a miR-29a miR-29a Chronic lymphocytic Leukemia (CLL) fludarabine fludarabine treatment CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine. Human Differential expression of the miR-29a, -181a, and -221 was observed between fludarabine resistant and fludarabine sensitive patients before treatment. 20487546 210 hsa-mir-125a miR-125a-5p miR-125a-5p Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 211 hsa-mir-126 miR-126 miR-126 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 212 hsa-mir-141 miR-141 miR-141 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 213 hsa-mir-16-1 miR-16 miR-16 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 214 hsa-mir-16-2 miR-16 miR-16 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 215 hsa-mir-30a miR-30a miR-30a Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 216 hsa-mir-34a miR-34a miR-34a Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 217 hsa-mir-7-1 miR-7 miR-7 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 218 hsa-mir-7-2 miR-7 miR-7 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 219 hsa-mir-7-3 miR-7 miR-7 Breast Cancer docetaxel Docetaxel treatment breast cancer cell line models (MCF-7, MDA-MB-231) Human Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. 21399894 220 hsa-mir-199a-1 miR-199a* miRNA-199a* Pancreatic Cancer curcumin 10 mmol/L curcumin treatment human BxPC-3 pancreatic cancer Human downregulate 18667010 221 hsa-mir-199a-2 miR-199a* miRNA-199a* Pancreatic Cancer curcumin 10 mmol/L curcumin treatment human BxPC-3 pancreatic cancer Human downregulate 18667010 222 hsa-mir-146a miR-146a miR-146a Alzheimer disease and in stressed Human brain cells Resveratrol Resveratrol treatment Alzheimer disease patients and in stressed human brain cells Human downregulated 18801740 223 hsa-let-7g let-7g let-7g Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 224 hsa-mir-15a miR-15a miR-15a Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 225 hsa-mir-21 miR-21 miR-21 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 226 hsa-mir-27a miR-27a miR-27a Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 227 hsa-mir-365-1 miR-365 miR-365 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 228 hsa-mir-365-2 miR-365 miR-365 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 229 hsa-mir-374a miR-374a miR-374 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 230 hsa-mir-374b miR-374b miR-374 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 231 hsa-mir-374c miR-374c miR-374 Breast Cancer 5-fluorouracil (5-FU) 5-FU treatment breast adenocarcinoma cell lineMCF-7 Human downregulated 21506117 232 hsa-mir-299 miR-299-3p miR-299-3p Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 233 hsa-mir-302e miR-302e miR-302e Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 234 hsa-mir-3170 miR-3170 miR-3170 Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 235 hsa-mir-605 miR-605 miR-605 Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 236 hsa-mir-625 miR-625 miR-625 Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 237 hsa-mir-653 miR-653 miR-653 Brain tumors irradiation irradiation treatment cell lines LN229, T98G, U-87 MG Human downregulated 21453501 238 hsa-mir-299 miR-299-3p miR-299-3p Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 239 hsa-mir-302e miR-302e miR-302e Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 240 hsa-mir-3170 miR-3170 miR-3170 Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 241 hsa-mir-605 miR-605 miR-605 Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 242 hsa-mir-625 miR-625 miR-625 Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 243 hsa-mir-653 miR-653 miR-653 Squamous cell carcinoma of the head and neck irradiation irradiation treatment cell lines SCC-4, SCC-25, CAL-27 Human downregulated 21453501 244 hsa-mir-200b miR-200b miR-200b Colon Cancer 5-fluorouracil (5-FU) 5-Fluorouracil 10 μM for 6 days colon cancer cells Human downregulated 17702597 245 hsa-mir-210 miR-210 miR-210 Colon Cancer 5-fluorouracil (5-FU) 5-Fluorouracil 10 μM for 6 days colon cancer cells Human downregulated 17702597 246 hsa-mir-224 miR-224 miR-224 Colon Cancer 5-fluorouracil (5-FU) 5-Fluorouracil 10 μM for 6 days colon cancer cells Human downregulated 17702597 247 hsa-mir-181a-1 miR-181a miR-181a Head and neck Squamous cell carcinoma cisplatin (CIS) cisplatin (CIS) treatment Head and neck squamous cell carcinoma (HNSCC) cells Human downregulated 21274007 248 hsa-mir-181a-2 miR-181a miR-181a Head and neck Squamous cell carcinoma cisplatin (CIS) cisplatin (CIS) treatment Head and neck squamous cell carcinoma (HNSCC) cells Human downregulated 21274007 249 hsa-mir-374a miR-374a miR-374a Head and neck Squamous cell carcinoma cisplatin (CIS) cisplatin (CIS) treatment Head and neck squamous cell carcinoma (HNSCC) cells Human downregulated 21274007 250 hsa-mir-519a miR-519a miR-519a Head and neck Squamous cell carcinoma cisplatin (CIS) cisplatin (CIS) treatment Head and neck squamous cell carcinoma (HNSCC) cells Human downregulated 21274007 251 hsa-mir-10a miR-10a miR-10a Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 252 hsa-mir-129-1 miR-129 miR-129 Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 253 hsa-mir-129-2 miR-129 miR-129 Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 254 hsa-mir-181d miR-181d miR-181d Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 255 hsa-mir-18a miR-18a miR-18a Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 256 hsa-mir-19a miR-19a miR-19a Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 257 hsa-mir-26b miR-26b miR-26b Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 258 hsa-mir-29b-1 miR-29b miR-29b Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 259 hsa-mir-29b-2 miR-29b miR-29b Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 260 hsa-mir-34b miR-34b miR-34b Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 261 hsa-mir-98 miR-98 miR-98 Hepatocellular carcinoma Epigallocatechin gallate (EGCG) Epigallocatechin gallate (EGCG) treatment hepatocellular carcinoma HepG2 cells Human downregulated 19269153 262 hsa-mir-192 miR-192 miR-192 Hepatocellular carcinoma hepatitis C virus (HCV) virus infection human liver Human downregulated 20103677 263 hsa-mir-375 miR-375 miR-375 Hepatocellular carcinoma hepatitis C virus (HCV) virus infection human liver Human downregulated 20103677 264 hsa-mir-200c hsa-miR-200c hsa-miR-200c Breast Cancer doxorubicin (Dox) doxorubicin treatment MCF-7 cells Human downregulated 18645025 265 hsa-mir-27b hsa-miR-27b hsa-miR-27b Breast Cancer doxorubicin (Dox) doxorubicin treatment MCF-7 cells Human downregulated 18645025 266 hsa-mir-1-1 miR-1 miR-1 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 267 hsa-mir-1-2 miR-1 miR-1 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 268 hsa-mir-10b miR-10b miR-10b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 269 hsa-mir-124-1 miR-124a miR-124a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 270 hsa-mir-124-2 miR-124a miR-124a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 271 hsa-mir-124-3 miR-124a miR-124a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 272 hsa-mir-126 miR-126 miR-126 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 273 hsa-mir-126 miR-126* miR-126* Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 274 hsa-mir-128-1 miR-128a miR-128a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 275 hsa-mir-128-2 miR-128a miR-128a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 276 hsa-mir-128-1 miR-128b miR-128b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 277 hsa-mir-128-2 miR-128b miR-128b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 278 hsa-mir-143 miR-143 miR-143 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 279 hsa-mir-146a miR-146a miR-146 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 280 hsa-mir-146b miR-146b miR-146 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 281 hsa-mir-211 miR-211 miR-211 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 282 hsa-mir-216a miR-216a miR-216 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 283 hsa-mir-216b miR-216b miR-216 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 284 hsa-mir-337 miR-337 miR-337 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 285 hsa-mir-34b miR-34b miR-34b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 286 hsa-mir-409 miR-409-5p miR-409-5p Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 287 hsa-mir-506 miR-506 miR-506 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 288 hsa-mir-518c miR-518c* miR-518c* Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 289 hsa-mir-518d miR-518d miR-518d Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 290 hsa-mir-518e miR-518e miR-518e Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 291 hsa-mir-524 miR-524 miR-524 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 292 hsa-mir-526b miR-526b miR-526b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7AKT breast cancer cells Human downregulated 19528081 293 hsa-mir-143 miR-143 miR-143 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 294 hsa-mir-27a miR-27a miR-27a Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 295 hsa-mir-27b miR-27b miR-27b Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 296 hsa-mir-302b miR-302b* miR-302b* Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 297 hsa-mir-506 miR-506 miR-506 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 298 hsa-mir-524 miR-524* miR-524* Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 299 hsa-mir-9-1 miR-9 miR-9 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 300 hsa-mir-9-2 miR-9 miR-9 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 301 hsa-mir-9-3 miR-9 miR-9 Breast Cancer Estradiol (E2) Estradiol (E2) treatment MCF-7 breast cancer cells Human downregulated 19528081 302 hsa-let-7b let-7b let-7b Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 303 hsa-mir-128-1 miR-128a miR-128a Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 304 hsa-mir-128-2 miR-128a miR-128a Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 305 hsa-mir-129-2 miR-129-2 miR-129-2 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 306 hsa-mir-133a-1 miR-133a-1 miR-133a-1 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 307 hsa-mir-139 miR-139 miR-139 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 308 hsa-mir-149 miR-149 miR-149 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 309 hsa-mir-154 miR-154 miR-154 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 310 hsa-mir-186 miR-186 miR-186 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 311 hsa-mir-187 miR-187 miR-187 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 312 hsa-mir-197 miR-197 miR-197 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 313 hsa-mir-199a-2 miR-199a-2 miR-199a-2 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 314 hsa-mir-204 miR-204 miR-204 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 315 hsa-mir-205 miR-205 miR-205 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 316 hsa-mir-211 miR-211 miR-211 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 317 hsa-mir-212 miR-212 miR-212 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 318 n/a miR-220 miR-220 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 319 n/a miR-290 miR-290 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 320 n/a miR-291-3p miR-291-3p Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 321 n/a miR-294 miR-294 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 322 hsa-mir-299 miR-299 miR-299 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 323 hsa-mir-302c miR-302c miR-302c Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 324 hsa-mir-324 miR-324-3p miR-324-3p Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 325 hsa-mir-324 miR-324-5p miR-324-5p Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 326 hsa-mir-326 miR-326 miR-326 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 327 hsa-mir-328 miR-328 miR-328 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 328 hsa-mir-337 miR-337 miR-337 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 329 hsa-mir-339 miR-339 miR-339 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 330 hsa-mir-342 miR-342 miR-342 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 331 hsa-mir-345 miR-345 miR-345 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 332 hsa-mir-346 miR-346 miR-346 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 333 hsa-mir-373 miR-373* miR-373* Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 334 hsa-mir-409 miR-409 miR-409 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 335 hsa-mir-412 miR-412 miR-412 Xenograft tumor gemcitabine 120 mg/kg, i.p.every 3 days for five doses Mz-ChA-1 cell Human downregulated 16762633 336 n/a miR-1826 miR-1826 Colon Cancer 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) treatment HCT-8 and HCT-116 colon cancer cells Human downregulated compared to matched control cells 19956872 337 hsa-mir-191 miR-191 miR-191 Colon Cancer 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) treatment HCT-8 and HCT-116 colon cancer cells Human downregulated compared to matched control cells 19956872 338 hsa-mir-197 miR-197 miR-197 Colon Cancer 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) treatment HCT-8 and HCT-116 colon cancer cells Human downregulated compared to matched control cells 19956872 339 hsa-mir-222 miR-222 miR-222 Colon Cancer 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) treatment HCT-8 and HCT-116 colon cancer cells Human downregulated compared to matched control cells 19956872 340 hsa-mir-93 miR-93 miR-93 Colon Cancer 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) treatment HCT-8 and HCT-116 colon cancer cells Human downregulated compared to matched control cells 19956872 341 hsa-mir-135b miR-135b miR-135b n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 342 hsa-mir-26b miR-26b miR-26b n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 343 hsa-mir-27a miR-27a miR-27a n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 344 hsa-mir-31 miR-31* miR-31* n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 345 hsa-mir-374a miR-374a miR-374a n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 346 hsa-mir-96 miR-96 miR-96 n/a diesel exhaust particles acutely exposed to diesel exhaust particles human bronchial epithelial cells grown at air-Cliquid-interface (ALI) when acutely exposed to diesel exhaust particles Human downregulated compared with control 20049127 347 hsa-mir-223 miR-223 miR-223 Severe and fatal lymphoproliferative disease Human T-lymphotropic virus type 1 (HTLV-1) Human T-lymphotropic virus type 1 (HTLV-1) infection HTLV-1-transformed cells Human downregulated in HTLV-1-transformed cells 19014482 348 hsa-mir-106a miR-106a miR-106a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 349 hsa-mir-106b miR-106b miR-106b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 350 hsa-mir-10b miR-10b miR-10b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 351 hsa-mir-125b-1 miR-125b miR-125b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 352 hsa-mir-125b-2 miR-125b miR-125b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 353 hsa-mir-128-1 miR-128a miR-128a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 354 hsa-mir-128-2 miR-128a miR-128a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 355 hsa-mir-128-1 miR-128b miR-128b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 356 hsa-mir-128-2 miR-128b miR-128b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 357 hsa-mir-130a miR-130a miR-130a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 358 hsa-mir-146a miR-146a miR-146 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 359 hsa-mir-146b miR-146b miR-146 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 360 hsa-mir-150 miR-150 miR-150 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 361 hsa-mir-15a miR-15a miR-15a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 362 hsa-mir-17 miR-17-3p miR-17-3p n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 363 hsa-mir-199b miR-199b miR-199b n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 364 hsa-mir-218-1 miR-218 miR-218 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 365 hsa-mir-218-2 miR-218 miR-218 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 366 hsa-mir-223 miR-223 miR-223 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 367 hsa-mir-30a miR-30a-3p miR-30a-3p n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 368 hsa-mir-338 miR-338 miR-338 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 369 hsa-mir-362 miR-362 miR-362 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 370 hsa-mir-363 miR-363 miR-363 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 371 hsa-mir-500a miR-500a miR-500 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 372 hsa-mir-500b miR-500b miR-500 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 373 hsa-mir-625 miR-625 miR-625 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 374 hsa-mir-652 miR-652 miR-652 n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 375 hsa-mir-99a miR-99a miR-99a n/a tobacco cigarette smoke human bronchial airway epithelium from current and never smokers Human downregulated in smokers 19168627 376 hsa-mir-181a-1 miR-181a miR-181a Glioblastoma radiation exposure to radiation glioblastoma multiform U87MG cell line Human downregulated; miR-181a may modulate radiosensitivity by targeting Bcl-2 in human malignant glioma cells. 20204284 377 hsa-mir-181a-2 miR-181a miR-181a Glioblastoma radiation exposure to radiation glioblastoma multiform U87MG cell line Human downregulated; miR-181a may modulate radiosensitivity by targeting Bcl-2 in human malignant glioma cells. 20204284 378 hsa-mir-181b-1 miR-181b miR-181b Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia (APL) patients blasts Human downregulation 19749800 379 hsa-mir-181b-2 miR-181b miR-181b Leukemia Retinoic Acid Retinoic Acid treatment acute promyelocytic leukemia (APL) patients blasts Human downregulation 19749800 380 hsa-let-7a-1 let-7a let-7a Acute promyelocytic Leukemia (APL) retinoic acid 100 nmol/L all-trans retinoic acid APL cell lines Human downregulation 18667010 381 hsa-let-7a-2 let-7a let-7a Acute promyelocytic Leukemia (APL) retinoic acid 100 nmol/L all-trans retinoic acid APL cell lines Human downregulation 18667010 382 hsa-let-7a-3 let-7a let-7a Acute promyelocytic Leukemia (APL) retinoic acid 100 nmol/L all-trans retinoic acid APL cell lines Human downregulation 18667010 383 hsa-mir-15a miR-15a miR-15a Acute promyelocytic Leukemia (APL) retinoic acid 100 nmol/L all-trans retinoic acid APL cell lines Human downregulation 18667010 384 hsa-mir-16-1 miR-16-1 miR-16-1 Acute promyelocytic Leukemia (APL) retinoic acid 100 nmol/L all-trans retinoic acid APL cell lines Human downregulation 18667010 385 hsa-mir-15b miR-15b miR-15b Gastric Cancer drug drug treatment human gastric adenocarcinoma cell line SGC7901 Human downregulation 18449891 386 hsa-mir-16-1 miR-16 miR-16 Gastric Cancer drug drug treatment human gastric adenocarcinoma cell line SGC7901 Human downregulation 18449891 387 hsa-mir-16-2 miR-16 miR-16 Gastric Cancer drug drug treatment human gastric adenocarcinoma cell line SGC7901 Human downregulation 18449891 388 hsa-mir-100 miR-100 miR-100 Oral Squamous cell carcinoma (OSCC) radiation radiation treatment OSCC tumor and cell lines Human Down-regulation of miR-125b and miR-100 in OSCC appears to play an important role in the development and/or progression of disease and may contribute to the loss of sensitivity to ionizing radiation 19396866 389 hsa-mir-125b-1 miR-125b miR-125b Oral Squamous cell carcinoma (OSCC) radiation radiation treatment OSCC tumor and cell lines Human Down-regulation of miR-125b and miR-100 in OSCC appears to play an important role in the development and/or progression of disease and may contribute to the loss of sensitivity to ionizing radiation 19396866 390 hsa-mir-125b-2 miR-125b miR-125b Oral Squamous cell carcinoma (OSCC) radiation radiation treatment OSCC tumor and cell lines Human Down-regulation of miR-125b and miR-100 in OSCC appears to play an important role in the development and/or progression of disease and may contribute to the loss of sensitivity to ionizing radiation 19396866 391 hsa-mir-451 miR-451 miR-451 Breast Cancer doxorubicin (Dox) doxorubicin treatment MCF-7 cells Human DOX-resistant MCF-7 cells (MCF-7/DOX) exhibit a considerable dysregulation of the miRNAome profile. microRNA-451 regulates the expression of multidrug resistance 1 gene. More importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 res 18645025 392 hsa-mir-10a miR-10a miR-10a Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 393 hsa-mir-146a miR-146a miR-146a Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 394 hsa-mir-200b miR-200b miR-200b Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 395 hsa-mir-200c miR-200c miR-200c Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 396 hsa-mir-221 miR-221 miR-221 Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 397 hsa-mir-222 miR-222 miR-222 Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 398 hsa-mir-345 miR-345 miR-345 Breast Cancer cisplatin Cisplatin treatment MCF-7 human breast adenocarcinoma cells Human dysregulated in MCF-7 cells resistant to cisplatin. 20099276 399 hsa-mir-21 miR-21 miR-21 Breast Cancer Estradiol (E2) estradiol (E(2)) treatment MCF-7 cells Human E(2) represses the expression of an oncogenic miRNA, miR-21, by activating estrogen receptor in MCF-7 cells. 19264808 400 hsa-mir-181a-1 miR-181a miR-181a Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol (E(2)) treatment breast tumor cell lines Human E(2)-repressed miR-26a and miR-181a regulate many genes associated with cell growth and proliferation, including the progesterone receptor gene, a key actor in estrogen signaling. 19826037 401 hsa-mir-181a-2 miR-181a miR-181a Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol (E(2)) treatment breast tumor cell lines Human E(2)-repressed miR-26a and miR-181a regulate many genes associated with cell growth and proliferation, including the progesterone receptor gene, a key actor in estrogen signaling. 19826037 402 hsa-mir-26a-1 miR-26a miR-26a Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol (E(2)) treatment breast tumor cell lines Human E(2)-repressed miR-26a and miR-181a regulate many genes associated with cell growth and proliferation, including the progesterone receptor gene, a key actor in estrogen signaling. 19826037 403 hsa-mir-26a-2 miR-26a miR-26a Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol (E(2)) treatment breast tumor cell lines Human E(2)-repressed miR-26a and miR-181a regulate many genes associated with cell growth and proliferation, including the progesterone receptor gene, a key actor in estrogen signaling. 19826037 404 hsa-mir-17 miR-17 miR-17 Human umbilical vein endothelial cells homeostasis ionizing radiation ionizing radiation treatment human umbilical vein endothelial cells (HUVEC) Human early transcriptional induction 21361781 405 hsa-mir-18a miR-18a miR-18a Human umbilical vein endothelial cells homeostasis ionizing radiation ionizing radiation treatment human umbilical vein endothelial cells (HUVEC) Human early transcriptional induction 21361781 406 hsa-mir-19a miR-19a miR-19a Human umbilical vein endothelial cells homeostasis ionizing radiation ionizing radiation treatment human umbilical vein endothelial cells (HUVEC) Human early transcriptional induction 21361781 407 hsa-mir-20a miR-20a miR-20a Human umbilical vein endothelial cells homeostasis ionizing radiation ionizing radiation treatment human umbilical vein endothelial cells (HUVEC) Human early transcriptional induction 21361781 408 hsa-mir-192 miR-192 miR-192 Colorectal Cancer 5-fluorouracil (5-FU) 5-fluoruracil (FU) treatment colorectal cancer cell lines Human Ectopic expression of miR-192/215 might have stronger impact to predict FU response than Thymidylate synthase (TYMS) inhibition 20647341 409 hsa-mir-215 miR-215 miR-215 Colorectal Cancer 5-fluorouracil (5-FU) 5-fluoruracil (FU) treatment colorectal cancer cell lines Human Ectopic expression of miR-192/215 might have stronger impact to predict FU response than Thymidylate synthase (TYMS) inhibition 20647341 410 hsa-mir-421 miR-421 miR-421 Ataxia-telangiectasia ionizing radiation ionizing radiation treatment Neuroblastoma cell lines Human Ectopic expression of miR-421 resulted in S-phase cell cycle checkpoint changes and an increased sensitivity to ionizing radiation 20080624 411 hsa-mir-21 miR-21 miR-21 Acute promyelocytic Leukemia (APL) Arsenic trioxide (ATO) Arsenic trioxide (ATO) treatment HL60 and K562 cells Human enforced pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. 20143188 412 hsa-mir-217 miR-217 miR-217 Excess heme metabolism changes hemin hemin exposure cell lines Human Exposure to hemin induced a significant reduction in miR-217 expression and a trend toward decreased miR-377 expression in two different cells lines.These data suggests that the combination of miR-377 and miR-217 help regulate HO-1 protein expression in t 21106538 413 hsa-mir-377 miR-377 miR-377 Excess heme metabolism changes hemin hemin exposure cell lines Human Exposure to hemin induced a significant reduction in miR-217 expression and a trend toward decreased miR-377 expression in two different cells lines.These data suggests that the combination of miR-377 and miR-217 help regulate HO-1 protein expression in t 21106538 414 hsa-mir-34a miR-34a miR-34a Undergo mucociliary differentiation tobacco exposure to tobacco smoke epithelial cells from human airways Human Exposure to tobacco smoke induces a moderate further increase in the levels of miR-34a, in differentiated airway epithelia. 21088493 415 hsa-mir-152 miR-152 miR-152 Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 416 hsa-mir-155 miR-155 miR-155 Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 417 hsa-mir-15a miR-15a miR-15a Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 418 hsa-mir-181c miR-181c miR-181c Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 419 hsa-mir-221 miR-221 miR-221 Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 420 hsa-mir-34a miR-34a miR-34a Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 421 hsa-mir-494 miR-494 miR-494 Bipolar disorder lithium lithium treatment lymphoblastoid cell lines Human expression altered 19254429 422 hsa-mir-101-1 miR-101 miR-101 Innate immune responses of Macrophages LPS, peptidoglycan, or polyinosinic-polycytidylic acid LPS, peptidoglycan, or polyinosinic-polycytidylic acid treatment macrophage cells Human expression of miR-101 is induced by multiple TLR ligands, including LPS, peptidoglycan, or polyinosinic-polycytidylic acid 21068409 423 hsa-mir-101-2 miR-101 miR-101 Innate immune responses of Macrophages LPS, peptidoglycan, or polyinosinic-polycytidylic acid LPS, peptidoglycan, or polyinosinic-polycytidylic acid treatment macrophage cells Human expression of miR-101 is induced by multiple TLR ligands, including LPS, peptidoglycan, or polyinosinic-polycytidylic acid 21068409 424 hsa-mir-21 miR-21 miR-21 Breast Cancer TAM TAM treatment endocrine-resistant LCC2, LCC9, and LY2/ MCF-7 breast cancer cells Human Expression of oncomiR miR-21 was lower in TAM-resistant LCC9 and LY2 cells compared to MCF-7 cells.Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells. 20302909 425 hsa-mir-132 miR-132 miR-132 Metabolic syndrome Omental fat Omental fat accumulation omentum and sc fat tissues, and blood samples, from a total of 50 obese and nonobese patients Human Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016). 21367929 426 hsa-mir-17 miR-17-5p miR-17-5p Metabolic syndrome Omental fat Omental fat accumulation omentum and sc fat tissues, and blood samples, from a total of 50 obese and nonobese patients Human Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016). 21367929 427 hsa-mir-30e miR-30e miR-30e Depress Task auditory odd-ball task depressed patients, Chinese population Human For miR-30e polymorphism ss178077483, individuals with the C/T genotype had a longer P300 latency than those carrying the C/C genotype. 20579744 428 hsa-mir-21 miR-21 miR-21 n/a 17beta-estradiol (E(2)) 17β estradiol (E2) treatment myometrium and leiomyoma smooth muscle cells Human found that E2 inhibited the expression of miR-21 and miR-26a in MSMC and LSMC respectively, while enhancing miR-26a expression in MSMC as compared to controls 18182067 429 hsa-mir-26a-1 miR-26a miR-26a n/a 17beta-estradiol (E(2)) 17β estradiol (E2) treatment myometrium and leiomyoma smooth muscle cells Human found that E2 inhibited the expression of miR-21 and miR-26a in MSMC and LSMC respectively, while enhancing miR-26a expression in MSMC as compared to controls 18182067 430 hsa-mir-26a-2 miR-26a miR-26a n/a 17beta-estradiol (E(2)) 17β estradiol (E2) treatment myometrium and leiomyoma smooth muscle cells Human found that E2 inhibited the expression of miR-21 and miR-26a in MSMC and LSMC respectively, while enhancing miR-26a expression in MSMC as compared to controls 18182067 431 hsa-mir-21 miR-21 miR-21 Pancreatic Cancer gemcitabine gemcitabine treatment pancreatic cancer (PC) cell lines Human gemcitabine-resistant cells have attenuated expression of miR-200 and increased expression of miR-21 (a signature of tumor aggressiveness) relative to gemcitabine-sensitive cells. 20388782 432 hsa-mir-27a miR-27a miR-27a Uveal melanoma genistein genistein treatment uveal melanoma cell Human genistein significantly inhibits uveal melanoma cell growth in a time- and dose-related manner in vitro and in vivo.the levels of miR-27a and its target gene zinc finger and BTB domain containing 10 (ZBTB10) were significantly different based on the dose 19639204 433 hsa-mir-192 miR-192 miR-192 Cancer genotoxic stress genotoxic stress HCT116, TOV21G and U-2-OS cell Human Genotoxic stress promotes the p53-dependent up-regulation of miR-192 and miR-215. Activation of miR-192/215 induces cell cycle arrest. 19074876 434 hsa-mir-215 miR-215 miR-215 Cancer genotoxic stress genotoxic stress HCT116, TOV21G and U-2-OS cell Human Genotoxic stress promotes the p53-dependent up-regulation of miR-192 and miR-215. Activation of miR-192/215 induces cell cycle arrest. 19074876 435 hsa-mir-122 miR-122 miR-122 Hepatocellular carcinoma sorafenib sorafenib treatment HCC cells Human Growth and clonogenic survival of miR-122-expressing HCC cells were significantly reduced upon treatment with sorafenib, a multi-kinase inhibitor clinically effective against HCC. Collectively, these results suggest that the loss of multifunctional miR-12 19726678 436 hsa-mir-27a miR-27a miR-27a Colon Cancer Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) treatment RKO and SW480 colon cancer cells Human GT-094-mediated repression of Sp and Sp-regulated gene products was due to downregulation of microRNA-27a (miR-27a) and induction of ZBTB10, an Sp repressor that is regulated by miR-27a in colon cancer cells. 21156786 437 hsa-mir-126 miR-126 miR-126 Hepatocellular carcinoma alcohol alcohol consumption human liver Human HCC cases associated with alcohol consumption displayed a decrease in miR-126 expression 18433021 438 hsa-mir-125b-1 miR-125b miR-125b HIV infection opioids (morphine and heroin) opioids (morphine and heroin) treatment people infected with HIV Human heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects. 21224041 439 hsa-mir-125b-2 miR-125b miR-125b HIV infection opioids (morphine and heroin) opioids (morphine and heroin) treatment people infected with HIV Human heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects. 21224041 440 hsa-mir-150 miR-150 miR-150 HIV infection opioids (morphine and heroin) opioids (morphine and heroin) treatment people infected with HIV Human heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects. 21224041 441 hsa-mir-28 miR-28 miR-28 HIV infection opioids (morphine and heroin) opioids (morphine and heroin) treatment people infected with HIV Human heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects. 21224041 442 hsa-mir-382 miR-382 miR-382 HIV infection opioids (morphine and heroin) opioids (morphine and heroin) treatment people infected with HIV Human heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects. 21224041 443 hsa-mir-210 miR-210 miR-210 Cancer hypoxia hypoxia treatment cancer patients Human High levels of miR-210 have been linked to an in vivo hypoxic signature and associated with adverse prognosis in cancer patients. 21360638 444 hsa-let-7g let-7g let-7g Cancer 5-fluorouracil-based antimetabolite S-1 5-fluorouracil-based antimetabolite S-1 treatment cancer cells Human hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1. 19948396 445 hsa-mir-181b-1 miR-181b miR-181b Cancer 5-fluorouracil-based antimetabolite S-1 5-fluorouracil-based antimetabolite S-1 treatment cancer cells Human hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1. 19948396 446 hsa-mir-181b-2 miR-181b miR-181b Cancer 5-fluorouracil-based antimetabolite S-1 5-fluorouracil-based antimetabolite S-1 treatment cancer cells Human hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1. 19948396 447 hsa-mir-485 miR-485-3p miR-485-3p Lymphoblastic Leukemia teniposide teniposide treatment human lymphoblastic leukemia CEM cells (CEM/VM-1-5) Human hsa-miR-485-3p mediates drug responsiveness by decreasing NF-YB expression, which in turn negatively regulates Top2alpha expression. 21252292 448 hsa-mir-297 miR-297 miR-297 Cancer hypoxia hypoxia treatment n/a Human hypoxia completely reverses miRNA-mediated repression of VEGFA expression. 21343907 449 hsa-mir-299 miR-299 miR-299 Cancer hypoxia hypoxia treatment n/a Human hypoxia completely reverses miRNA-mediated repression of VEGFA expression. 21343907 450 hsa-mir-449a miR-449a miR-449a n/a hypoxia hypoxia treatment fibroblast Human hypoxia-induced a decrease of clustered miRNA-449a/b. 20356416 451 hsa-mir-449b miR-449b miR-449b n/a hypoxia hypoxia treatment fibroblast Human hypoxia-induced a decrease of clustered miRNA-449a/b. 20356416 452 hsa-mir-200b miR-200b miR-200b Induction of angiogenesis hypoxia hypoxia treatment human microvascular endothelial cells (HMECs) Human hypoxia-sensitive miR-200b is involved in induction of angiogenesis via directly targeting Ets-1 in HMECs. 21081489 453 hsa-mir-21 miR-21 miR-21 Glioblastoma taxol taxol treatment Human glioblastoma U251 (PTEN-mutant) and LN229 (PTEN wild-type) cells Human IC(50) values were dramatically decreased in cells treated with miR-21 inhibitor combine with taxol, to a greater extent than those treated with taxol alone. 20110541 454 hsa-mir-15a miR-15a miR-15a B-acute lymphoblastic Leukemia (B-ALL) Interleukin (IL)-23 Interleukin (IL)-23 treatment pediatric B-acute lymphoblastic leukemia (B-ALL) cells Human IL-23R is up-regulated in primary B-ALL cells, compared with normal early B lymphocytes. IL-23-induced up-regulation of miR15a expression. IL-23 may be a candidate novel drug for the treatment of B-ALL patients unresponsive to current therapeutic standard 20671120 455 hsa-mir-200a miR-200a miR-200a Ovarian Cancer (OVCA) paclitaxel-carboplatin paclitaxel-carboplatin treatment ovarian carcinoma patients Human In conclusion, miR-200 family members affect the final beta-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stag 21051560 456 hsa-mir-200b miR-200b miR-200b Ovarian Cancer (OVCA) paclitaxel-carboplatin paclitaxel-carboplatin treatment ovarian carcinoma patients Human In conclusion, miR-200 family members affect the final beta-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stag 21051560 457 hsa-mir-200c miR-200c miR-200c Ovarian Cancer (OVCA) paclitaxel-carboplatin paclitaxel-carboplatin treatment ovarian carcinoma patients Human In conclusion, miR-200 family members affect the final beta-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stag 21051560 458 hsa-mir-429 miR-429 miR-429 Ovarian Cancer (OVCA) paclitaxel-carboplatin paclitaxel-carboplatin treatment ovarian carcinoma patients Human In conclusion, miR-200 family members affect the final beta-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stag 21051560 459 hsa-mir-519c hsa-miR-519c hsa-miR-519c Cancer mitoxantrone mitoxantrone treatment cancer cells Human In drug-sensitive cells, inhibitors against hsa-miR-519c and hsa-miR-520h could augment the cytotoxic effect of mitoxantrone 19825807 460 hsa-mir-520h hsa-miR-520h hsa-miR-520h Cancer mitoxantrone mitoxantrone treatment cancer cells Human In drug-sensitive cells, inhibitors against hsa-miR-519c and hsa-miR-520h could augment the cytotoxic effect of mitoxantrone 19825807 461 hsa-mir-146a miR-146a miR-146a Inflammatory responses; neurodegenerative disease aluminum-sulfate- and reactive oxygen species (ROS) aluminum-sulfate- and reactive oxygen species (ROS) treatment human neural (HN) cells Human In human neural (HN) cells, aluminum-sulfate- and reactive oxygen species (ROS)-mediated the up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation. 19540598 462 hsa-mir-126 miR-126 miR-126 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 463 hsa-mir-128-1 miR-128 miR-128 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 464 hsa-mir-128-2 miR-128 miR-128 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 465 hsa-mir-138-1 miR-138 miR-138 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 466 hsa-mir-138-2 miR-138 miR-138 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 467 hsa-mir-323 miR-323 miR-323 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 468 hsa-mir-326 miR-326 miR-326 Breast Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 469 hsa-mir-126 miR-126 miR-126 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 470 hsa-mir-128-1 miR-128 miR-128 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 471 hsa-mir-128-2 miR-128 miR-128 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 472 hsa-mir-138-1 miR-138 miR-138 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 473 hsa-mir-138-2 miR-138 miR-138 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 474 hsa-mir-323 miR-323 miR-323 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 475 hsa-mir-326 miR-326 miR-326 Colon Cancer hypoxia hypoxia treatment breast and colon cancer cells Human In our study, we have also detected microRNAs that exhibited downregulation at the level of microarrays (miR-126, 128, 138, 323, 326); however, the changes seemed restricted to one cell line and were not pursued at this stage (R Kulshreshtha et al., unpub 18219318 476 hsa-mir-17 miR-17 miR-17 Gastric Cancer CagA CagA exposure nonpolarized epithelial cells Human In polarized epithelial cells, CagA-driven Erk signals prevent p21(Waf1/Cip1) expression by activating a guanine nucleotide exchange factor-H1-RhoA-RhoA-associated kinase-c-Myc pathway. The microRNAs miR-17 and miR-20a, induced by c-Myc, are needed to sup 20855497 477 hsa-mir-20a miR-20a miR-20a Gastric Cancer CagA CagA exposure nonpolarized epithelial cells Human In polarized epithelial cells, CagA-driven Erk signals prevent p21(Waf1/Cip1) expression by activating a guanine nucleotide exchange factor-H1-RhoA-RhoA-associated kinase-c-Myc pathway. The microRNAs miR-17 and miR-20a, induced by c-Myc, are needed to sup 20855497 478 hsa-mir-133b miR-133b miR-133b Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to its pre-training expression level 14 days after ceasing the training programme. 20724368 479 hsa-mir-206 miR-206 miR-206 Human Skeletal muscle adaptation to physiological stimuli exercise acute endurance exercise before and after 12 weeks of endurance training muscle biopsies from vastus lateralis of healthy young males Human In resting biopsies, endurance training for 12 weeks decreased basal expression of this miRNA. Interestingly, this miRNA reverted to its pre-training expression level 14 days after ceasing the training programme. 20724368 480 hsa-mir-375 miR-375 miR-375 head and neck Squamous cell carcinomas alcohol alcohol consumption human head and neck Human In tumors of pharyngeal and laryngeal origin, expression of miR-375 was shown to be highly expressed andwas shown to increase with alcohol consumption 19901002 481 hsa-mir-125b-1 miR-125b miR-125b Astrogliosis interleukin-6 (IL-6) interleukin-6 (IL-6) treatment normal human astrocytes (NHA) Human In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth 20347935 482 hsa-mir-125b-2 miR-125b miR-125b Astrogliosis interleukin-6 (IL-6) interleukin-6 (IL-6) treatment normal human astrocytes (NHA) Human In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth 20347935 483 hsa-mir-125b-1 miR-125b miR-125b Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human increased expression 20352393 484 hsa-mir-125b-2 miR-125b miR-125b Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human increased expression 20352393 485 hsa-mir-382 miR-382 miR-382 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human increased expression 20352393 486 hsa-mir-452 miR-452 miR-452 Cellular responses to hyperthermia stress heat stress Normal adult human dermal fibroblasts (HDF) were cultured as described previously (Wilmink et al. 2006). In brief, HDFs were plated in 60-mm dishes (5,000 cells/cm2) and were incubated overnight. On day 2, the plates were sealed with Para-film and were he Normal adult human dermal fibroblasts (HDF) Human increased expression 20352393 487 hsa-let-7e let-7e let-7e Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 488 hsa-let-7g let-7g let-7g Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 489 hsa-let-7i let-7i let-7i Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 490 hsa-mir-21 miR-21 miR-21 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 491 hsa-mir-26b miR-26b miR-26b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 492 hsa-mir-638 miR-638 miR-638 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 493 hsa-mir-663 miR-663 miR-663 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative Etoposide Etoposide treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 494 hsa-let-7b let-7b let-7b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 495 hsa-let-7d let-7d let-7d Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 496 hsa-let-7e let-7e let-7e Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 497 hsa-mir-15b miR-15b miR-15b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative H2O2 H2O2 treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 498 hsa-let-7d let-7d let-7d Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 499 hsa-let-7e let-7e let-7e Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 500 hsa-let-7g let-7g let-7g Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 501 hsa-let-7i let-7i let-7i Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 502 hsa-mir-15b miR-15b miR-15b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 503 hsa-mir-21 miR-21 miR-21 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 504 hsa-mir-26b miR-26b miR-26b Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 505 hsa-mir-663 miR-663 miR-663 Cellular defense against exogenous stress and generalized cellular response to genotoxic oxidative radiation radiation treatment Normal human fibroblasts (AG01522) Human Increased expression 19633716 506 hsa-mir-23b miR-23b miR-23b Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Increased expression 19237188 507 hsa-mir-340 miR-340 miR-340 Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Increased expression 19237188 508 hsa-mir-381 miR-381 miR-381 Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Increased expression 19237188 509 hsa-mir-520f miR-520f miR-520f Ovarian Cancer (OVCA) cisplatin Cisplatin treatment OVCA cell lines Human Increased expression 19237188 510 hsa-mir-371 miR-371 miR-371 Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 511 hsa-mir-502 miR-502 miR-502 Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 512 hsa-mir-514-1 miR-514 miR-514 Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 513 hsa-mir-514-2 miR-514 miR-514 Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 514 hsa-mir-514-3 miR-514 miR-514 Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 515 hsa-mir-518c miR-518c-AS miR-518c-AS Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 516 hsa-mir-99b miR-99b miR-99b Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 517 hsa-mir-181a-1 miR-181a miR-181a Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 518 hsa-mir-181a-2 miR-181a miR-181a Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 519 hsa-mir-181b-1 miR-181b miR-181b Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 520 hsa-mir-181b-2 miR-181b miR-181b Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 521 hsa-mir-21 miR-21 miR-21 Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 522 n/a miR-213 miR-213 Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 523 hsa-mir-520f miR-520f miR-520f Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 524 hsa-let-7e let-7e let-7e Ovarian Cancer (OVCA) doxorubicin (Dox) doxorubicin treatment OVCA cell lines Human increased expression 19237188 525 hsa-mir-181a-1 miR-181a miR-181a Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Increased expression 19237188 526 hsa-mir-181a-2 miR-181a miR-181a Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Increased expression 19237188 527 hsa-mir-181b-1 miR-181b miR-181b Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Increased expression 19237188 528 hsa-mir-181b-2 miR-181b miR-181b Ovarian Cancer (OVCA) gemcitabine gemcitabine treatment OVCA cell lines Human Increased expression 19237188 529 hsa-mir-126 miR-126 miR-126 Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Increased expression 19237188 530 hsa-mir-514-1 miR-514 miR-514 Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Increased expression 19237188 531 hsa-mir-514-2 miR-514 miR-514 Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Increased expression 19237188 532 hsa-mir-514-3 miR-514 miR-514 Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Increased expression 19237188 533 hsa-mir-99b miR-99b miR-99b Ovarian Cancer (OVCA) Paclitaxel (Taxol) paclitaxel treatment OVCA cell lines Human Increased expression 19237188 534 hsa-mir-34b miR-34b miR-34b Ovarian Cancer (OVCA) topotecan topotecan treatment OVCA cell lines Human Increased expression 19237188 535 hsa-mir-431 miR-431 miR-431 Ovarian Cancer (OVCA) topotecan topotecan treatment OVCA cell lines Human Increased expression 19237188 536 hsa-mir-518c miR-518c-AS miR-518c-AS Ovarian Cancer (OVCA) topotecan topotecan treatment OVCA cell lines Human Increased expression 19237188 537 hsa-mir-515-1 miR-515-5p miR-515-5p Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 538 hsa-mir-515-2 miR-515-5p miR-515-5p Ovarian Cancer (OVCA) docetaxel docetaxel treatment OVCA cell lines Human Increased expression 19237188 539 hsa-mir-181a-1 miR-181a miR-181 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 540 hsa-mir-181a-2 miR-181a miR-181 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 541 hsa-mir-181b-1 miR-181b miR-181 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 542 hsa-mir-181b-2 miR-181b miR-181 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 543 hsa-mir-21 miR-21 miR-21 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 544 hsa-mir-221 miR-221 miR-221 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 545 hsa-mir-222 miR-222 miR-222 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 546 hsa-mir-342 miR-342 miR-342 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 547 hsa-mir-489 miR-489 miR-489 Breast Cancer Tamoxifen tamoxifen therapy MCF-7 cell lines Human Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR 18708351 548 hsa-mir-375 miR-375 miR-375 Hepatocellular carcinoma mitogen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) TCPOBOP treatment hepatocellular carcinomas developed in mice given Diethylnitrosamine (DENA) Human Increased levels of YAP which were associated with down-regulation of miR-375, known to control YAP expression 21391223 549 hsa-mir-20a miR-20a miR-20a n/a E2+ICI-182780 E2+ICI-182780 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-20a in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 550 hsa-mir-26a-1 miR-26a miR-26a n/a E2+ICI-182780 E2+ICI-182780 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-20a in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 551 hsa-mir-26a-2 miR-26a miR-26a n/a E2+ICI-182780 E2+ICI-182780 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-20a in MSMC and LSMC, and miR-26a in MSMC, while inhibiting the expression of miR-26a in LSMC 18182067 552 hsa-mir-21 miR-21 miR-21 n/a MPA+RU-486 MPA+RU-486 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-21 and miR-26a in LSMC and MSMC respectively, and inhibited miR-26a in LSMC 18182067 553 hsa-mir-26a-1 miR-26a miR-26a n/a MPA+RU-486 MPA+RU-486 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-21 and miR-26a in LSMC and MSMC respectively, and inhibited miR-26a in LSMC 18182067 554 hsa-mir-26a-2 miR-26a miR-26a n/a MPA+RU-486 MPA+RU-486 treatment myometrium and leiomyoma smooth muscle cells Human increased the expression of miR-21 and miR-26a in LSMC and MSMC respectively, and inhibited miR-26a in LSMC 18182067 555 hsa-mir-146a miR-146a miR-146a Alzheimer's disease (AD) curcumin curcumin treatment early-, moderate- and late-stage Alzheimer's disease (AD) neocortex and hippocampus, in several human primary brain and retinal cell lines, and in 5 different transgenic mouse models of AD including Tg2576, TgCRND8, PSAPP, 3xTg-AD and 5xFAD Human Inducible expression of miRNA-146a was found to be significantly up-regulated in a primary co-culture of human neuronal-glial (HNG) cells stressed using interleukin1-beta (IL-1beta), and this up-regulation was quenched using specific NF-small ka, Cyrillic 20934487 556 hsa-mir-146a miR-146a miR-146a Mycobacterium tuberculosis Herpes simplex virus type-1 (HSV-1) Herpes simplex virus type-1 (HSV-1) infection human primary neural cells Human Infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.Thes 19801956 557 hsa-mir-200b miR-200b miR-200b Cholangiocarcinoma gemcitabine gemcitabine treatment cholangiocarcinoma cell lines Human Inhibition of miR-21 and miR-200b increased sensitivity to gemcitabine in cholangiocarcinoma cell lines 19948396 558 hsa-mir-21 miR-21 miR-21 Cholangiocarcinoma gemcitabine gemcitabine treatment cholangiocarcinoma cell lines Human Inhibition of miR-21 and miR-200b increased sensitivity to gemcitabine in cholangiocarcinoma cell lines 19948396 559 hsa-mir-375 miR-375 miR-375 Beta cellular dysfunction and beta-mass lose in type 2 diabetes palmitate palmitate treatment NIT-1 cells Human It was found that NIT-1 cells with ectopic mir-375 expression were much more susceptible to palmitate-induced lipoapoptosis. 20224724 560 hsa-mir-19a miR-19a miR-19a Multiple myeloma ITF2357 ITF2357 treatment KMS18 multiple myeloma cell line Human ITF2357 significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma. 19713220 561 hsa-mir-19a miR-19a miR-19a n/a laminar shear stress laminar shear stress (12 dyn/cm(2), 12 h) Endothelial cells (ECs) Human Laminar shear stress (12 dyn/cm(2), 12 h) regulated the EC expression of miR-19a. 20133739 562 hsa-let-7b let-7b let-7b Colorectal Cancer cetuximab (Caco-2 and HCT-116) cetuximab (Caco-2 and HCT-116) treatment human CRC (colorectal cancer) cell lines, one sensitive and the other resistant to cetuximab Human let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. 20881268 563 hsa-let-7e let-7e let-7e Colorectal Cancer cetuximab (Caco-2 and HCT-116) cetuximab (Caco-2 and HCT-116) treatment human CRC (colorectal cancer) cell lines, one sensitive and the other resistant to cetuximab Human let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. 20881268 564 hsa-mir-17 miR-17* miR-17* Colorectal Cancer cetuximab (Caco-2 and HCT-116) cetuximab (Caco-2 and HCT-116) treatment human CRC (colorectal cancer) cell lines, one sensitive and the other resistant to cetuximab Human let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. 20881268 565 hsa-let-7e let-7e let-7e Advanced ovarian Cancer the combination carboplatin/cisplatin with paclitaxel Chemotherapy human ovarian cancer cells Human Let-7e was upregulated in A2780TAX cells, while it was downregulated in the other resistant cell lines 18823650 566 hsa-let-7g let-7g let-7g Lung Cancer ionizing radiation ionizing radiation (IR) treatment lung cancer cells Human let-7g was down-regulated in radio-resistant H1299 cells, and the level of let-7g was higher in radio-sensitive cells in qRT-PCR analysis than in radio-resistant cells. 19745602 567 hsa-let-7i let-7i let-7i Ovarian Cancer (OVCA) cis-platinum cis-platinum treatment ovarian cancer cells Human let-7i expression was significantly reduced in chemotherapy-resistant patients.Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly 19074899 568 hsa-mir-130a miR-130a miR-130a n/a hypoxia hypoxia treatment human kidney cell line HEK293 Human Levels of the miR-130 family are elevated under hypoxia 21486751 569 hsa-mir-130b miR-130b miR-130b n/a hypoxia hypoxia treatment human kidney cell line HEK293 Human Levels of the miR-130 family are elevated under hypoxia 21486751 570 hsa-mir-301a miR-301a miR-301a n/a hypoxia hypoxia treatment human kidney cell line HEK293 Human Levels of the miR-130 family are elevated under hypoxia 21486751 571 hsa-mir-301b miR-301b miR-301b n/a hypoxia hypoxia treatment human kidney cell line HEK293 Human Levels of the miR-130 family are elevated under hypoxia 21486751 572 hsa-mir-21 miR-21 miR-21 Pancreatic ductal adenocarcinoma (PDAC) adjuvant therapy adjuvant therapy treatment 82 resected Korean PDAC cases Human lower than median miR-21 expression was associated with a significantly lower hazard ratio (HR) for death (HR = 0.316; 95%CI = 0.166-0.600; P = 0.0004) and recurrence (HR = 0.521; 95%CI = 0.280-0.967; P = 0.04).MiR-21 expression status emerged as the sing 20498843 573 hsa-mir-181a-1 miR-181a miR-181a Breast Cancer metformin metformin treatment MCF-7 cells Human metformin co-treatment fully prevented TGFbeta-induced down-regulation of the tumor suppressor miRNA-96 (~10-fold). 21368581 574 hsa-mir-181a-2 miR-181a miR-181a Breast Cancer metformin metformin treatment MCF-7 cells Human metformin co-treatment fully prevented TGFbeta-induced down-regulation of the tumor suppressor miRNA-96 (~10-fold). 21368581 575 hsa-mir-181a-1 miR-181a miR-181a Breast Cancer metformin metformin treatment MCF-7 cells Human metformin is able to impede TGFbeta-enhanced propensity of breast cancer stem cells to form mammospheres in a miRNA-181a-related manner. 21368581 576 hsa-mir-181a-2 miR-181a miR-181a Breast Cancer metformin metformin treatment MCF-7 cells Human metformin is able to impede TGFbeta-enhanced propensity of breast cancer stem cells to form mammospheres in a miRNA-181a-related manner. 21368581 577 hsa-let-7a-1 let-7a let-7a Breast Cancer metformin metformin treatment MCF-7 cells Human Metformin-treated MCF-7 cells notably exhibited up to 18-fold increases in miRNA lethal-7a (let-7a) expression compared with untreated control cells. 21368581 578 hsa-let-7a-2 let-7a let-7a Breast Cancer metformin metformin treatment MCF-7 cells Human Metformin-treated MCF-7 cells notably exhibited up to 18-fold increases in miRNA lethal-7a (let-7a) expression compared with untreated control cells. 21368581 579 hsa-let-7a-3 let-7a let-7a Breast Cancer metformin metformin treatment MCF-7 cells Human Metformin-treated MCF-7 cells notably exhibited up to 18-fold increases in miRNA lethal-7a (let-7a) expression compared with untreated control cells. 21368581 580 hsa-mir-125b-1 miR125b miR125b Rectal Cancer capecitabine chemoradiotherapy Tumor biopsies from 35 patients with rectal cancer Human micro-RNAs miR125b, miR137 showed a significant increase in median expression levels after starting therapy in most samples 18695884 581 hsa-mir-125b-2 miR-125b miR125b Rectal Cancer capecitabine chemoradiotherapy Tumor biopsies from 35 patients with rectal cancer Human micro-RNAs miR125b, miR137 showed a significant increase in median expression levels after starting therapy in most samples 18695884 582 hsa-mir-137 miR-137 miR137 Rectal Cancer capecitabine chemoradiotherapy Tumor biopsies from 35 patients with rectal cancer Human micro-RNAs miR125b, miR137 showed a significant increase in median expression levels after starting therapy in most samples 18695884 583 hsa-mir-548a miR-548a-3p miR-548-3p n/a X-ray 2.0 Gy of radiation human fibroblasts Human MicroRNAs miR-579, 608, 548-3p, and 585 are noted for targeting genes involved in radioresponsive mechanisms, such as cell cycle checkpoint and apoptosis. 18729083 584 hsa-mir-579 miR-579 miR-579 n/a X-ray 2.0 Gy of radiation human fibroblasts Human MicroRNAs miR-579, 608, 548-3p, and 585 are noted for targeting genes involved in radioresponsive mechanisms, such as cell cycle checkpoint and apoptosis. 18729083 585 hsa-mir-585 miR-585 miR-585 n/a X-ray 2.0 Gy of radiation human fibroblasts Human MicroRNAs miR-579, 608, 548-3p, and 585 are noted for targeting genes involved in radioresponsive mechanisms, such as cell cycle checkpoint and apoptosis. 18729083 586 hsa-mir-608 miR-608 miR-608 n/a X-ray 2.0 Gy of radiation human fibroblasts Human MicroRNAs miR-579, 608, 548-3p, and 585 are noted for targeting genes involved in radioresponsive mechanisms, such as cell cycle checkpoint and apoptosis. 18729083 587 hsa-mir-1-1 miR-1 miR-1 Insulin resistance changes Insulin Insulin treatment human skeletal muscle Human miR-1 and miR-133a are regulated by Insulin in human skeletal muscle. 19720801 588 hsa-mir-1-2 miR-1 miR-1 Insulin resistance changes Insulin Insulin treatment human skeletal muscle Human miR-1 and miR-133a are regulated by Insulin in human skeletal muscle. 19720801 589 hsa-mir-133a-1 miR-133a miR-133a Insulin resistance changes Insulin Insulin treatment human skeletal muscle Human miR-1 and miR-133a are regulated by Insulin in human skeletal muscle. 19720801 590 hsa-mir-133a-2 miR-133a miR-133a Insulin resistance changes Insulin Insulin treatment human skeletal muscle Human miR-1 and miR-133a are regulated by Insulin in human skeletal muscle. 19720801 591 hsa-mir-101-1 miR-101 miR-101 Hepatocellular carcinoma serum starvation and chemotherapeutic drug serum starvation and chemotherapeutic drug treatment hepatoma cell lines Human miR-101 could sensitize hepatoma cell lines to both serum starvation- and chemotherapeutic drug-induced apoptosis. 19155302 592 hsa-mir-101-2 miR-101 miR-101 Hepatocellular carcinoma serum starvation and chemotherapeutic drug serum starvation and chemotherapeutic drug treatment hepatoma cell lines Human miR-101 could sensitize hepatoma cell lines to both serum starvation- and chemotherapeutic drug-induced apoptosis. 19155302 593 hsa-mir-106a miR-106a miR-106a Chemical carcinogenesis anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide treatment malignant human bronchial epithelial cells Human miR-106a might function as an oncogene in transformation induced by a chemical carcinogen. Thus, knock down of miR-106a in malignant cells is a potential therapeutic strategy. 20889678 594 hsa-mir-107 miR-107 miR-107 Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol treatment estrogen stimulated MCF-7 and ZR-75.1 cells Human miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol 20348243 595 hsa-mir-424 miR-424 miR-424 Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol treatment estrogen stimulated MCF-7 and ZR-75.1 cells Human miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol 20348243 596 hsa-mir-570 miR-570 miR-570 Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol treatment estrogen stimulated MCF-7 and ZR-75.1 cells Human miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol 20348243 597 hsa-mir-618 miR-618 miR-618 Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol treatment estrogen stimulated MCF-7 and ZR-75.1 cells Human miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol 20348243 598 hsa-mir-760 miR-760 miR-760 Breast Cancer 17beta-estradiol (E(2)) 17beta-estradiol treatment estrogen stimulated MCF-7 and ZR-75.1 cells Human miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol 20348243 599 hsa-mir-10a miR-10a miR-10a Pancreatic Cancer Retinoic Acid Retinoic Acid treatment pancreatic cancer cell Human miR-10a is a retinoic acid target, and retinoic acid receptor antagonists effectively repress miR-10a expression and completely block metastasis. 19747919 600 hsa-mir-122 miR-122 miR-122 Chronic liver disease hepatitis C virus (HCV) virus infection human liver Human miR-122 expression inversely correlated with fibrosis and biochemicalmarkers of hepatocyte damage. 20625373 601 hsa-mir-122 miR-122 miR-122 Hepatocellular carcinoma hepatitis B virus (HBV) virus infection human hepatoma cells Human miR-122 has a role in the regulation of HBV replication through the HO-1 down-regulation 20633528 602 hsa-mir-122 miR-122 miR-122 Chronic hepatitis B viral infections d-galactosamine- and alcohol d-galactosamine- and alcohol treatment plasma samples from 83 patients with chronic hepatitis B viral infections, 15 patients with skeletal muscle disease, and 40 healthy controls Human miR-122 presented a disease severity-dependent change in plasma concentration in the patients and animal models. Compared with an increase in aminotransferase activity in the blood, the change in miR-122 concentration appeared earlier. 20930130 603 hsa-mir-122 miR-122 miR-122 Hepatocellular carcinoma hepatitis C virus (HCV) virus infection human liver Human miR-122 stimulates HCV translation by enhancing the association of ribosomeswith viralRNAat an early initiation stage, contributing to the liver tropism of the virus 19020517 604 hsa-mir-124-1 miR-124a miR-124a Adaptation to stress, metabolism, immunity, and neuronal development Glucocorticoids (GCs) Glucocorticoids (GCs) treatment P19 cells Human miR-124a expression varies over time during the stress hyporesponsive period 19131573 605 hsa-mir-124-2 miR-124a miR-124a Adaptation to stress, metabolism, immunity, and neuronal development Glucocorticoids (GCs) Glucocorticoids (GCs) treatment P19 cells Human miR-124a expression varies over time during the stress hyporesponsive period 19131573 606 hsa-mir-124-3 miR-124a miR-124a Adaptation to stress, metabolism, immunity, and neuronal development Glucocorticoids (GCs) Glucocorticoids (GCs) treatment P19 cells Human miR-124a expression varies over time during the stress hyporesponsive period 19131573 607 hsa-mir-125b-1 miR-125b miR-125b Rectal Cancer Capecitabine Capecitabine treatment Rectal cancer patients, paired tumor biopsies Human miR-125b and miR-137 significantly increased in most samples 18695884 608 hsa-mir-125b-2 miR-125b miR-125b Rectal Cancer Capecitabine Capecitabine treatment Rectal cancer patients, paired tumor biopsies Human miR-125b and miR-137 significantly increased in most samples 18695884 609 hsa-mir-137 miR-137 miR-137 Rectal Cancer Capecitabine Capecitabine treatment Rectal cancer patients, paired tumor biopsies Human miR-125b and miR-137 significantly increased in most samples 18695884 610 hsa-mir-221 miR-221 miR-221 Cancer Paclitaxel (Taxol) Paclitaxel (Taxol) treatment Taxol-resistant and their Taxol-sensitive parental cells Human miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells. 20460378 611 hsa-mir-222 miR-222 miR-222 Cancer Paclitaxel (Taxol) Paclitaxel (Taxol) treatment Taxol-resistant and their Taxol-sensitive parental cells Human miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells. 20460378 612 hsa-mir-125b-1 miR-125b miR-125b Cancer Paclitaxel (Taxol) Paclitaxel (Taxol) treatment Taxol-resistant and their Taxol-sensitive parental cells Human miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells.miR-125b was up-regulated in Taxol-resistant cells, causing a marked inhibition of Taxol-induced cytotoxicity and apoptosis and a subsequent increase in the resistan 20460378 613 hsa-mir-125b-2 miR-125b miR-125b Cancer Paclitaxel (Taxol) Paclitaxel (Taxol) treatment Taxol-resistant and their Taxol-sensitive parental cells Human miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells.miR-125b was up-regulated in Taxol-resistant cells, causing a marked inhibition of Taxol-induced cytotoxicity and apoptosis and a subsequent increase in the resistan 20460378 614 hsa-mir-125b-1 miR-125b miR-125b Advanced ovarian Cancer the combination carboplatin/cisplatin with paclitaxel Chemotherapy human ovarian cancer cells Human miR-125b, which was downregulated in A2780TAX and upregulated in the other cell lines 18823650 615 hsa-mir-125b-2 miR-125b miR-125b Advanced ovarian Cancer the combination carboplatin/cisplatin with paclitaxel Chemotherapy human ovarian cancer cells Human miR-125b, which was downregulated in A2780TAX and upregulated in the other cell lines 18823650 616 hsa-mir-103a-1 miR-103 miR-103 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 617 hsa-mir-103a-2 miR-103 miR-103 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 618 hsa-mir-103b-1 miR-103 miR-103 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 619 hsa-mir-103b-2 miR-103 miR-103 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 620 hsa-mir-126 miR-126 miR-126 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 621 hsa-mir-130a miR-130a miR-130a Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 622 hsa-mir-18b miR-18b miR-18b Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 623 hsa-mir-210 miR-210 miR-210 Leukemia hemin hemin treatment K562 cells, human Human miR-126 exhibited up-regulation while miR-103, miR-130a, miR-210, and miR-18b exhibited down-regulation after hemin induction 19350553 624 hsa-mir-138-1 miR-138 miR-138 Leukemia vincristine vincristine (VCR) treatment vincristine-induced multidrug resistance (MDR) leukemia cell line HL-60/VCR and HL-60 cells Human miR-138 could significantly down-regulate the expression of P-glycoprotein, Bcl-2, and the transcription of the multidrug resistance gene 1. 19896708 625 hsa-mir-138-2 miR-138 miR-138 Leukemia vincristine vincristine (VCR) treatment vincristine-induced multidrug resistance (MDR) leukemia cell line HL-60/VCR and HL-60 cells Human miR-138 could significantly down-regulate the expression of P-glycoprotein, Bcl-2, and the transcription of the multidrug resistance gene 1. 19896708 626 n/a miR-14 miR-14 Insulin level changes nutrition nutritionally variable environment Drosophila brain Human miR-14 acts in the Insulin-producing neurosecretory cells in the adult Drosophila brain to control metabolism. miR-14 acts in these cells through its direct target, sugarbabe. sugarbabe encodes a predicted zinc finger protein that regulates Insulin gene e 21159815 627 hsa-mir-140 miR-140 miR-140 Osteosarcoma tumor methotrexate and 5-fluorouracil (5-FU) methotrexate and 5-fluorouracil (5-FU) treatment Tumor cells Human miR-140 is involved in the chemoresistance by reduced cell proliferation through G(1) and G(2) phase arrest mediated in part through the suppression of HDAC4. miR-140 may be a candidate target to develop novel therapeutic strategy to overcome drug resista 19734943 628 hsa-mir-146a miR-146a miR-146a T-cell Leukemia (ATL) Human T-cell leukemia virus type 1 (HTLV-1) Human T-cell leukemia virus type 1 (HTLV-1) infection T-cell lines Human miR-146a was upregulated in HTLV-1-infected T-cell lines compared to uninfected T-cell lines. 20017139 629 hsa-mir-148a miR-148a miR-148a Oesophageal Cancer Cisplatin-/5-fluorouracil Cisplatin-/5-fluorouracil treatment oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines Human MiR-148a upregulation significantly increased sensitivity to chemotherapy in seven out of ten cell lines, represented by a decrease in cell viability of 22.6 +/- 7.9% to 50.5 +/- 10.6% after cisplatin (p 10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2149 rno-mir-192 miR-192 miR-192 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2150 rno-mir-194-1 miR-194 miR-194 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2151 rno-mir-194-2 miR-194 miR-194 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2152 rno-mir-215 miR-215 miR-215 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2153 rno-mir-223 miR-223 miR-223 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2154 rno-mir-224 miR-224 miR-224 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2155 rno-mir-34a miR-34a miR-34a Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2156 rno-mir-375 miR-375 miR-375 Colon Cancer oil or fish oil Sprague-Dawley rats were fed diets containing corn oil or fish oil with pectin or cellulose and injected with azoxymethane (AOM, a colon-specific carcinogen) or saline (control). Sprague-Dawley rats Rat miR-34a, 132, 223 and 224 were overexpressed at >10-fold in tumors. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (< or = 0.32-fold) in adenocarcinomas. 19825969 2157 rno-mir-98 miR-98 miR-98 Ischemic heart propranolol propranolol interven long-term MI (myocardial infarction) model of rat Rat miR-98 stressed on inflammation 21386882 2158 rno-mir-129-1 miR-129 miR-129 Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2159 rno-mir-129-2 miR-129 miR-129 Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2160 rno-mir-183 miR-183 miR-183 Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2161 n/a miR-189 miR-189 Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2162 rno-mir-200a miR-200a miR-200a Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2163 rno-mir-200b miR-200b miR-200b Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2164 rno-mir-215 miR-215 miR-215 Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2165 rno-mir-29c miR-29c miR-29c Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2166 n/a miR-422b miR-422b Offspring vascular phenotype changes nutrition maternal undernutrition (MUN) aortic specimens in 1-day-old (P1) and 12-mo-old offspring aortas of dams Sprague-Dawley rats Rat MUN significantly downregulated the expression of miRNAs 29c, 183, and 422b in the P1 group and 200a, 129, 215, and 200b in the 12-mo group, and upregulated the expression of miRNA 189 in the P1 group and 337 in the 12-mo group. 20200130 2167 rno-mir-140 miR-140* miR-140* n/a nicotine more nicotine rodent miRNA microarray and rat PC12 cell model Rat nicotine increases expression of miR-140*, coordinated with the nicotine-augmented expression of its host gene WWP2 18845019 2168 rno-mir-101a miR-101a miR-101 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2169 rno-mir-101b miR-101b miR-101 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2170 rno-mir-126 miR-126* miR-126* Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2171 rno-mir-199a miR-199a miR-199 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2172 rno-mir-34a miR-34a miR-34 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2173 rno-mir-34b miR-34b miR-34 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2174 rno-mir-34c miR-34c miR-34 Lung Cancer tobacco 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment male F344 rats Rat NNK treatment reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-199 and miR-34 18780894 2175 ambi-mir-13232 ambi-miR-13232 ambi-miR-13232 n/a sleep Sleep deprivation(SD) rats Rat Prefrontal cortex:down-regulate 17597302 2176 rno-mir-124-1 miR-124 miR-124a Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2177 rno-mir-124-2 miR-124 miR-124a Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2178 rno-mir-124-3 miR-124 miR-124a Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2179 rno-mir-125b-1 miR-125B miR-125B Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2180 rno-mir-125b-2 miR-125B miR-125B Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2181 rno-mir-9-1 miR-9 miR-9 Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2182 rno-mir-9-2 miR-9 miR-9 Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2183 rno-mir-9-3 miR-9 miR-9 Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2184 rno-mir-9-1 miR-9* miR-9* Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2185 rno-mir-9-2 miR-9* miR-9* Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2186 rno-mir-9-3 miR-9* miR-9* Spina bifida Retinoic Acid Retinoic Acid treatment spinal cord in a spina bifida rat model Rat Retinoic acid downregulates several microRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) to induce abnormal development of the spinal cord in a spina bifida rat model 19747919 2187 rno-mir-124-1 miR-124 miR-124a n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2188 rno-mir-124-2 miR-124 miR-124a n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2189 rno-mir-124-3 miR-124 miR-124a n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2190 rno-mir-125b-1 miR-125B miR-125B n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2191 rno-mir-125b-2 miR-125B miR-125B n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2192 rno-mir-9-1 miR-9/9* miR-9/9* n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2193 rno-mir-9-2 miR-9/9* miR-9/9* n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2194 rno-mir-9-3 miR-9/9* miR-9/9* n/a retinoic acid retinoic acid treatment a rat model of spina bifida Rat retinoic acid downregulates specific miRNAs (i.e., miR-9/9*, miR-124a, and miR-125B) 18667010 2195 rno-mir-15b miR-15b miR-15b Spinal cord injury (SCI) exercise exercise injured rat spinal cord Rat SCI results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. 20816819 2196 rno-mir-21 miR-21 miR-21 Spinal cord injury (SCI) exercise exercise injured rat spinal cord Rat SCI results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. 20816819 2197 rno-mir-141 miR-141 miR-141 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2198 rno-mir-182 miR-182 miR-182 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2199 rno-mir-183 miR-183 miR-183 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2200 rno-mir-183 miR-183* miR-183* Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2201 n/a miR-198 miR-198 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2202 rno-mir-200a miR-200a miR-200a Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2203 rno-mir-200a miR-200a* miR-200a* Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2204 rno-mir-200b miR-200b miR-200b Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2205 rno-mir-200b miR-200b* miR-200b* Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2206 rno-mir-200c miR-200c miR-200c Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2207 rno-mir-429 miR-429 miR-429 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2208 rno-mir-96 miR-96 miR-96 Learned helplessness Stress inescapable shock rats Rat showed particularly large, significant,and consistent alterations in NLH (non learned helplessness) rats 21515361 2209 rno-mir-128-1 miR-128 hsa-miR-128b n/a sleep Sleep deprivation(SD) rats Rat Somatosensory cortex:down-regulate;Hypothalamus:down-regulate 17597302 2210 rno-mir-128-2 miR-128 hsa-miR-128b n/a sleep Sleep deprivation(SD) rats Rat Somatosensory cortex:down-regulate;Hypothalamus:down-regulate 17597302 2211 ambi-mir-917 ambi-miR-917 ambi-miR-917 n/a sleep Sleep deprivation(SD) rats Rat Somatosensory cortex:up-regulate 17597302 2212 rno-mir-18a miR-18a miR-18 Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2213 rno-mir-182 miR-182 miR-182 Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2214 rno-mir-200a miR-200a miR-200a Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2215 rno-mir-200b miR-200b miR-200b Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2216 rno-mir-200c miR-200c miR-200c Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2217 rno-mir-21 miR-21 miR-21 Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2218 rno-mir-429 miR-429 miR-429 Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat substantial deregulation of expression in the livers of 2-AAF-exposed rats 19167416 2219 rno-mir-34a miR-34a miR-34a Hepatocellular carcinoma aromatic amine 2-acetylaminofluore (2-AAF) Male Sprague-Dawley rats were fed NIH-31 diet containing 0.02% of 2-AAF for 12 and 24 weeks livers of 2-AAF-exposed rats Rat the long-term-administration of 2-AAF resulted in disruption of regulatory miR-34a-p53 feed-back loop that mediates apoptosis. This was evidenced by an increased expression of miR-34a in response to genotoxic effects of 2-AAF in the absence of p53 up-regu 19167416 2220 rno-mir-16 miR-16 miR-16 Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2221 rno-mir-19b-1 miR-19b miR-19b Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2222 rno-mir-19b-2 miR-19b miR-19b Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2223 rno-mir-203 miR-203 miR-203 Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2224 rno-mir-21 miR-21 miR-21 Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2225 rno-mir-26b miR-26b miR-26b Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2226 rno-mir-27b miR-27b miR-27b Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2227 rno-mir-93 miR-93 miR-93 Colon Cancer azoxymethane azoxymethane injection Sprague Dawley rats were fed diets containing corn oil/fish oil with pectin/cellulose and injected with azoxymethane (AOM,) or saline (control) Rat This miRNA was modulated by diet and carcinogen exposure 21406606 2228 rno-mir-124-1 miR-124-1 miR-124-1 Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2229 rno-mir-132 miR-132 miR-132 Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2230 rno-mir-212 miR-212 miR-212 Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2231 rno-mir-29a miR-29a miR-29a Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2232 rno-mir-9-1 miR-9-1 miR-9-1 Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2233 rno-mir-9-3 miR-9-3 miR-9-3 Stress-related disorders, such as depression Early life stress maternal separation rats Rat This miRNA was significantly increased in the medial prefrontal cortex of these stressed rats. 21068306 2234 rno-mir-21 miR-21 miR-21 Affecting liver regeneration ursodeoxycholic acid (UDCA) ursodeoxycholic acid (UDCA) feeding rats Rat UDCA was a strong inducer of miR-21 both during LR and in cultured HepG2 cells.UDCA feeding appeared to induce a sustained increase of proliferative miRNAs observed at early time points after PH. In conclusion, miRNAs, in particular miR-21, may play a sig 20689055 2235 rno-mir-153 miR-153 miR-153 Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2236 n/a miR-302b-AS miR-302b-AS Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2237 rno-mir-337 miR-337 miR-337 Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2238 rno-mir-363 miR-363 miR-363 Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2239 rno-mir-409 miR-409-5p miR-409-5p Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2240 rno-mir-542 miR-542-3p miR-542-3p Toxic response in liver APAP and CCl4 APAP (1 g/kg, gavage, 6 - 24 h) CCl4 (0.3 ml/kg, gavage, 6 - 24 h) Crl(SD)IGS rat livers Rat upregulated 17965554 2241 rno-mir-106b miR-106b miR-106a Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2242 rno-mir-15b miR-15b miR-15a Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2243 rno-mir-16 miR-16 miR-16 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2244 rno-mir-17-1 miR-17-5p miR-17-5p Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2245 rno-mir-17-2 miR-17-5p miR-17-5p Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2246 rno-mir-18a miR-18a miR-18 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2247 rno-mir-199a miR-199a miR-199b Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2248 rno-mir-25 miR-25 miR-25 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2249 rno-mir-31 miR-31 miR-31 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2250 rno-mir-345 miR-345 miR-345 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2251 rno-mir-34a miR-34a miR-34a Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2252 rno-mir-365 miR-365 miR-365 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2253 rno-mir-375 miR-375 miR-375 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2254 n/a miR-424 miR-424 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2255 rno-mir-92a-1 miR-92a miR-92 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2256 rno-mir-92a-2 miR-92a miR-92 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2257 rno-mir-92b miR-92b miR-92 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2258 rno-mir-93 miR-93 miR-93 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2259 rno-mir-193 rno-miR-193 rno-miR-193 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2260 rno-mir-20a rno-miR-20a rno-miR-20a Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2261 rno-mir-20b rno-miR-20b rno-miR-20b Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2262 rno-mir-324 rno-miR-324-5p rno-miR-324-5p Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2263 rno-mir-362 rno-miR-362 rno-miR-362 Hepatocellular carcinoma Tamoxifen Tamoxifen 420 ppm in NIH-31 diet for 24 weeks F344 rat livers Rat upregulated 17343880 2264 rno-mir-294 miR-294 miR-294 n/a cigarette healthy lungs of rats exposed to environmental cigarette smoke (ECS) for 28 days. lungs of rats Rat upregulated 18952709 2265 rno-mir-144 miR-144 miR-144 Bipolar disorder lithium and valproate long-term drug treatment rat hippocampus Rat upregulated 18704095 2266 rno-let-7a-1 rno-let-7a rno-let-7a Potential risk to Human health by furan in various foods furan rat liver treated with furan concentrations of 0.1 and 2 mg/kg bw rat liver Rat upregulated 20562052 2267 rno-let-7a-2 rno-let-7a rno-let-7a Potential risk to Human health by furan in various foods furan rat liver treated with furan concentrations of 0.1 and 2 mg/kg bw rat liver Rat upregulated 20562052 2268 rno-mir-28 rno-miR-28 rno-miR-28 Potential risk to Human health by furan in various foods furan rat liver treated with furan concentrations of 0.1 and 2 mg/kg bw rat liver Rat upregulated 20562052 2269 rno-mir-125a rno-miR-125a-5p rno-miR-125a-5p Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2270 rno-mir-137 rno-miR-137 rno-miR-137 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2271 rno-mir-140 rno-miR-140* rno-miR-140* Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2272 rno-mir-154 rno-miR-154 rno-miR-154 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2273 rno-mir-185 rno-miR-185 rno-miR-185 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2274 rno-mir-200a rno-miR-200a rno-miR-200a Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2275 rno-mir-203 rno-miR-203 rno-miR-203 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2276 rno-mir-210 rno-miR-210 rno-miR-210 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2277 rno-mir-219-1 rno-miR-219-5p rno-miR-219-5p Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2278 rno-mir-219-2 rno-miR-219-5p rno-miR-219-5p Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2279 rno-mir-27b rno-miR-27b rno-miR-27b Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2280 rno-mir-30a rno-miR-30a* rno-miR-30a* Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2281 rno-mir-34a rno-miR-34a rno-miR-34a Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2282 rno-mir-34b rno-miR-34b rno-miR-34b Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2283 rno-mir-375 rno-miR-375 rno-miR-375 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2284 rno-mir-500 rno-miR-500 rno-miR-500 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2285 rno-mir-672 rno-miR-672 rno-miR-672 Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2286 rno-mir-7a-1 rno-miR-7a rno-miR-7a Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2287 rno-mir-7a-2 rno-miR-7a rno-miR-7a Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2288 rno-let-7d rno-miR-let-7d, rno-miR-let-7d, Damage of rat small intestine heat stress Male Sprague-Dawley rats were subjected to 2 h of heat stress daily for ten consecutive days. rat small intestine Rat upregulated 21057845 2289 rno-mir-34a rno-miR-34a rno-miR-34a Hepatic fibrosis diethylnitrosamine (DEN) dimethylnitrosamine induce rats Rat upregulated 21366874 2290 rno-mir-34b rno-miR-34b rno-miR-34b Hepatic fibrosis diethylnitrosamine (DEN) dimethylnitrosamine induce rats Rat upregulated 21366874 2291 rno-mir-34c rno-miR-34c rno-miR-34c Hepatic fibrosis diethylnitrosamine (DEN) dimethylnitrosamine induce rats Rat upregulated 21366874 2292 rno-mir-106b rno-miR-106b rno-miR-106b Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2293 rno-mir-128-1 rno-miR-128 rno-miR-128 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2294 rno-mir-128-2 rno-miR-128 rno-miR-128 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2295 rno-mir-130a rno-miR-130a rno-miR-130a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2296 rno-mir-130b rno-miR-130b rno-miR-130b Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2297 rno-mir-132 rno-miR-132 rno-miR-132 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2298 rno-mir-146b rno-miR-146b rno-miR-146b Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2299 rno-mir-148b rno-miR-148b-3p rno-miR-148b-3p Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2300 rno-mir-152 rno-miR-152 rno-miR-152 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2301 rno-mir-181a-1 rno-miR-181a rno-miR-181a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2302 rno-mir-181a-2 rno-miR-181a rno-miR-181a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2303 rno-mir-182 rno-miR-182 rno-miR-182 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2304 rno-mir-183 rno-miR-183 rno-miR-183 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2305 rno-mir-185 rno-miR-185 rno-miR-185 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2306 rno-mir-191 rno-miR-191 rno-miR-191 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2307 rno-mir-199a rno-miR-199a-3p rno-miR-199a-3p Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2308 rno-mir-199a rno-miR-199a-5p rno-miR-199a-5p Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2309 rno-mir-200a rno-miR-200a rno-miR-200a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2310 rno-mir-200b rno-miR-200b rno-miR-200b Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2311 rno-mir-210 rno-miR-210 rno-miR-210 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2312 rno-mir-214 rno-miR-214 rno-miR-214 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2313 rno-mir-221 rno-miR-221 rno-miR-221 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2314 rno-mir-222 rno-miR-222 rno-miR-222 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2315 rno-mir-23a rno-miR-23a rno-miR-23a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2316 rno-mir-23b rno-miR-23b rno-miR-23b Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2317 rno-mir-24-1 rno-miR-24 rno-miR-24 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2318 rno-mir-24-2 rno-miR-24 rno-miR-24 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2319 rno-mir-29a rno-miR-29a rno-miR-29a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2320 rno-mir-30c-1 rno-miR-30c rno-miR-30c Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2321 rno-mir-30c-2 rno-miR-30c rno-miR-30c Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2322 rno-mir-328a rno-miR-328a rno-miR-328 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2323 rno-mir-328b rno-miR-328b rno-miR-328 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2324 rno-mir-34a rno-miR-34a rno-miR-34a Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2325 rno-mir-34c rno-miR-34c* rno-miR-34c* Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2326 rno-mir-429 rno-miR-429 rno-miR-429 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2327 rno-mir-505 rno-miR-505 rno-miR-505 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2328 rno-mir-93 rno-miR-93 rno-miR-93 Cancer comfrey diet containing 8% comfrey root rats fed with a normal diet or a diet containing 8% comfrey root Rat upregulated 21370286 2329 rno-mir-101a miR-101a miR-101a Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2330 rno-mir-10a miR-10a miR-10a Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2331 rno-mir-181c miR-181c miR-181c Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2332 rno-mir-20b miR-20b miR-20b Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2333 rno-mir-21 miR-21 miR-21 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2334 rno-mir-214 miR-214 miR-214 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2335 rno-mir-25 miR-25 miR-25 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2336 rno-mir-27a miR-27a miR-27a Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2337 rno-mir-27a miR-27a miR-27a Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2338 rno-mir-27b miR-27b miR-27b Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2339 rno-mir-29c miR-29c miR-29c Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2340 rno-mir-31 miR-31 miR-31 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2341 rno-mir-324 miR-324-3p miR-324-3p Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2342 rno-mir-339 miR-339-5p miR-339-5p Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2343 rno-mir-345 miR-345-5p miR-345-5p Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2344 rno-mir-351 miR-351 miR-351 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2345 rno-mir-539 miR-539 miR-539 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2346 rno-mir-667 miR-667 miR-667 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2347 n/a miR-687 miR-687 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2348 rno-mir-760 miR-760 miR-760 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2349 rno-mir-9-1 miR-9 miR-9 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2350 rno-mir-9-2 miR-9 miR-9 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2351 rno-mir-9-3 miR-9 miR-9 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2352 rno-mir-24-1 rno-miR-24-1 rno-miR-24-1 Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2353 rno-mir-345 rno-miR-345-3p rno-miR-345-3p Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2354 rno-mir-450a rno-miR-450a rno-miR-450a Cardioprotection Longevinex Longevinex treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2355 rno-mir-101a miR-101a miR-101a Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2356 rno-mir-10a miR-10a miR-10a Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2357 rno-mir-181c miR-181c miR-181c Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2358 rno-mir-21 miR-21 miR-21 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2359 rno-mir-214 miR-214 miR-214 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2360 rno-mir-25 miR-25 miR-25 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2361 rno-mir-27a miR-27a miR-27a Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2362 rno-mir-27a miR-27a miR-27a Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2363 rno-mir-29c miR-29c miR-29c Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2364 rno-mir-31 miR-31 miR-31 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2365 rno-mir-324 miR-324-3p miR-324-3p Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2366 rno-mir-339 miR-339-5p miR-339-5p Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2367 rno-mir-345 miR-345-5p miR-345-5p Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2368 rno-mir-351 miR-351 miR-351 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2369 rno-mir-539 miR-539 miR-539 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2370 rno-mir-667 miR-667 miR-667 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2371 n/a miR-687 miR-687 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2372 rno-mir-9-1 miR-9 miR-9 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2373 rno-mir-9-2 miR-9 miR-9 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2374 rno-mir-9-3 miR-9 miR-9 Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2375 rno-mir-345 rno-miR-345-3p rno-miR-345-3p Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2376 rno-mir-450a rno-miR-450a rno-miR-450a Cardioprotection Resveratrol Resveratrol treatment ischemia/reperfusion model of rat Rat upregulated compared with basal line 21203465 2377 rno-mir-122 miR-122a miR-122a n/a vitamin E VE-deficiency diets rats Rat VE-deficiency resulted in reduced concentrations of miRNA-122a and miRNA-125b 18817776 2378 rno-mir-125b-1 miR-125b miR-125b n/a vitamin E VE-deficiency diets rats Rat VE-deficiency resulted in reduced concentrations of miRNA-122a and miRNA-125b 18817776 2379 rno-mir-125b-2 miR-125b miR-125b n/a vitamin E VE-deficiency diets rats Rat VE-deficiency resulted in reduced concentrations of miRNA-122a and miRNA-125b 18817776 2380 rno-mir-298 miR-298 miR-298 n/a acetaminophen (APAP) or carbon tetrachloride(CCL4) acetaminophen (APAP) or carbon tetrachloride(CCL4)treatment rat liver Rat changes in expression 17965554 2381 rno-mir-370 miR-370 miR-370 n/a acetaminophen (APAP) or carbon tetrachloride(CCL4) acetaminophen (APAP) or carbon tetrachloride(CCL4)treatment rat liver Rat changes in expression 17965554 2382 rno-mir-130a miR-130a miR-130 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2383 rno-mir-130b miR-130b miR-130 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2384 rno-mir-17-92 miR-17-92 miR-17-92 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2385 rno-mir-190 miR-190 miR-190 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2386 rno-mir-23a miR-23a miR-23 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2387 rno-mir-23b miR-23b miR-23 n/a folate/methyl folate/methyl-deficient diet rats Rat animals fed the folate/methyl-deficient diet showed increased expression of let-7a, miR-21, miR-23, miR-130, miR-190, and miR-17-92 and decreased expression of miR-122 compared to livers of rats on the normal diet 18667010 2388 n/a miR-1 miR-1 Mammalian hibernation torpor hibernating bat Bat Expression levels of miR-1, -29b, -181b and -23a were elevated significantly in torpid bats. 21177365 2389 n/a miR-181b miR-181b Mammalian hibernation torpor hibernating bat Bat Expression levels of miR-1, -29b, -181b and -23a were elevated significantly in torpid bats. 21177365 2390 n/a miR-23a miR-23a Mammalian hibernation torpor hibernating bat Bat Expression levels of miR-1, -29b, -181b and -23a were elevated significantly in torpid bats. 21177365 2391 n/a miR-29b miR-29b Mammalian hibernation torpor hibernating bat Bat Expression levels of miR-1, -29b, -181b and -23a were elevated significantly in torpid bats. 21177365 2392 cel-lin-4 lin-4 lin-4 Adaptation to nutrient deprivation nutrient nutrient deprivation Caenorhabditis elegans C.elegans Nutrient deprivation results in loss of lin-14 mRNA, but not protein, repression. In worms removed from feeding conditions, lin-14 mRNA reaccumulates despite the continued expression of lin-4 miRNA.The relative increase in lin-14 mRNA levels during nutrient deprivation is less pronounced in genetic mutants lacking lin-4 miRNA or the lin-14 3'UTR target sites. 19155321 2393 cel-mir-34 miR-34 miR-34 Cellular survival response to radiation radiation radiation treatment Caenorhabditis elegans C.elegans Caenorhabditis elegans with loss-of-function mutations in the mir-34 gene have an abnormal cellular survival response to radiation. 19421141 2394 gga-mir-181b miR-181b miR-181b Arsenic-induced diseases and developmental toxicity inorganic arsenic compounds arsenite administration chick embryos Chicken massive decrease in expression;miR-9 and mir-181b inhibited the arsenic-induced EA.hy926 cell migration and tube formation by targeting NRP1. 21503876 2395 gga-mir-9-1 miR-9 miR-9 Arsenic-induced diseases and developmental toxicity inorganic arsenic compounds arsenite administration chick embryos Chicken massive decrease in expression;miR-9 and mir-181b inhibited the arsenic-induced EA.hy926 cell migration and tube formation by targeting NRP1. 21503876 2396 gga-mir-9-2 miR-9 miR-9 Arsenic-induced diseases and developmental toxicity inorganic arsenic compounds arsenite administration chick embryos Chicken massive decrease in expression;miR-9 and mir-181b inhibited the arsenic-induced EA.hy926 cell migration and tube formation by targeting NRP1. 21503876 2397 gga-mir-202 miR-202* miR-202* Vertebrate gonadogenesis estradiol-17beta estradiol-17beta injection embryonic chicken gonads Chicken up-regulation of MIR202* coincides with testicular differentiation in embryonic chicken gonads. 21389341 2398 ptr-mir-122 miR-122 miR-122 Hepatocellular carcinoma hepatitis C virus (HCV) virus infection chimpanzee liver Chimpanzee miR-122 is essential for accumulation of HCV RNA in vivo 19965718 2399 ptr-mir-122 miR-122 miR-122 Hepatitis C SPC3649 SPC3649 treatment hepatitis C virus (HCV)-infected chimpanzee Chimpanzee Serum concentrations of cholesterol and HCV RNA were reduced in chimpanzees treated with 12 weekly intravenous infusions of SPC3649, a second-generation antisense RNA molecule that is complementary to the microRNA miR-122. 20371461 2400 cfa-mir-133a miR-133a miR-133 Atrial fibrillation (AF) nicotine nicotine treatment dog Dog Nicotine produced a 60-70% decrease in the levels of miRNAs miR-133 and miR-590. Profibrotic response to nicotine in canine atrium is critically dependent upon downregulation of miR-133 and miR-590. 19398468 2401 cfa-mir-133b miR-133b miR-133 Atrial fibrillation (AF) nicotine nicotine treatment dog Dog Nicotine produced a 60-70% decrease in the levels of miRNAs miR-133 and miR-590. Profibrotic response to nicotine in canine atrium is critically dependent upon downregulation of miR-133 and miR-590. 19398468 2402 cfa-mir-133c miR-133c miR-133 Atrial fibrillation (AF) nicotine nicotine treatment dog Dog Nicotine produced a 60-70% decrease in the levels of miRNAs miR-133 and miR-590. Profibrotic response to nicotine in canine atrium is critically dependent upon downregulation of miR-133 and miR-590. 19398468 2403 cfa-mir-590 miR-590 miR-590 Atrial fibrillation (AF) nicotine nicotine treatment dog Dog Nicotine produced a 60-70% decrease in the levels of miRNAs miR-133 and miR-590. Profibrotic response to nicotine in canine atrium is critically dependent upon downregulation of miR-133 and miR-590. 19398468 2404 xtr-mir-16a miR-16a miR-16 Reorganization of metabolic priorities temperature temperature below zero wood frog Frog miR-16 and miR-21 were evaluated using RT-PCR in liver and skeletal muscle of wood frogs (Rana sylvatica) comparing controls (5 degrees C acclimated) with animals frozen for 24h at -3 degrees C. Levels of miR-21 increased significantly during freezing by 1.5-fold and 1.3-fold in liver and skeletal muscle, respectively. MiR-16 transcripts also rose significantly by 1.5-fold in liver of frozen frogs but fell by 50% in skeletal muscle. 19735650 2405 xtr-mir-16b miR-16b miR-16 Reorganization of metabolic priorities temperature temperature below zero wood frog Frog miR-16 and miR-21 were evaluated using RT-PCR in liver and skeletal muscle of wood frogs (Rana sylvatica) comparing controls (5 degrees C acclimated) with animals frozen for 24h at -3 degrees C. Levels of miR-21 increased significantly during freezing by 1.5-fold and 1.3-fold in liver and skeletal muscle, respectively. MiR-16 transcripts also rose significantly by 1.5-fold in liver of frozen frogs but fell by 50% in skeletal muscle. 19735650 2406 xtr-mir-16c miR-16c miR-16 Reorganization of metabolic priorities temperature temperature below zero wood frog Frog miR-16 and miR-21 were evaluated using RT-PCR in liver and skeletal muscle of wood frogs (Rana sylvatica) comparing controls (5 degrees C acclimated) with animals frozen for 24h at -3 degrees C. Levels of miR-21 increased significantly during freezing by 1.5-fold and 1.3-fold in liver and skeletal muscle, respectively. MiR-16 transcripts also rose significantly by 1.5-fold in liver of frozen frogs but fell by 50% in skeletal muscle. 19735650 2407 n/a miR-21 miR-21 Reorganization of metabolic priorities temperature temperature below zero wood frog Frog miR-16 and miR-21 were evaluated using RT-PCR in liver and skeletal muscle of wood frogs (Rana sylvatica) comparing controls (5 degrees C acclimated) with animals frozen for 24h at -3 degrees C. Levels of miR-21 increased significantly during freezing by 1.5-fold and 1.3-fold in liver and skeletal muscle, respectively. MiR-16 transcripts also rose significantly by 1.5-fold in liver of frozen frogs but fell by 50% in skeletal muscle. 19735650 2408 bta-mir-484 miR-484 miR-484 Thermal tolerance thermal tolerance dairy cattle thermal tolerant breeding Chinese Holstein cattle Cow Cows with TT genotype had lower PCE (p < 0.01) and higher HTC (p < 0.05) at the 4693 position. Quantitative reverse transcription-polymerase chain reaction demonstrated that 4693-T mutation caused the disruption of microRNA target binding, resulting in the relief of the transcriptional repression, which, in turn, resulted in increased expression. Thus, the HSF1 gene is useful in dairy cattle thermal tolerant breeding. 21189066 2409 n/a miR-23b miR-23b n/a morphine long-term morphine treatment Mouse neuronal cells N2A and N2A-MOR and human neuronal cells NMB and SHSY-5Y Human;Mouse Long-term morphine treatment increases miRNA23b expression in a dose- and time-dependent manner and represses the association of MOR1 mRNA with polysomes through the MOR1 3'-UTR. 19144786 2410 n/a miR-14 miR-14 Insect cell apoptosis Actinomycin-D (Act-D) Actinomycin-D (Act-D) treatment lepidopteran insect cells Insect The mimics of miR-14 precursor molecules could partially inhibit the Act-D-induced Sf9 cell death. 20486901 2411 n/a miR-9 miR-9 n/a alcohol alcohol adult mammalian brain Mammalian animal alcohol upregulates microRNA miR-9 18667155 2412 n/a miR-34 miR-34 Cancer radiation radiation treatment mammalian Mammalian animal mammalian miR-34 is upregulated by p53 in response to radiation. mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer. 19421141 2413 n/a let-7d let-7d Neuroadaptive changes cocaine cocaine treatment HEK293 cells or rat brain parts Human;Rat downregulated 19703567 2414 n/a miR-124 miR-124 Neuroadaptive changes cocaine cocaine treatment HEK293 cells or rat brain parts Human;Rat downregulated 19703567 2415 ssc-mir-202 miR-202 miR-202 n/a psychosocial stress aggressive behaviour pig Pig mir-202 is a intronic miRNA hosted by LOC100039095, one of the most upregulated genes. 21266515 2416 ssc-mir-122 miR-122 miR-122 Obesity dietary high-fat young male minipigs fed either high-cholesterol diet for 11 wk Gottingen minipig Pig Pigs fed high-cholesterol had lower miRNA-122 levels than did those fed the standard diet. 20412689 2417 dre-mir-124-1 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2418 dre-mir-124-2 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2419 dre-mir-124-3 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2420 dre-mir-124-4 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2421 dre-mir-124-5 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2422 dre-mir-124-6 miR-124 miR-124a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2423 dre-mir-133a-1 miR-133a miR-133a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2424 dre-mir-133a-2 miR-133a miR-133a Retarded development of zebrafish embryos sodium thiosulfate (STS) sodium thiosulfate (STS) treatment Zebrafish Zebrafish miR-124a and miR-133a were deregulated in STS-treated embryos. 19273302 2425 dre-mir-125b-1 miR-125b miR-125b Response to DNA damage gamma-irradiation/camptothecin gamma-irradiation/camptothecin treatment zebrafish embryos Zebrafish miR-125b is down-regulated when zebrafish embryos are treated with gamma-irradiation or camptothecin, corresponding to the rapid increase in p53 protein in response to DNA damage. 19293287 2426 dre-mir-125b-2 miR-125b miR-125b Response to DNA damage gamma-irradiation/camptothecin gamma-irradiation/camptothecin treatment zebrafish embryos Zebrafish miR-125b is down-regulated when zebrafish embryos are treated with gamma-irradiation or camptothecin, corresponding to the rapid increase in p53 protein in response to DNA damage. 19293287 2427 dre-mir-125b-3 miR-125b miR-125b Response to DNA damage gamma-irradiation/camptothecin gamma-irradiation/camptothecin treatment zebrafish embryos Zebrafish miR-125b is down-regulated when zebrafish embryos are treated with gamma-irradiation or camptothecin, corresponding to the rapid increase in p53 protein in response to DNA damage. 19293287 2428 osa-MIR528 osa-miR528 miR528 cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly upregulated by Cadmium treatment 21362738 2429 osa-MIR162a osa-miR162a miR162a cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2430 osa-MIR168a osa-miR168a miR168a cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2431 osa-MIR168b osa-miR168b miR168b cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2432 osa-MIR166m osa-miR166m miR166m cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2433 osa-MIR166i osa-miR166i miR166i cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2434 osa-MIR166e osa-miR166e miR166e cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2435 osa-MIR166k osa-miR166k miR166k cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2436 osa-MIR166g osa-miR166g miR166g cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2437 osa-MIR171b osa-miR171b miR171b cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2438 osa-MIR171a osa-miR171a miR171a cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2439 osa-MIR171g osa-miR171g miR171g cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2440 osa-MIR396d osa-miR396d miR396d cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2441 osa-MIR390 osa-miR390 miR390 cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2442 osa-MIR156l osa-miR156l miR156l cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2443 osa-MIR156k osa-miR156k miR156k cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2444 osa-MIR156a osa-miR156a miR156a cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2445 osa-MIR1432 osa-miR1432 miR1432 cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2446 osa-MIR444b osa-miR444b.1 miR444b.1 cellular toxicity Cadmium 7-day-old seedlings were exposed to 60 njM CdCl2 for 24 h. Roots were harvested as a pool for each sample at 0, 3, 6, 12, and 24 h after Cd treatment. Seedlings not treated with Cd served as controls. seedling Rice highly downregulated by Cadmium treatment 21362738 2447 mmu-mir-21 miR-21 miR-21 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2448 mmu-mir-541 miR-541 miR-541 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2449 mmu-mir-29a miR-29a miR-29a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2450 mmu-mir-24-1 miR-24 miR-24 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2451 mmu-mir-24-2 miR-24 miR-24 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2452 mmu-mir-218-1 miR-218 miR-218 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2453 mmu-mir-218-2 miR-218 miR-218 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2454 mmu-mir-130a miR-130a miR-130a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2455 mmu-mir-374 miR-374 miR-374 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2456 mmu-mir-351 miR-351 miR-351 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2457 mmu-mir-222 miR-222 miR-222 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2458 mmu-mir-29c miR-29c miR-29c cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2459 mmu-mir-130b miR-130b miR-130b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2460 mmu-mir-146b miR-146b miR-146b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2461 mmu-mir-152 miR-152 miR-152 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2462 mmu-mir-182 miR-182 miR-182 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2463 mmu-mir-23b miR-23b miR-23b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2464 mmu-mir-99b miR-99b miR-99b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse downregulated by CdTe QD treatment 21376392 2465 mmu-mir-107 miR-107 miR-107 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2466 mmu-let-7i let-7i let-7i cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2467 mmu-mir-350 miR-350 miR-350 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2468 mmu-mir-196a-1 miR-196a miR-196a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2469 mmu-mir-196a-1 miR-196a miR-196a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2470 mmu-mir-669c miR-669c miR-669c cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2471 mmu-mir-204 miR-204 miR-204 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2472 mmu-mir-148b miR-148b miR-148b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2473 mmu-let-7b let-7b let-7b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2474 mmu-mir-451 miR-451 miR-451 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2475 mmu-mir-199b miR-199b miR-199b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2476 mmu-mir-128-1 miR-128 miR-128 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2477 mmu-mir-128-2 miR-128 miR-128 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2478 mmu-mir-202 miR-202 miR-202 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2479 mmu-mir-365-1 miR-365 miR-365 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2480 mmu-mir-365-2 miR-365 miR-365 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2481 mmu-mir-93 miR-93 miR-93 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2482 mmu-mir-22 miR-22 miR-22 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2483 mmu-mir-129-1 miR-129 miR-129 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2484 mmu-mir-129-1 miR-129 miR-129 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2485 mmu-let-7d let-7d let-7d cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2486 mmu-mir-199a-1 miR-199a miR-199a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2487 mmu-mir-199a-1 miR-199a miR-199a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2488 mmu-mir-30c-1 miR-30c miR-30c cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2489 mmu-mir-692-2 miR-692 miR-692 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2490 mmu-mir-692-1 miR-692 miR-692 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2491 mmu-let-7a-1 let-7a let-7a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2492 mmu-let-7a-2 let-7a let-7a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2493 mmu-mir-138-1 miR-138 miR-138 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2494 mmu-mir-138-2 miR-138 miR-138 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2495 mmu-mir-192 miR-192 miR-192 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2496 mmu-mir-125b-1 miR-125b miR-125b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2497 mmu-mir-125b-1 miR-125b miR-125b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2498 mmu-let-7f-1 let-7f let-7f cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2499 mmu-let-7f-1 let-7f let-7f cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2500 mmu-mir-29b-1 miR-29b miR-29b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2501 mmu-mir-29b-1 miR-29b miR-29b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2502 mmu-mir-34c miR-34c miR-34c cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2503 mmu-mir-221 miR-221 miR-221 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2504 mmu-mir-19b-1 miR-19b miR-19b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2505 mmu-mir-19b-1 miR-19b miR-19b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2506 mmu-mir-145 miR-145 miR-145 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2507 mmu-mir-34b miR-34b miR-34b cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2508 mmu-mir-31 miR-31 miR-31 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2509 mmu-mir-34a miR-34a miR-34a cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2510 mmu-mir-214 miR-214 miR-214 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2511 n/a n/a miR-689 cytotoxicity CdTe QD cells were incubated with CdTe QDs at terminal concentrations of 15 mg/ml, 30 mg/ml and 45 mg/ml for 12 h and 24 h, respectively. NIH/3T3 cells Mouse upregulated by CdTe QD treatment 21376392 2512 hsa-mir-181a-1 miR-181a miR-181a Non-small cell lung carcinoma (NSCLC) cisplatin cisplatin treatment A549 cells Human miR-181a and miR-630 regulate cisplatin-induced cancer cell death. 20145152 2513 hsa-mir-181a-2 miR-181a miR-181a Non-small cell lung carcinoma (NSCLC) cisplatin cisplatin treatment A549 cells Human miR-181a and miR-630 regulate cisplatin-induced cancer cell death. 20145152 2514 hsa-mir-630 miR-630 miR-630 Non-small cell lung carcinoma (NSCLC) cisplatin cisplatin treatment A549 cells Human miR-181a and miR-630 regulate cisplatin-induced cancer cell death. 20145152 2515 hsa-mir-146a miR-146a miR-146a responses to metal components Cadmium Cadmium exposure blood leukocyte RNA Human Postexposure expression of miR-146a was negatively correlated with exposure to lead (beta = -0.51, p = 0.011) and cadmium (beta = -0.42, p = 0.04). 20061215 2516 hsa-mir-146a miR-146a miR-146a responses to metal components Lead Lead exposure blood leukocyte RNA Human Postexposure expression of miR-146a was negatively correlated with exposure to lead (beta = -0.51, p = 0.011) and cadmium (beta = -0.42, p = 0.04). 20061215 2517 hsa-mir-222 miR-222 miR-222 responses to metal components Lead Lead exposure blood leukocyte RNA Human In postexposure samples, miR-222 expression was positively correlated with lead exposure 20061215 2518 hsa-mir-222 has-miR-222 has-miR-222 n/a folate folate-deficient diets lymphoblastoid cells Human Hsa-miR-222 is expressed at higher levels in subjects with folate-deficient diets. 17108120 2519 mmu-mir-101a miR-101a miR-101a n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2520 mmu-mir-101b miR-101b miR-101b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2521 mmu-mir-106a miR-106a miR-106a n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2522 mmu-mir-138-1 miR-138 miR-138 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2523 mmu-mir-138-2 miR-138 miR-138 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2524 mmu-mir-148b miR-148b miR-148b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2525 mmu-mir-18b miR-18b miR-18b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2526 mmu-mir-202 miR-202 miR-202 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2527 mmu-mir-203 miR-203 miR-203 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2528 mmu-mir-20a miR-20a miR-20a n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2529 mmu-mir-212 miR-212 miR-212 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2530 mmu-mir-291b miR-291b-5p miR-291b-5p n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2531 mmu-mir-292 miR-292-5p miR-292-5p n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2532 mmu-mir-29b-1 miR-29b miR-29b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2533 mmu-mir-29b-2 miR-29b miR-29b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2534 mmu-mir-29c miR-29c miR-29c n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2535 mmu-mir-30b miR-30b miR-30b n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2536 mmu-mir-33 miR-33 miR-33 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2537 mmu-mir-345 miR-345 miR-345 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2538 mmu-mir-346 miR-346 miR-346 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2539 n/a n/a miR-373* n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2540 mmu-mir-381 miR-381 miR-381 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2541 mmu-mir-433 miR-433 miR-433 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2542 mmu-mir-485 miR-485-3p miR-485-3p n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2543 n/a n/a miR-498 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2544 n/a n/a miR-519d n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2545 mmu-mir-542 miR-542-5p miR-542-5p n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse downregulated 17698510 2546 mmu-mir-92a-1 miR-92a miR-92 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2547 mmu-mir-92a-2 miR-92a miR-92 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2548 mmu-mir-92b miR-92b miR-92 n/a dioxin male Ahr-null (Ahr?/?) mice in a C57BL/6J background (10 weeks old) and WT (Ahr+/+) C57BL/6J mice (15 weeks old) were given a single dose of 1000 njg/kg TCDD or corn oil vehicle by gavage. Liver was harvested 19 h after treatment. We tested three TCDD-treated and three control mice in the Ahr?/? groups and four TCDD-treated and four control mice in the Ahr+/+ groups. Liver Mouse upregulated 17698510 2549 mmu-mir-101a miR-101a miR-101a Liver damage 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure Liver Mouse miR-101a and miR-122 are differentially downregulated by TCDD in a time-dependent manner. 21602190 2550 mmu-mir-122 miR-122 miR-122 Liver damage 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure Liver Mouse miR-101a and miR-122 are differentially downregulated by TCDD in a time-dependent manner. 21602190 2551 hsa-mir-191 miR-191 miR-191 Hepatocellular carcinoma stem cell dioxin dioxin treatment HCC cells Human miR-191 was found to be upregulated by a dioxin, a known liver carcinogen, and was found to be a regulator of a variety of cancer-related pathways. Our findings offer a preclinical proof of concept for miR-191 targeting as a rational strategy to pursue for improving HCC treatment. 20924108 2552 hsa-mir-190 miR-190 miR-190 carcinogenesis arsenic arsenic induce bronchial epithelial cells Human miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. 21750348 2553 hsa-mir-200b miR-200b miR-200b Cancer arsenic arsenic induce Bronchial Epithelial Cell Human Reversal and Prevention of Arsenic-Induced Human Bronchial Epithelial Cell Malignant Transformation by MicroRNA-200b. 21670143 2554 hsa-mir-9-3 miR-9 miR-9 Breast cancer diethylstilbestrol diethylstilbestrol exposure breast epithelial cells Human miR-9-3, in epithelial cells preexposed to diethylstilbestrol 19549897 2555 hsa-mir-146a miR-146a miR-146a n/a bisphenol A (BPA) bisphenol A (BPA) exposure human placental cells Human miR-146a was particularly strongly induced and its overexpression in cells led to slower proliferation as well as higher sensitivity to the DNA damaging agent, bleomycin. Overall, these results suggest that BPA can alter miRNA expression in placental cells, a potentially novel mode of BPA toxicity. 20417706 2556 hsa-mir-181b-1 miR-181b miR-181b Gastric cancer Doxifluridine Doxifluridine treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2557 hsa-mir-181b-2 miR-181b miR-181b Gastric cancer Doxifluridine Doxifluridine treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2558 hsa-mir-21 miR-21 miR-21 Gastric cancer Doxifluridine Doxifluridine treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2559 hsa-mir-181b-1 miR-181b miR-181b Gastric cancer Oxaliplatin Oxaliplatin treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2560 hsa-mir-181b-2 miR-181b miR-181b Gastric cancer Oxaliplatin Oxaliplatin treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2561 hsa-mir-21 miR-21 miR-21 Gastric cancer Oxaliplatin Oxaliplatin treatment gastric tissue Human Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. 21876743 2562 hsa-mir-138-1 miR-138 miR-138 n/a folate folate diet embryos Human Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p. In our model, folate reversed these epigenetic marks in folate-rescued Sp(-/-) embryos. 20833714 2563 hsa-mir-138-2 miR-138 miR-138 n/a folate folate diet embryos Human Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p. In our model, folate reversed these epigenetic marks in folate-rescued Sp(-/-) embryos. 20833714 2564 hsa-mir-148a miR-148a miR-148a n/a folate folate diet embryos Human Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p. In our model, folate reversed these epigenetic marks in folate-rescued Sp(-/-) embryos. 20833714 2565 hsa-mir-185 miR-185 miR-185 n/a folate folate diet embryos Human Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p. In our model, folate reversed these epigenetic marks in folate-rescued Sp(-/-) embryos. 20833714 2566 hsa-mir-339 miR-339-5p miR-339-5p n/a folate folate diet embryos Human Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p. In our model, folate reversed these epigenetic marks in folate-rescued Sp(-/-) embryos. 20833714 2567 hsa-mir-203 miR-203 miR-203 Bladder cancer Curcumin Curcumin treatment bladder cancer cell Human Curcumin modulates microRNA-203 mediated regulation of the Src-Akt axis in bladder cancer. 21836020 2568 hsa-mir-125b miR-125b miR-125b Ovarian cancer cisplatin Cisplatin treatment ovarian cancer cell Human miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. 21823019 2569 hsa-mir-21 miR-21 miR-21 Breast cancer 3,3'-Diindolylmethane (DIM) 3,3'-Diindolylmethane (DIM) treatment breast cancer cell Human 3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation. 21761201 2570 hsa-mir-542 miR-542-3p miR-542-3p carcinogenesis anti-benzo(a) pyrene-7,8-diol-9,10-epoxide anti-benzo(a) pyrene-7,8-diol-9,10-epoxide induce cancer cell Human miR-542-3p affects carcinogenesis induced by anti-benzo(a) pyrene-7,8-diol-9,10-epoxide 21756784 2571 hsa-mir-199a miR-199a-5p miR-199a-5p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2572 hsa-mir-302f miR-302f miR-302f Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2573 hsa-mir-302a miR-320a miR-320a Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2574 hsa-mir-342 miR-342-3p miR-342-3p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2575 hsa-mir-425 miR-425 miR-425 Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2576 hsa-mir-455 miR-455-3p miR-455-3p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2577 hsa-mir-486 miR-486-3p miR-486-3p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2578 hsa-mir-519c miR-519c-5p miR-519c-5p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2579 hsa-mir-548d miR-548d-5p miR-548d-5p Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2580 hsa-mir-617 miR-617 miR-617 Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2581 hsa-mir-758 miR-758 miR-758 Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2582 hsa-mir-766 miR-766 miR-766 Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2583 hsa-mir-1286 miR-1286 miR-1286 Esophageal Cancer cisplatin Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. esophageal carcinoma cell Human Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy. 21743970 2584 hsa-mir-21 miR-21 miR-21 Myeloma dexamethasone (Dex), doxorubicin (Dox), or bortezomib combination treatment of dexamethasone (Dex), doxorubicin (Dox), or bortezomib myeloma cell Human Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. 21718132 2585 hsa-mir-34a miR-34a miR-34a Bladder cancer cisplatin Cisplatin treatment bladder cancer cell Human MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. 21702042 2586 hsa-mir-451 miR-451 miR-451 Breast cancer Tamoxifen Tamoxifen treatment breast cancer cell Human Tamoxifen downregulation of miR-451 increases 14-3-3dž and promotes breast cancer cell survival and endocrine resistance 21666713 2587 hsa-mir-195 miR-195 miR-195 cardiomyocyte apoptosis palmitate palmitate stimulated cultured neonatal mouse cardiomyocytes Human MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. 21622680 2588 hsa-mir-98 miR-98 miR-98 Non-small cell lung carcinoma (NSCLC) cisplatin Cisplatin treatment A549 cell Human miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. 21880462 2589 hsa-mir-29a miR-29a miR-29a Acute myeloid Leukemia cytarabine cytarabine treatment adult cytogenetically normal acute myeloid leukemia patient samples Human miR-29a and miR-30c might contribute to the sensitivity to cytarabine 21880628 2590 hsa-mir-30c-1 miR-30c miR-30c Acute myeloid Leukemia cytarabine cytarabine treatment adult cytogenetically normal acute myeloid leukemia patient samples Human miR-29a and miR-30c might contribute to the sensitivity to cytarabine 21880628 2591 hsa-mir-30c-1 miR-30c miR-30c Acute myeloid Leukemia cytarabine cytarabine treatment adult cytogenetically normal acute myeloid leukemia patient samples Human miR-29a and miR-30c might contribute to the sensitivity to cytarabine 21880628 2592 hsa-mir-26b miR-26b miR-26b Lung Cancer ionizing radiation ǃ-irradiation treatment H1299 lung cancer cells Human Expression of miR-26b was down regulated, and its target activating transcription factor 2 (ATF2) mRNA was up regulated in ǃ-irradiated H1299 cells. 21901137 2593 mmu-mir-210 miR-210 miR-210 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2594 mmu-mir-96 miR-96 miR-96 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2595 mmu-mir-182 miR-182 miR-182 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2596 mmu-mir-183 miR-183 miR-183 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2597 mmu-mir-200b miR-200b miR-200b Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2598 mmu-mir-429 miR-429 miR-429 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2599 mmu-mir-141 miR-141 miR-141 Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2600 mmu-mir-126 miR-126-5p miR-126b-5p Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2601 mmu-mir-30d miR-30d miR-30d Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2602 mmu-mir-30b miR-30b miR-30b Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2603 mmu-mir-27b miR-27b miR-27b Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2604 mmu-mir-23b miR-23b miR-23b Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2605 mmu-mir-135b miR-135b miR-135b Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2606 mmu-mir-881 miR-881* miR-881* Ehrlich ascites tumor doxorubicin/cisplatin drug treatment Ehrlich ascites tumor cell Mouse differentially expressed in sensitive (EHR2) and resistant EAT cells. 21899346 2607 hsa-let-7a-1 hsa-let-7a hsa-let-7a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2608 hsa-let-7a-2 hsa-let-7a hsa-let-7a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2609 hsa-let-7a-3 hsa-let-7a hsa-let-7a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2610 hsa-mir-105 hsa-miR-105 hsa-miR-105 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2611 hsa-mir-106a hsa-miR-106a hsa-miR-106a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2612 hsa-mir-10b hsa-miR-10b hsa-miR-10b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2613 hsa-mir-146a hsa-miR-146a hsa-miR-146a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2614 hsa-mir-148b hsa-miR-148b hsa-miR-148b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2615 hsa-mir-17 hsa-miR-17-3p hsa-miR-17-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2616 hsa-mir-17 hsa-miR-17-5p hsa-miR-17-5p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2617 hsa-mir-182 hsa-miR-182* hsa-miR-182* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2618 hsa-mir-193a hsa-miR-193a hsa-miR-193a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2619 hsa-mir-196a-1 hsa-miR-196a hsa-miR-196a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2620 hsa-mir-196a-2 hsa-miR-196a hsa-miR-196a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2621 hsa-mir-205 hsa-miR-205 hsa-miR-205 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2622 hsa-mir-21 hsa-miR-21 hsa-miR-21 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2623 hsa-mir-210 hsa-miR-210 hsa-miR-210 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2624 hsa-mir-217 hsa-miR-217 hsa-miR-217 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2625 hsa-mir-222 hsa-miR-222 hsa-miR-222 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2626 hsa-mir-25 hsa-miR-25 hsa-miR-25 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2627 hsa-mir-29a hsa-miR-29a hsa-miR-29a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2628 hsa-mir-302b hsa-miR-302b* hsa-miR-302b*_MM2 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2629 hsa-mir-302c hsa-miR-302c* hsa-miR-302c* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2630 hsa-mir-30a hsa-miR-30a-5p hsa-miR-30a-5p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2631 hsa-mir-34c hsa-miR-34c hsa-miR-34c Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2632 hsa-mir-372 hsa-miR-372 hsa-miR-372 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2633 hsa-mir-376a-1 hsa-miR-376a hsa-miR-376a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2634 hsa-mir-376a-2 hsa-miR-376a hsa-miR-376a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2635 hsa-mir-379 hsa-miR-379 hsa-miR-379 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2636 hsa-mir-432 hsa-miR-432 hsa-miR-432 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2637 hsa-mir-450a-1 hsa-miR-450a hsa-miR-450 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2638 hsa-mir-450a-2 hsa-miR-450a hsa-miR-450 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2639 hsa-mir-450b hsa-miR-450b hsa-miR-450 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2640 hsa-mir-493 hsa-miR-493-3p hsa-miR-493-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2641 hsa-mir-508 hsa-miR-508 hsa-miR-508 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2642 hsa-mir-517c hsa-miR-517c hsa-miR-517c Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2643 hsa-mir-519e hsa-miR-519e hsa-miR-519e Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2644 hsa-mir-96 hsa-miR-96 hsa-miR-96 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2645 hsa-mir-98 hsa-miR-98 hsa-miR-98 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 2646 hsa-mir-107 hsa-miR-107 hsa-miR-107 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2647 hsa-mir-124a hsa-miR-124a hsa-miR-124a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2648 hsa-mir-125a hsa-miR-125a hsa-miR-125a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2649 hsa-mir-125b hsa-miR-125b hsa-miR-125b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2650 hsa-mir-133b hsa-miR-133b hsa-miR-133b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2651 hsa-mir-134 hsa-miR-134 hsa-miR-134 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2652 hsa-mir-139 hsa-miR-139 hsa-miR-139 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2653 hsa-mir-144 hsa-miR-144 hsa-miR-144 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2654 hsa-mir-150 hsa-miR-150 hsa-miR-150 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2655 hsa-mir-151 hsa-miR-151 hsa-miR-151 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2656 hsa-mir-181c hsa-miR-181c hsa-miR-181c Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2657 hsa-mir-18a hsa-miR-18a* hsa-miR-18a* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2658 hsa-mir-195 hsa-miR-195 hsa-miR-195 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2659 hsa-mir-197 hsa-miR-197 hsa-miR-197 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2660 hsa-mir-200a hsa-miR-200a* hsa-miR-200a* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2661 hsa-mir-202 hsa-miR-202 hsa-miR-202 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2662 hsa-mir-208a hsa-miR-208a hsa-miR-208 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2663 hsa-mir-208b hsa-miR-208b hsa-miR-208 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2664 hsa-mir-212 hsa-miR-212 hsa-miR-212 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2665 hsa-mir-214 hsa-miR-214 hsa-miR-214 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2666 hsa-mir-223 hsa-miR-223 hsa-miR-223 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2667 hsa-mir-24-1 hsa-miR-24 hsa-miR-24 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2668 hsa-mir-24-2 hsa-miR-24 hsa-miR-24 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2669 hsa-mir-296 hsa-miR-296 hsa-miR-296 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2670 hsa-mir-302c hsa-miR-302c* hsa-miR-302c* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2671 hsa-mir-30d hsa-miR-30d hsa-miR-30d Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2672 hsa-mir-320a hsa-miR-320a hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2673 hsa-mir-320b-1 hsa-miR-320b hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2674 hsa-mir-320b-2 hsa-miR-320b hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2675 hsa-mir-320c-1 hsa-miR-320c hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2676 hsa-mir-320c-1 hsa-miR-320c hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2677 hsa-mir-320d-1 hsa-miR-320d hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2678 hsa-mir-320d-1 hsa-miR-320d hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2679 hsa-mir-320e hsa-miR-320e hsa-miR-320 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2680 hsa-mir-324 hsa-miR-324-3p hsa-miR-324-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2681 hsa-mir-324 hsa-miR-324-5p hsa-miR-324-5p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2682 hsa-mir-326 hsa-miR-326 hsa-miR-326 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2683 hsa-mir-330 hsa-miR-330 hsa-miR-330 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2684 hsa-mir-345 hsa-miR-345 hsa-miR-345 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2685 hsa-mir-346 hsa-miR-346 hsa-miR-346 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2686 hsa-mir-361 hsa-miR-361 hsa-miR-361 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2687 hsa-mir-365-1 hsa-miR-365 hsa-miR-365 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2688 hsa-mir-365-2 hsa-miR-365 hsa-miR-365 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2689 hsa-mir-370 hsa-miR-370 hsa-miR-370 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2690 hsa-mir-373 hsa-miR-373* hsa-miR-373* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2691 hsa-mir-381 hsa-miR-381 hsa-miR-381 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2692 hsa-mir-381 hsa-miR-381 hsa-miR-381 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2693 hsa-mir-409 hsa-miR-409-3p hsa-miR-409-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2694 hsa-mir-409 hsa-miR-409-5p hsa-miR-409-5p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2695 hsa-mir-378 hsa-miR-378 hsa-miR-422b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2696 hsa-mir-423 hsa-miR-423 hsa-miR-423 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2697 hsa-mir-483 hsa-miR-483 hsa-miR-483 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2698 hsa-mir-484 hsa-miR-484 hsa-miR-484 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2699 hsa-mir-485 hsa-miR-485-3p hsa-miR-485-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2700 hsa-mir-486 hsa-miR-486 hsa-miR-486 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2701 hsa-mir-489 hsa-miR-489 hsa-miR-489 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2702 hsa-mir-490 hsa-miR-490 hsa-miR-490 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2703 hsa-mir-492 hsa-miR-492 hsa-miR-492 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2704 hsa-mir-498 hsa-miR-498 hsa-miR-498 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2705 hsa-mir-500 hsa-miR-500 hsa-miR-500 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2706 hsa-mir-503 hsa-miR-503 hsa-miR-503 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2707 hsa-mir-518b hsa-miR-518b hsa-miR-518b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2708 hsa-mir-519e hsa-miR-519e* hsa-miR-519e* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2709 hsa-mir-520d hsa-miR-520d* hsa-miR-520d* Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2710 hsa-mir-526a-2 hsa-miR-526a hsa-miR-526 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2711 hsa-mir-526a-1 hsa-miR-526a hsa-miR-526 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2712 hsa-mir-526b hsa-miR-526b hsa-miR-526 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2713 hsa-mir-527 hsa-miR-527 hsa-miR-527 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2714 hsa-mir-542 hsa-miR-542-3p hsa-miR-542-3p Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2715 hsa-mir-92a-1 hsa-miR-92a hsa-miR-92 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2716 hsa-mir-92a-2 hsa-miR-92a hsa-miR-92 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2717 hsa-mir-92b hsa-miR-92b hsa-miR-92 Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2718 hsa-mir-99b hsa-miR-99b hsa-miR-99b Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-ǂ-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was down-regulated in HepG2 cells treated with BJA32515. 22027761 2719 hsa-mir-155 hsa-miR-155 hsa-miR-155 Lung cancer irradiation irradiation treatment lung cancer cell Human we find that increased levels of miR-155 radioprotects lung cancer cells, while inhibition of miR-155 radiosensitizes these cells. Moreover, we reveal a therapeutically important link between miR-155 expression, hypoxia, and irradiation by demonstrating that anti-miR-155 molecules also sensitize hypoxic lung cancer cells to irradiation. 22027557 2720 mmu-mir-222 mmu-miR-222 mmu-miR-222 Breast cancer tamoxifen tamoxifen treatment tamoxifen resistant MCF-7 (OHTR) cells Mouse Anti-miR-222 and -181B suppresses growth of tamoxifen resistant xenografts in mouse by targeting TIMP3 and modulating mitogenic signal. 22009755 2721 mmu-mir-181b-1 mmu-miR-181b mmu-miR-181b Breast cancer tamoxifen tamoxifen treatment tamoxifen resistant MCF-7 (OHTR) cells Mouse Anti-miR-222 and -181B suppresses growth of tamoxifen resistant xenografts in mouse by targeting TIMP3 and modulating mitogenic signal. 22009755 2722 mmu-mir-181b-2 mmu-miR-181b mmu-miR-181b Breast cancer tamoxifen tamoxifen treatment tamoxifen resistant MCF-7 (OHTR) cells Mouse Anti-miR-222 and -181B suppresses growth of tamoxifen resistant xenografts in mouse by targeting TIMP3 and modulating mitogenic signal. 22009755 2723 mmu-mir-467b mmu-miR-467b mmu-miR-467b Hepatic Steatosis diet High fat diet liver tissues Mouse High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. 21986524 2724 hsa-mir-1224 hsa-miR-1224-3p hsa-miR-1224-3p Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-1224-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2725 hsa-mir-449b hsa-miR-449b* hsa-miR-449b* Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-449b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2726 hsa-mir-197 hsa-miR-197 hsa-miR-197 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-197 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2727 hsa-mir-1249 hsa-miR-1249 hsa-miR-1249 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-1249 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2728 hsa-mir-1234 hsa-miR-1234 hsa-miR-1234 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-1234 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2729 hsa-mir-532 hsa-miR-532-3p hsa-miR-532-3p Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-532-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2730 hsa-mir-15b hsa-miR-15b* hsa-miR-15b* Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-15b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2731 hsa-mir-522 hsa-miR-522 hsa-miR-522 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-522 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2732 hsa-mir-744 hsa-miR-744* hsa-miR-744* Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-744* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2733 hsa-mir-2110 hsa-miR-2110 hsa-miR-2110 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-2110 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2734 hsa-mir-483 hsa-miR-483-5p hsa-miR-483-5p Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-483-5p was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2735 hsa-mir-320c-1 hsa-miR-320c hsa-miR-320c Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2736 hsa-mir-320c-2 hsa-miR-320c hsa-miR-320c Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2737 hsa-mir-323b hsa-miR-323b hsa-miR-323b Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-453 (note: this miRNA was replaced by hsa-mir-323b) was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2738 hsa-mir-1290 hsa-miR-1290 hsa-miR-1290 Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-1290 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2739 hsa-mir-30b hsa-miR-30b* hsa-miR-30b* Carcinoma, Hepatocellular grape seed proanthocyanidin grape seed proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-30b* was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. 21998738 2740 hsa-mir-197 hsa-miR-197 hsa-miR-197 Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-197 was up-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2741 hsa-mir-1224 hsa-miR-1224-3p hsa-miR-1224-3p Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-1224-3p was up-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2742 hsa-mir-532 hsa-miR-532-3p hsa-miR-532-3p Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-532-3p was up-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2743 hsa-mir-765 hsa-miR-765 hsa-miR-765 Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-765 was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2744 hsa-mir-187 hsa-miR-187* hsa-miR-187* Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-187* was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2745 hsa-mir-30b hsa-miR-30b hsa-miR-30b Carcinoma, Hepatocellular cocoa proanthocyanidin cocoa proanthocyanidin treatment HepG2 human hepatocarcinoma cells Human hsa-miR-30b was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. 21998738 2746 hsa-mir-30b hsa-miR-30b* hsa-miR-30b* Carcinoma, Hepatocellular epigallocatechin gallate epigallocatechin gallate treatment HepG2 human hepatocarcinoma cells Human hsa-miR-30b* was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 2747 hsa-mir-323b hsa-miR-323b hsa-miR-323b Carcinoma, Hepatocellular epigallocatechin gallate epigallocatechin gallate treatment HepG2 human hepatocarcinoma cells Human hsa-miR-453 (note: this miRNA was replaced by hsa-mir-323b) was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 2748 hsa-mir-520e hsa-miR-520e hsa-miR-520e Carcinoma, Hepatocellular epigallocatechin gallate epigallocatechin gallate treatment HepG2 human hepatocarcinoma cells Human hsa-miR-520e was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 2749 hsa-mir-629 hsa-miR-629 hsa-miR-629 Carcinoma, Hepatocellular epigallocatechin gallate epigallocatechin gallate treatment HepG2 human hepatocarcinoma cells Human hsa-miR-629 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 2750 hsa-mir-608 hsa-miR-608 hsa-miR-608 Carcinoma, Hepatocellular epigallocatechin gallate epigallocatechin gallate treatment HepG2 human hepatocarcinoma cells Human hsa-miR-608 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. 21998738 2751 rno-mir-192 miR-192 miR-192 renal fibrosis paclitaxel Rats in groups of 12 were subjected to 5/6 nephrectomy and received low-dose intraperitoneal injection of paclitaxel. kidney Rat paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney. In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-ǂ1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and ǁ-SMA expression. Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity. Over-expression of miR-192 in NRK-52E mimicked the changes seen in the remnant kidney, while inclusion of miR-192 inhibitor in the culture medium blocked TGF-ǂ1-induced COL(I)A1 and COL(IV)A2 expression, while ILK and ǁ-SMA were unaffected. These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-ǂ/Smad signalling. 21984124 2752 rno-mir-217 rno-miR-217 rno-miR-217 renal fibrosis paclitaxel Rats in groups of 12 were subjected to 5/6 nephrectomy and received low-dose intraperitoneal injection of paclitaxel. kidney Rat paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney. In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-ǂ1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and ǁ-SMA expression. Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity. Over-expression of miR-192 in NRK-52E mimicked the changes seen in the remnant kidney, while inclusion of miR-192 inhibitor in the culture medium blocked TGF-ǂ1-induced COL(I)A1 and COL(IV)A2 expression, while ILK and ǁ-SMA were unaffected. These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-ǂ/Smad signalling. 21984124 2753 rno-mir-377 rno-miR-377 rno-miR-377 renal fibrosis paclitaxel Rats in groups of 12 were subjected to 5/6 nephrectomy and received low-dose intraperitoneal injection of paclitaxel. kidney Rat paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney. In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-ǂ1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and ǁ-SMA expression. Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity. Over-expression of miR-192 in NRK-52E mimicked the changes seen in the remnant kidney, while inclusion of miR-192 inhibitor in the culture medium blocked TGF-ǂ1-induced COL(I)A1 and COL(IV)A2 expression, while ILK and ǁ-SMA were unaffected. These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-ǂ/Smad signalling. 21984124 2754 rno-mir-15 rno-miR-15 rno-miR-15 renal fibrosis paclitaxel Rats in groups of 12 were subjected to 5/6 nephrectomy and received low-dose intraperitoneal injection of paclitaxel. kidney Rat paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney. In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-ǂ1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and ǁ-SMA expression. Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity. Over-expression of miR-192 in NRK-52E mimicked the changes seen in the remnant kidney, while inclusion of miR-192 inhibitor in the culture medium blocked TGF-ǂ1-induced COL(I)A1 and COL(IV)A2 expression, while ILK and ǁ-SMA were unaffected. These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-ǂ/Smad signalling. 21984124 2755 hsa-mir-146a hsa-miR-146a hsa-miR-146a Carcinoma, Hepatocellular interferon-ǁ interferon-ǁ treatment IFN-ǁ-resistant clones of PLC/PRF/5 (PLC-Rs) and their parental cells (PLC-P) Human miR-146a suppresses the sensitivity to interferon-ǁ in hepatocellular carcinoma cells. 21982769 2756 mmu-mir-34 mmu-miR-34 mmu-miR-34 Anxiety stress stress induce the central amygdala (CeA) of adult mice Mouse One of the prominent stress-induced microRNAs found in this screen, miR-34c, was further confirmed to be upregulated after acute and chronic stressful challenge and downregulated in Dicer ablated cells. Lentivirally mediated overexpression of miR34c specifically within the adult CeA induced anxiolytic behavior after challenge. Of particular interest, one of the miR-34c targets is the stress-related corticotropin releasing factor receptor type 1 (CRFR1) mRNA, regulated via a single evolutionary conserved seed complementary site on its 3' UTR. Additional in vitro studies demonstrated that miR-34c reduces the responsiveness of cells to CRF in neuronal cells endogenously expressing CRFR1. Our results suggest a physiological role for microRNAs in regulating the central stress response and position them as potential targets for treatment of stress-related disorders. 21976504 2757 hsa-mir-210 hsa-miR-210 hsa-miR-210 Lung cancer (-)-Epigallocatechin-3-gallate (EGCG) (-)-Epigallocatechin-3-gallate (EGCG) treatment lung cancer cell Human Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1{alpha} 21965273 2758 mmu-mir-34a mmu-miR-34a mmu-miR-34a Liver cancer susceptibility Benzo(a)pyrene (BaP) Adult male mice were exposed by oral gavage to 25, 50, and 75 mg/kg/day BaP for 28 days. Liver tissue was collected 3 days following the last treatment. Mouse In this study, we found a significant 2.0 and 3.6-fold increase following exposure to 50 and 75 mg/kg/day BaP, respectively, relative to controls for miR-34a. This miRNA is involved in p53 response. 21964900 2759 hsa-mir-29a hsa-miR-29a hsa-miR-29a Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2760 hsa-mir-16-1 hsa-miR-16 hsa-miR-16 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2761 hsa-mir-16-2 hsa-miR-16 hsa-miR-16 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2762 hsa-mir-22 hsa-miR-22 hsa-miR-22 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2763 hsa-mir-20b hsa-miR-20b hsa-miR-20b Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2764 hsa-mir-29c hsa-miR-29c hsa-miR-29c Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2765 hsa-mir-30c-1 hsa-miR-30c hsa-miR-30c Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2766 hsa-mir-30c-2 hsa-miR-30c hsa-miR-30c Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2767 hsa-mir-17 hsa-miR-17 hsa-miR-17 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2768 hsa-mir-25 hsa-miR-25 hsa-miR-25 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2769 hsa-mir-206 hsa-miR-206 hsa-miR-206 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2770 hsa-mir-183 hsa-miR-183 hsa-miR-183 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2771 hsa-mir-224 hsa-miR-224 hsa-miR-224 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2772 hsa-mir-145 hsa-miR-145 hsa-miR-145 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2773 hsa-mir-26a-1 hsa-miR-26a hsa-miR-26a Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2774 hsa-mir-26a-2 hsa-miR-26a hsa-miR-26a Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2775 hsa-mir-181a hsa-miR-181a hsa-miR-181a Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2776 hsa-mir-208a hsa-miR-208a hsa-miR-208 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2777 hsa-mir-208b hsa-miR-208b hsa-miR-208 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2778 hsa-mir-143 hsa-miR-143 hsa-miR-143 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2779 hsa-mir-20a hsa-miR-20a hsa-miR-20a Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2780 hsa-mir-149 hsa-miR-149 hsa-miR-149 Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2781 hsa-mir-125b-1 hsa-miR-125b hsa-miR-125b Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2782 hsa-mir-125b-2 hsa-miR-125b hsa-miR-125b Glioblastoma Polyunsaturated fatty acids (PUFAs) Polyunsaturated fatty acids (PUFAs) treatment Glioblastoma cells Human altered expression 21961478 2783 hsa-mir-210 hsa-mir-210 hsa-mir-210 Carcinoma, Hepatocellular Hypoxia Hypoxia induce hepatocellular carcinoma (HCC) samples and cells Human Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. 22144109 2784 mmu-mir-183 mmu-miR-183 mmu-miR-183 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2785 mmu-mir-339 mmu-miR-339-3p mmu-miR-339-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2786 mmu-mir-380 mmu-miR-380-3p mmu-miR-380-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2787 mmu-mir-383 mmu-miR-383 mmu-miR-383 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2788 mmu-mir-409 mmu-miR-409-5p mmu-miR-409-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2789 mmu-mir-154 mmu-miR-154 mmu-miR-154 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2790 mmu-let-7f-1 mmu-let-7f mmu-let-7f neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2791 mmu-let-7f-2 mmu-let-7f mmu-let-7f neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2792 mmu-mir-126 mmu-miR-126-3p mmu-miR-126-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2793 mmu-mir-126 mmu-miR-126-5p mmu-miR-126-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2794 mmu-mir-129-1 mmu-miR-129-3p mmu-miR-129-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2795 mmu-mir-129-2 mmu-miR-129-3p mmu-miR-129-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2796 mmu-mir-129-1 mmu-miR-129-5p mmu-miR-129-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2797 mmu-mir-129-2 mmu-miR-129-5p mmu-miR-129-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2798 mmu-mir-132 mmu-miR-132 mmu-miR-132 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2799 mmu-mir-133b mmu-miR-133b mmu-miR-133b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2800 mmu-mir-134 mmu-miR-134 mmu-miR-134 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2801 mmu-mir-136 mmu-miR-136 mmu-miR-136 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2802 mmu-mir-138-1 mmu-miR-138 mmu-miR-138 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2803 mmu-mir-138-2 mmu-miR-138 mmu-miR-138 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2804 mmu-mir-139 mmu-miR-139-5p mmu-miR-139-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2805 mmu-mir-140 mmu-miR-140 mmu-miR-140 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2806 mmu-mir-182 mmu-miR-182 mmu-miR-182 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2807 mmu-mir-187 mmu-miR-187 mmu-miR-187 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2808 mmu-mir-188 mmu-miR-188-5p mmu-miR-188-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2809 mmu-mir-190 mmu-miR-190 mmu-miR-190 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2810 mmu-mir-191 mmu-miR-191 mmu-miR-191 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2811 mmu-mir-193b mmu-miR-193b mmu-miR-193b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2812 mmu-mir-215 mmu-miR-215 mmu-miR-215 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2813 mmu-mir-222 mmu-miR-222 mmu-miR-222 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2814 mmu-mir-29c mmu-miR-29c mmu-miR-29c neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2815 mmu-mir-323 mmu-miR-323-3p mmu-miR-323-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2816 mmu-mir-331 mmu-miR-331-5p mmu-miR-331-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2817 mmu-mir-337 mmu-miR-337-3p mmu-miR-337-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2818 mmu-mir-369 mmu-miR-369-3p mmu-miR-369-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2819 mmu-mir-370 mmu-miR-370 mmu-miR-370 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2820 mmu-mir-376a mmu-miR-376a mmu-miR-376a neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2821 mmu-mir-379 mmu-miR-379 mmu-miR-379 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2822 mmu-mir-380 mmu-miR-380-5p mmu-miR-380-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2823 mmu-mir-382 mmu-miR-382 mmu-miR-382 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2824 mmu-mir-384 mmu-miR-384-5p mmu-miR-384-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2825 mmu-mir-409 mmu-miR-409-3p mmu-miR-409-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2826 mmu-mir-410 mmu-miR-410 mmu-miR-410 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2827 mmu-mir-411 mmu-miR-411 mmu-miR-411 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2828 mmu-mir-429 mmu-miR-429 mmu-miR-429 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2829 mmu-mir-431 mmu-miR-431 mmu-miR-431 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2830 mmu-mir-433 mmu-miR-433 mmu-miR-433 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2831 mmu-mir-434 mmu-miR-434-3p mmu-miR-434-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2832 mmu-mir-434 mmu-miR-434-5p mmu-miR-434-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2833 mmu-mir-465b-1 mmu-miR-465b-5p mmu-miR-465b-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2834 mmu-mir-465b-2 mmu-miR-465b-5p mmu-miR-465b-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2835 mmu-mir-467b mmu-miR-467b mmu-miR-467b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2836 mmu-mir-467e mmu-miR-467e mmu-miR-467e neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2837 mmu-mir-491 mmu-miR-491 mmu-miR-491 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2838 mmu-mir-495 mmu-miR-495 mmu-miR-495 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2839 mmu-mir-544 mmu-miR-544 mmu-miR-544 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2840 mmu-mir-547 mmu-miR-547 mmu-miR-547 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2841 mmu-mir-582 mmu-miR-582-3p mmu-miR-582-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2842 mmu-mir-598 mmu-miR-598 mmu-miR-598 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2843 mmu-mir-665 mmu-miR-665 mmu-miR-665 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2844 mmu-mir-666 mmu-miR-666-5p mmu-miR-666-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2845 mmu-mir-667 mmu-miR-667 mmu-miR-667 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2846 mmu-mir-668 mmu-miR-668 mmu-miR-668 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2847 mmu-mir-770 mmu-miR-770-3p mmu-miR-770-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2848 mmu-mir-873 mmu-miR-873 mmu-miR-873 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2849 mmu-mir-879 mmu-miR-879 mmu-miR-879 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2850 mmu-mir-96 mmu-miR-96 mmu-miR-96 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2851 mmu-mir-98 mmu-miR-98 mmu-miR-98 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2852 mmu-mir-29b-1 mmu-miR-29b mmu-miR-29b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2853 mmu-mir-29b-2 mmu-miR-29b mmu-miR-29b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2854 mmu-mir-100 mmu-miR-100 mmu-miR-100 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2855 mmu-mir-99a mmu-miR-99a mmu-miR-99a neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2856 mmu-mir-218-1 mmu-miR-218 mmu-miR-218 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2857 mmu-mir-218-2 mmu-miR-218 mmu-miR-218 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2858 mmu-mir-365-1 mmu-miR-365 mmu-miR-365 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2859 mmu-mir-365-2 mmu-miR-365 mmu-miR-365 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2860 mmu-mir-376b mmu-miR-376b mmu-miR-376b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2861 mmu-mir-377 mmu-miR-377 mmu-miR-377 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2862 mmu-mir-369 mmu-miR-369-5p mmu-miR-369-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2863 mmu-mir-490 mmu-miR-490 mmu-miR-490 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2864 mmu-mir-92a-1 mmu-miR-92a mmu-miR-92a neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2865 mmu-mir-92a-2 mmu-miR-92a mmu-miR-92a neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2866 mmu-mir-145 mmu-miR-145 mmu-miR-145 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2867 mmu-mir-216b mmu-miR-216b mmu-miR-216b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2868 mmu-mir-217 mmu-miR-217 mmu-miR-217 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2869 mmu-mir-223 mmu-miR-223 mmu-miR-223 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2870 mmu-mir-199a-1 mmu-miR-199a-5p mmu-miR-199a-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2871 mmu-mir-199a-2 mmu-miR-199a-5p mmu-miR-199a-5p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2872 mmu-mir-200b mmu-miR-200b mmu-miR-200b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2873 mmu-mir-302d mmu-miR-302d mmu-miR-302d neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2874 mmu-mir-486 mmu-miR-486 mmu-miR-486 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2875 mmu-mir-487b mmu-miR-487b mmu-miR-487b neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2876 mmu-mir-504 mmu-miR-504 mmu-miR-504 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2877 mmu-mir-539 mmu-miR-539 mmu-miR-539 neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2878 mmu-mir-540 mmu-miR-540-3p mmu-miR-540-3p neuroadaptations after alcohol removal Alcohol Chronic Intermittent Ethanol Exposure and Removal Primary Cortical Neuronal Cultures Mouse differentially expressed 22141737 2879 hsa-mir-200b hsa-mir-200b hsa-mir-200b Lung cancer docetaxel docetaxel treatment docetaxel-resistant SPC-A1/DTX cells and parental SPC-A1 cells Human MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. 22139708 2880 hsa-mir-330 hsa-mir-330 hsa-mir-330 Lung cancer gemcitabine gemcitabine treatment cancer cell Human Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK. 22132977 2881 hsa-mir-330 hsa-mir-330 hsa-mir-330 Colon cancer gemcitabine gemcitabine treatment cancer cell Human Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK. 22132977 2882 hsa-mir-221 hsa-mir-221 hsa-mir-221 Prostatic cancer castration castration treatment normal prostate tissues from 86 individuals, prostate tumor tissues from 34 individuals with localized hormone na?ve disease, and bone-derived metastatic CRPC tissues from 17 individuals Human The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. 22127852 2883 hsa-mir-222 hsa-mir-222 hsa-mir-222 Prostatic cancer castration castration treatment normal prostate tissues from 86 individuals, prostate tumor tissues from 34 individuals with localized hormone na?ve disease, and bone-derived metastatic CRPC tissues from 17 individuals Human The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. 22127852 2884 hsa-mir-23b hsa-mir-23b hsa-mir-23b Prostatic cancer castration castration treatment normal prostate tissues from 86 individuals, prostate tumor tissues from 34 individuals with localized hormone na?ve disease, and bone-derived metastatic CRPC tissues from 17 individuals Human The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. 22127852 2885 hsa-mir-27b hsa-mir-27b hsa-mir-27b Prostatic cancer castration castration treatment normal prostate tissues from 86 individuals, prostate tumor tissues from 34 individuals with localized hormone na?ve disease, and bone-derived metastatic CRPC tissues from 17 individuals Human The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. 22127852 2886 hsa-mir-1915 hsa-mir-1915 hsa-mir-1915 Colorectal cancer Drug Drug treatment multidrug resistant colorectal carcinoma cell line HCT116/L-OHP and its parent cell line HCT116 Human miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. 22121083 2887 hsa-mir-100 hsa-mir-100 hsa-mir-100 Lung cancer Docetaxel docetaxel treatment docetaxel-resistant SPC-A1/DTX cells compared with parental SPC-A1 cells Human MiR-100 Resensitizes Docetaxel-Resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1. 22120675 2888 hsa-mir-193a hsa-miR-193a-3p hsa-miR-193a-3p Hepatocellular Carcinoma 5-fluorouracil 5-fluorouracil treatment HCC cell lines Human DNA methylation regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via SRSF2. 22117060 2889 hsa-mir-17 hsa-mir-17 hsa-mir-17 Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2890 hsa-mir-18a hsa-mir-18a hsa-mir-18a Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2891 hsa-mir-19a hsa-mir-19a hsa-mir-19a Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2892 hsa-mir-20a hsa-mir-20a hsa-mir-20a Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2893 hsa-mir-19b-1 hsa-mir-19b hsa-mir-19b Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2894 hsa-mir-92a-1 hsa-mir-92a hsa-mir-92a Mantle-Cell Lymphoma Drug Drug treatment xenograft MCL mouse model Human The miRNA-17k92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. 22116552 2895 hsa-mir-195 hsa-miR-195 hsa-miR-195 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2896 hsa-mir-146b hsa-miR-146b hsa-miR-146b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2897 hsa-mir-26b hsa-miR-26b hsa-miR-26b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2898 hsa-mir-374a hsa-miR-374a hsa-miR-374 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2899 hsa-mir-374b hsa-miR-374b hsa-miR-374 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2900 hsa-mir-199b hsa-miR-199b hsa-miR-199b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2901 hsa-mir-132 hsa-miR-132 hsa-miR-132 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2902 hsa-mir-140 hsa-miR-140 hsa-miR-140 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2903 hsa-mir-487b hsa-miR-487b hsa-miR-487b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2904 hsa-let-7g hsa-let-7g hsa-let-7g Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2905 hsa-mir-340 hsa-miR-340 hsa-miR-340 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2906 hsa-mir-155 hsa-miR-155 hsa-miR-155 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2907 hsa-mir-95 hsa-miR-95 hsa-miR-95 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2908 hsa-mir-186 hsa-miR-186 hsa-miR-186 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2909 hsa-mir-130a hsa-miR-130a hsa-miR-130a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2910 hsa-mir-342 hsa-miR-342 hsa-miR-342 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2911 hsa-mir-577 hsa-miR-577 hsa-miR-577 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2912 hsa-mir-128b hsa-miR-128b hsa-miR-128b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2913 hsa-mir-146a hsa-miR-146a hsa-miR-146a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2914 hsa-mir-16-1 hsa-miR-16 hsa-miR-16 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2915 hsa-mir-16-2 hsa-miR-16 hsa-miR-16 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2916 hsa-mir-503 hsa-miR-503 hsa-miR-503 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2917 hsa-mir-224 hsa-miR-224 hsa-miR-224 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2918 hsa-mir-223 hsa-miR-223 hsa-miR-223 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2919 hsa-mir-128a hsa-miR-128a hsa-miR-128a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2920 hsa-mir-181b hsa-miR-181b hsa-miR-181b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2921 hsa-let-7f hsa-let-7f hsa-let-7f Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2922 hsa-mir-1-1 hsa-miR-1 hsa-miR-1 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2923 hsa-mir-1-2 hsa-miR-1 hsa-miR-1 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2924 hsa-mir-421 hsa-miR-421 hsa-miR-421 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2925 hsa-mir-127 hsa-miR-127 hsa-miR-127 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2926 hsa-mir-34c hsa-miR-34c hsa-miR-34c Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2927 hsa-mir-497 hsa-miR-497 hsa-miR-497 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity 22112324 2928 hsa-mir-526a-1 hsa-miR-526a hsa-miR-526a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2929 hsa-mir-526a-2 hsa-miR-526a hsa-miR-526a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2930 hsa-mir-122 hsa-miR-122 hsa-miR-122a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2931 hsa-mir-518f hsa-miR-518f* hsa-miR-518f* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2932 hsa-mir-591 hsa-miR-591 hsa-miR-591 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2933 hsa-mir-524 hsa-miR-524-3p hsa-miR-524-3p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2934 hsa-mir-320a hsa-miR-320a hsa-miR-320 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2935 hsa-mir-520a hsa-miR-520a* hsa-miR-520a* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2936 hsa-mir-183 hsa-miR-183 hsa-miR-183 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2937 hsa-mir-516a-1 hsa-miR-516a-5p hsa-miR-516-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2938 hsa-mir-516a-2 hsa-miR-516a-5p hsa-miR-516-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2939 hsa-mir-516b-1 hsa-miR-516b-5p hsa-miR-516-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2940 hsa-mir-516b-2 hsa-miR-516b-5p hsa-miR-516-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2941 hsa-mir-629 hsa-miR-629 hsa-miR-629 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2942 hsa-mir-595 hsa-miR-595 hsa-miR-595 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2943 hsa-mir-640 hsa-miR-640 hsa-miR-640 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2944 hsa-mir-520d hsa-miR-520d* hsa-miR-520d* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2945 hsa-mir-519e hsa-miR-519e* hsa-miR-519e* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2946 hsa-mir-363 hsa-miR-363* hsa-miR-363* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2947 hsa-mir-513a-1 hsa-miR-513a hsa-miR-513 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2948 hsa-mir-513a-2 hsa-miR-513a hsa-miR-513 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2949 hsa-mir-513b hsa-miR-513b hsa-miR-513 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2950 hsa-mir-513c hsa-miR-513c hsa-miR-513 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2951 hsa-mir-328 hsa-miR-328 hsa-miR-328 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2952 hsa-mir-519a-1 hsa-miR-519a hsa-miR-519a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2953 hsa-mir-519a-2 hsa-miR-519a hsa-miR-519a Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2954 hsa-mir-185 hsa-miR-185 hsa-miR-185 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2955 hsa-mir-658 hsa-miR-658 hsa-miR-658 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2956 hsa-mir-517a hsa-miR-517a* hsa-miR-517* Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2957 hsa-mir-515-1 hsa-miR-515-5p hsa-miR-515-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2958 hsa-mir-515-2 hsa-miR-515-5p hsa-miR-515-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2959 hsa-mir-519c hsa-miR-519c-5p hsa-miR-519c-5p Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2960 hsa-mir-661 hsa-miR-661 hsa-miR-661 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2961 hsa-mir-182 hsa-miR-182 hsa-miR-182 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2962 hsa-mir-206 hsa-miR-206 hsa-miR-206 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2963 hsa-mir-193b hsa-miR-193b hsa-miR-193b Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2964 hsa-mir-601 hsa-miR-601 hsa-miR-601 Gastric Cancer cisplatin/fluorouracil (CF) Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. Biopsy samples Human A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance 22112324 2965 hsa-mir-200c hsa-mir-200c hsa-mir-200c Breast cancer doxorubicin doxorubicin treatment MCF-7/ADR as compared to the parental MCF-7 cells Human Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.Down-regulated miR-200c was observed in non-responders as compared to responders. In addition, miR-200c expression was observed to be down-regulated over 800-fold in human breast cancer cells resistant to doxorubicin MCF-7/ADR as compared to the parental MCF-7 cells. Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein. Moreover, our study demonstrated that restoration of miR-200c in MCF-7/ADR cells could increase intracellular doxorubicin accumulation determined by flow cytometry. 22101791 2966 hsa-mir-125b-1 hsa-mir-125b hsa-mir-125b Immune Response metal (magnesium-, iron-, gallium, and aluminum)-sulfate metal-sulfate treatment human-astroglial (HAG) cells Human The combination of iron- plus aluminum-sulfate was found to be significantly synergistic in up-regulating reactive oxygen species (ROS) abundance, NF-ȜB-DNA binding and miRNA-125b and miRNA-146a expression. Treatment of metal-sulfate stressed HAG cells with the antioxidant phenyl butyl nitrone (PBN) or the NF-ȜB inhibitors curcumin, the metal chelator-anti-oxidant pyrollidine dithiocarbamate (PDTC), or the resveratrol analog CAY10512, abrogated both NF-ȜB signaling and induction of these miRNAs. 22099153 2967 hsa-mir-125b-2 hsa-mir-125b hsa-mir-125b Immune Response metal (magnesium-, iron-, gallium, and aluminum)-sulfate metal-sulfate treatment human-astroglial (HAG) cells Human The combination of iron- plus aluminum-sulfate was found to be significantly synergistic in up-regulating reactive oxygen species (ROS) abundance, NF-ȜB-DNA binding and miRNA-125b and miRNA-146a expression. Treatment of metal-sulfate stressed HAG cells with the antioxidant phenyl butyl nitrone (PBN) or the NF-ȜB inhibitors curcumin, the metal chelator-anti-oxidant pyrollidine dithiocarbamate (PDTC), or the resveratrol analog CAY10512, abrogated both NF-ȜB signaling and induction of these miRNAs. 22099153 2968 hsa-mir-146a hsa-mir-146a hsa-mir-146a Immune Response metal (magnesium-, iron-, gallium, and aluminum)-sulfate metal-sulfate treatment human-astroglial (HAG) cells Human The combination of iron- plus aluminum-sulfate was found to be significantly synergistic in up-regulating reactive oxygen species (ROS) abundance, NF-ȜB-DNA binding and miRNA-125b and miRNA-146a expression. Treatment of metal-sulfate stressed HAG cells with the antioxidant phenyl butyl nitrone (PBN) or the NF-ȜB inhibitors curcumin, the metal chelator-anti-oxidant pyrollidine dithiocarbamate (PDTC), or the resveratrol analog CAY10512, abrogated both NF-ȜB signaling and induction of these miRNAs. 22099153 2969 hsa-mir-145 hsa-mir-145 hsa-mir-145 Glioblastoma radiation radiation treatment GBM-CD133(+) cells and malignant glioma specimens Human The expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 in GBM-CD133(+) cells and malignant glioma specimens.miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+). Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibited their tumorigenic and CSC-like abilities and facilitated their differentiation into CD133(-)-non-CSCs. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice. Therefore, PU-PEI-miR145 is a novel therapeutic approach for malignant brain tumors. 22098779 2970 hsa-mir-145 hsa-mir-145 hsa-mir-145 Glioblastoma temozolomide temozolomide treatment GBM-CD133(+) cells and malignant glioma specimens Human The expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 in GBM-CD133(+) cells and malignant glioma specimens.miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+). Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibited their tumorigenic and CSC-like abilities and facilitated their differentiation into CD133(-)-non-CSCs. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice. Therefore, PU-PEI-miR145 is a novel therapeutic approach for malignant brain tumors. 22098779 2971 hsa-mir-21 hsa-mir-21 hsa-mir-21 stimulation of endothelial-to-mesenchymal transition (EndMT) TGF-beta TGF-beta treatment endothelial cells Human TGF-ǂ treatment of endothelial cells significantly increased miR-21 expression and induced EndMT characterized by suppression of endothelial and increase of fibroblast markers. Overexpression of miR-21 alone also stimulated EndMT. Importantly, miR-21 blockade by transfection of specific microRNA inhibitors partly prevented TGF-ǂ-induced EndMT. Mechanistically, miR-21 silenced phosphatase and tensin homolog in endothelial cells, resulting in activation of the Akt-pathway. Akt inhibition partly restored TGF-ǂ-mediated loss of endothelial markers during EndMT. In vivo, pressure overload of the left ventricle led to increased expression of miR-21 in sorted cardiac endothelial cells, which displayed molecular and phenotypic signs of EndMT. This was attenuated by treatment of mice subjected to left ventricular pressure overload with an antagomir against miR-21. 22095988 2972 hsa-mir-29a hsa-mir-29a hsa-mir-29a Renal Fibrosis TGF-beta1 TGF-beta1 treatment proximal tubular cells, primary mesangial cells, and podocytes Human Suppression of microRNA-29 Expression by TGF-ǂ1 Promotes Collagen Expression and Renal Fibrosis. 22095944 2973 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b Renal Fibrosis TGF-beta1 TGF-beta1 treatment proximal tubular cells, primary mesangial cells, and podocytes Human Suppression of microRNA-29 Expression by TGF-ǂ1 Promotes Collagen Expression and Renal Fibrosis. 22095944 2974 hsa-mir-29b-2 hsa-mir-29b hsa-mir-29b Renal Fibrosis TGF-beta1 TGF-beta1 treatment proximal tubular cells, primary mesangial cells, and podocytes Human Suppression of microRNA-29 Expression by TGF-ǂ1 Promotes Collagen Expression and Renal Fibrosis. 22095944 2975 hsa-mir-29c hsa-mir-29c hsa-mir-29c Renal Fibrosis TGF-beta1 TGF-beta1 treatment proximal tubular cells, primary mesangial cells, and podocytes Human Suppression of microRNA-29 Expression by TGF-ǂ1 Promotes Collagen Expression and Renal Fibrosis. 22095944 2976 osa-MIR528 osa-MIR528 osa-MIR528 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2977 osa-MIR160e osa-MIR160e osa-MIR160e aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2978 osa-MIR166k osa-MIR166k osa-MIR166k aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2979 osa-MIR166l osa-MIR166l osa-MIR166l aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2980 osa-MIR168a osa-MIR168a osa-MIR168a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2981 osa-MIR399d osa-MIR399d osa-MIR399d aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2982 osa-MIR819a osa-MIR819a osa-MIR819a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2983 osa-MIR819c osa-MIR819c osa-MIR819c aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2984 osa-MIR819d osa-MIR819d osa-MIR819d aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2985 osa-MIR819e osa-MIR819e osa-MIR819e aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2986 osa-MIR819f osa-MIR819f osa-MIR819f aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2987 osa-MIR819g osa-MIR819g osa-MIR819g aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2988 osa-MIR819h osa-MIR819h osa-MIR819h aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2989 osa-MIR819i osa-MIR819i osa-MIR819i aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2990 osa-MIR819j osa-MIR819j osa-MIR819j aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2991 osa-MIR819k osa-MIR819k osa-MIR819k aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice up-regulated 22095606 2992 osa-MIR156l osa-MIR156l osa-MIR156l aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2993 osa-MIR169f osa-MIR169f osa-MIR169f aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2994 osa-MIR169g osa-MIR169g osa-MIR169g aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2995 osa-MIR172a osa-MIR172a osa-MIR172a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2996 osa-MIR172d osa-MIR172d osa-MIR172d aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2997 osa-MIR393b osa-MIR393b osa-MIR393b aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2998 osa-MIR395a osa-MIR395a osa-MIR395a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 2999 osa-MIR398a osa-MIR398a osa-MIR398a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3000 osa-MIR398b osa-MIR398b osa-MIR398b aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3001 osa-MIR408 osa-MIR408 osa-MIR408 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3002 osa-MIR415 osa-MIR415 osa-MIR415 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3003 osa-MIR426 osa-MIR426 osa-MIR426 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3004 osa-MIR808 osa-MIR808 osa-MIR808 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3005 osa-MIR809a osa-MIR809a osa-MIR809a aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3006 osa-MIR809b osa-MIR809b osa-MIR809b aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3007 osa-MIR809d osa-MIR809d osa-MIR809d aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3008 osa-MIR809e osa-MIR809e osa-MIR809e aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3009 osa-MIR809f osa-MIR809f osa-MIR809f aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3010 osa-MIR809g osa-MIR809g osa-MIR809g aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3011 osa-MIR809h osa-MIR809h osa-MIR809h aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3012 osa-MIR813 osa-MIR813 osa-MIR813 aluminum toxicity and tolerance aluminum 8 h of aluminum treatment rice root Rice down-regulated 22095606 3013 hsa-mir-26a-1 hsa-mir-26a hsa-mir-26a Breast Neoplasms tamoxifen tamoxifen treatment primary breast cancer specimens of 235 estrogen receptor-ǁ (ER)-positive patients Human High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. 22094936 3014 hsa-mir-26a-2 hsa-mir-26a hsa-mir-26a Breast Neoplasms tamoxifen tamoxifen treatment primary breast cancer specimens of 235 estrogen receptor-ǁ (ER)-positive patients Human High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. 22094936 3015 rno-mir-29b-1 rno-mir-29b rno-mir-29b ischemic brain injury oxygen-glucose oxygen-glucose deprivation rat brain Rat Upregulated miR-29b promotes neuronal cell death by inhibiting Bcl2L2 after ischemic brain injury.The miR-29b levels were significantly increased in rat brain after transient middle cerebral artery occlusion and neurons after oxygen-glucose deprivation. Moreover, ectopic expression of miR-29b promoted neuronal cell death, whereas its repression decreased cell death. Furthermore, we verified that miR-29b directly targeted and inhibited Bcl2L2 gene expression, and then increased neuronal cell death. Importantly, Bcl2L2 overexpression rescued neuronal cell death induced by miR-29b. 22094713 3016 rno-mir-29b-2 rno-mir-29b rno-mir-29b ischemic brain injury oxygen-glucose oxygen-glucose deprivation rat brain Rat Upregulated miR-29b promotes neuronal cell death by inhibiting Bcl2L2 after ischemic brain injury.The miR-29b levels were significantly increased in rat brain after transient middle cerebral artery occlusion and neurons after oxygen-glucose deprivation. Moreover, ectopic expression of miR-29b promoted neuronal cell death, whereas its repression decreased cell death. Furthermore, we verified that miR-29b directly targeted and inhibited Bcl2L2 gene expression, and then increased neuronal cell death. Importantly, Bcl2L2 overexpression rescued neuronal cell death induced by miR-29b. 22094713 3017 hsa-mir-346 hsa-mir-346 hsa-mir-346 Schizophrenia risperidone risperidone treatment serum Human miR-346 is one of the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia. 22094284 3018 hsa-let-7a-1 hsa-let-7a hsa-let-7a Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3019 hsa-let-7a-2 hsa-let-7a hsa-let-7a Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3020 hsa-let-7a-3 hsa-let-7a hsa-let-7a Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3021 hsa-let-7b hsa-let-7b hsa-let-7b Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3022 hsa-mir-26a hsa-mir-26a hsa-mir-26a Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3023 hsa-mir-101-1 hsa-mir-101 hsa-mir-101 Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3024 hsa-mir-101-2 hsa-mir-101 hsa-mir-101 Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3025 hsa-mir-200b hsa-mir-200b hsa-mir-200b Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3026 hsa-mir-200c hsa-mir-200c hsa-mir-200c Pancreatic Neoplasms Metformin Metformin treatment human PC cells Human Wefound that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells. 22086681 3027 hsa-mir-1 hsa-mir-1 hsa-mir-1 cardiomyocytes apoptosis Calcitonin gene-related peptide Calcitonin gene-related peptide treatment cardiomyocytes Human Calcitonin gene-related peptide suppresses isoprenaline-induced cardiomyocyte apoptosis through regulation of microRNA-1 and microRNA-133a expression. 22086007 3028 hsa-mir-133a hsa-mir-133a hsa-mir-133a cardiomyocytes apoptosis Calcitonin gene-related peptide Calcitonin gene-related peptide treatment cardiomyocytes Human Calcitonin gene-related peptide suppresses isoprenaline-induced cardiomyocyte apoptosis through regulation of microRNA-1 and microRNA-133a expression. 22086007 3029 hsa-mir-199a-1 hsa-mir-199a hsa-mir-199a ischemic tolerance 3-nitropropionic acid (3-NPA) 3-nitropropionic acid (3-NPA) treatment rat brain Human We examined the expression of miR-199a after 3-nitropropionic acid (3-NPA) preconditioning in rat brain. 3-NPA (20mg/kg), an irreversible inhibitor of succinate dehydrogenase, was injected intraperitoneally to induce ischemic tolerance in rats. For comparison, the control group received intraperitoneal injections of vehicle (0.9% sodium chloride). Quantitative RT-PCR assay was applied to detect the expression of miR-199a. Luciferase reporter assays and Western blotting were used to verify the target genes of miR-199a. In cortex and striatum, miR-199a was downregulated at two separate time intervals (the 2nd and 4th day), while in the hippocampus, it was downregulated on the 2nd day after 3-NPA preconditioning. The maximum reduction of miR-199a was 66.3% in striatum (4th day), 54.9% in hippocampus (2nd day), and 27.6% in cortex (2nd day). The level of sirt1 protein, a putative target of miR-199a and a known mediator of neuroprotective effect in brain ischemic tolerance, decreased significantly in hippocampal neurons by overexpression of miR-199a, while it increased with knockdown of miR-199a. Taking these results together, we hypothesize miR-199a may have a role in the formation of cerebral ischemic tolerance. 22079324 3030 hsa-mir-199a-2 hsa-mir-199a hsa-mir-199a ischemic tolerance 3-nitropropionic acid (3-NPA) 3-nitropropionic acid (3-NPA) treatment rat brain Human We examined the expression of miR-199a after 3-nitropropionic acid (3-NPA) preconditioning in rat brain. 3-NPA (20mg/kg), an irreversible inhibitor of succinate dehydrogenase, was injected intraperitoneally to induce ischemic tolerance in rats. For comparison, the control group received intraperitoneal injections of vehicle (0.9% sodium chloride). Quantitative RT-PCR assay was applied to detect the expression of miR-199a. Luciferase reporter assays and Western blotting were used to verify the target genes of miR-199a. In cortex and striatum, miR-199a was downregulated at two separate time intervals (the 2nd and 4th day), while in the hippocampus, it was downregulated on the 2nd day after 3-NPA preconditioning. The maximum reduction of miR-199a was 66.3% in striatum (4th day), 54.9% in hippocampus (2nd day), and 27.6% in cortex (2nd day). The level of sirt1 protein, a putative target of miR-199a and a known mediator of neuroprotective effect in brain ischemic tolerance, decreased significantly in hippocampal neurons by overexpression of miR-199a, while it increased with knockdown of miR-199a. Taking these results together, we hypothesize miR-199a may have a role in the formation of cerebral ischemic tolerance. 22079324 3031 hsa-mir-223 hsa-mir-223 hsa-mir-223 HIV HIV HIV infection HIV-1-infected CD4(+)CD8(-) PBMC Human microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. 22080513 3032 hsa-mir-29a hsa-mir-29a hsa-mir-29a HIV HIV HIV infection HIV-1-infected CD4(+)CD8(-) PBMC Human microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. 22080513 3033 hsa-mir-29b hsa-mir-29b hsa-mir-29b HIV HIV HIV infection HIV-1-infected CD4(+)CD8(-) PBMC Human microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. 22080513 3034 hsa-mir-155 hsa-mir-155 hsa-mir-155 HIV HIV HIV infection HIV-1-infected CD4(+)CD8(-) PBMC Human microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. 22080513 3035 hsa-mir-21 hsa-mir-21 hsa-mir-21 HIV HIV HIV infection HIV-1-infected CD4(+)CD8(-) PBMC Human microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. 22080513 3036 rno-mir-136 rno-miR-136* rno-miR-136* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3037 rno-mir-141 rno-miR-141 rno-miR-141 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3038 rno-mir-142 rno-miR-142-3p rno-miR-142-3p carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3039 rno-mir-146a rno-miR-146a rno-miR-146a carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3040 rno-mir-146b rno-miR-146b rno-miR-146b carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3041 rno-mir-181a-1 rno-miR-181a* rno-miR-181a* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3042 rno-mir-181a-2 rno-miR-181a* rno-miR-181a* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3043 rno-mir-183 rno-miR-183 rno-miR-183 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3044 rno-mir-184 rno-miR-184 rno-miR-184 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3045 rno-mir-199a rno-miR-199a-3p rno-miR-199a-3p carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3046 rno-mir-199a rno-miR-199a-5p rno-miR-199a-5p carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3047 rno-mir-200a rno-miR-200a rno-miR-200a carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3048 rno-mir-200b rno-miR-200b rno-miR-200b carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3049 rno-mir-200c rno-miR-200c rno-miR-200c carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3050 rno-mir-204 rno-miR-204 rno-miR-204 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3051 rno-mir-211 rno-miR-211 rno-miR-211 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3052 rno-mir-215 rno-miR-215 rno-miR-215 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3053 rno-mir-218a-1 rno-miR-218a rno-miR-218 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3054 rno-mir-218a-2 rno-miR-218a rno-miR-218 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3055 rno-mir-218b rno-miR-218b rno-miR-218 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3056 rno-mir-223 rno-miR-223 rno-miR-223 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3057 rno-mir-26b rno-miR-26b rno-miR-26b carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3058 rno-mir-376b rno-miR-376b-5p rno-miR-376b-5p carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3059 rno-mir-376c rno-miR-376c rno-miR-376c carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3060 rno-mir-379 rno-miR-379* rno-miR-379* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3061 rno-mir-429 rno-miR-429 rno-miR-429 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was up-regulated in three months furan treatment. 22079235 3062 rno-mir-101b rno-miR-101b rno-miR-101b carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3063 rno-mir-122 rno-miR-122 rno-miR-122 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3064 rno-mir-181c rno-miR-181c rno-miR-181c carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3065 rno-mir-184 rno-miR-184 rno-miR-184 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3066 rno-mir-192 rno-miR-192 rno-miR-192 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3067 rno-mir-193 rno-miR-193 rno-miR-193 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3068 rno-mir-193 rno-miR-193* rno-miR-193* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3069 rno-mir-194-1 rno-miR-194 rno-miR-194 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3070 rno-mir-194-2 rno-miR-194 rno-miR-194 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3071 rno-mir-203 rno-miR-203 rno-miR-203 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3072 rno-mir-22 rno-miR-22* rno-miR-22* carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3073 rno-mir-335 rno-miR-335 rno-miR-335 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3074 rno-mir-378 rno-miR-378 rno-miR-378 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3075 rno-mir-448 rno-miR-448 rno-miR-448 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3076 rno-mir-451 rno-miR-451 rno-miR-451 carcinogenic effect furan furan treatment at 30mg/kg (5 daily doses per week) rat liver Rat The miRNA was down-regulated in three months furan treatment. 22079235 3077 hsa-mir-449a hsa-miR-449a hsa-miR-449a Lung cancer HDAC inhibitor: apicidin and TSA The cells were treated with apicidin 0.5 M and TSA 100ng/ml after transfection. The media contained with apicidine or TSA was changed every 24h. Lung cancer cells (A549, H522, HCC1438, HCC95 and H1299);Tumor and corresponding normal lung tissue specimens Human miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin. 22078727 3078 hsa-mir-132 hsa-miR-132 hsa-miR-132 regulatory effects on natural killer (NK) cells Interleukin (IL)-12 prolonged IL-12 treatment natural killer (NK) cells Human Prolonged IL-12 treatment significantly upregulates microRNAs (miRNAs), including miR-132, -212, and -200a in primary human NK cells. 22077060 3079 hsa-mir-212 hsa-miR-212 hsa-miR-212 regulatory effects on natural killer (NK) cells Interleukin (IL)-12 prolonged IL-12 treatment natural killer (NK) cells Human Prolonged IL-12 treatment significantly upregulates microRNAs (miRNAs), including miR-132, -212, and -200a in primary human NK cells. 22077060 3080 hsa-mir-200a hsa-miR-200a hsa-miR-200a regulatory effects on natural killer (NK) cells Interleukin (IL)-12 prolonged IL-12 treatment natural killer (NK) cells Human Prolonged IL-12 treatment significantly upregulates microRNAs (miRNAs), including miR-132, -212, and -200a in primary human NK cells. 22077060 3081 hsa-mir-1231 hsa-mir-1207 hsa-mir-1207 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3082 hsa-mir-1228 hsa-mir-1228 hsa-mir-1228 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3083 hsa-mir-663 hsa-mir-1231 hsa-mir-1231 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3084 hsa-mir-149 hsa-mir-1246 hsa-mir-1246 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3085 hsa-mir-638 hsa-mir-1268 hsa-mir-1268 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3086 hsa-mir-1207 hsa-mir-1308 hsa-mir-1308 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3087 hsa-mir-92b hsa-mir-132 hsa-mir-132 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3088 hsa-mir-1246 hsa-mir-138 hsa-mir-138 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3089 hsa-mir-1268 hsa-mir-138 hsa-mir-138 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3090 hsa-mir-203 hsa-mir-141 hsa-mir-141 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3091 hsa-mir-923 hsa-mir-146b hsa-mir-146b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3092 hsa-mir-146b hsa-mir-149 hsa-mir-149 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3093 hsa-mir-193a hsa-mir-155 hsa-mir-155 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3094 hsa-mir-132 hsa-mir-193a hsa-mir-193a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3095 hsa-mir-196a-2 hsa-mir-196a hsa-mir-196a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3096 hsa-mir-196a-1 hsa-mir-196a hsa-mir-196a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3097 hsa-mir-30a hsa-mir-203 hsa-mir-203 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3098 hsa-mir-500 hsa-mir-27a hsa-mir-27a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3099 hsa-mir-296 hsa-mir-27b hsa-mir-27b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3100 hsa-mir-138-2 hsa-mir-296 hsa-mir-296 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3101 hsa-mir-138-1 hsa-mir-30a hsa-mir-30a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3102 hsa-mir-155 hsa-mir-339 hsa-mir-339 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3103 hsa-mir-1308 hsa-mir-378 hsa-mir-378 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3104 hsa-mir-503 hsa-mir-432 hsa-mir-432 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3105 hsa-mir-671 hsa-mir-500 hsa-mir-500 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3106 hsa-mir-141 hsa-mir-503 hsa-mir-503 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3107 hsa-mir-432 hsa-mir-638 hsa-mir-638 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3108 hsa-mir-378 hsa-mir-663 hsa-mir-663 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3109 hsa-mir-339 hsa-mir-671 hsa-mir-671 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3110 hsa-mir-27b hsa-mir-923 hsa-mir-923 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3111 hsa-mir-27a hsa-mir-92b hsa-mir-92b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3112 hsa-mir-29b-2 hsa-mir-29b hsa-mir-29b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in HB2 Treated vs. HB2 Un-treated 22076154 3113 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in MDA Treated vs. MDA Un-treated 22076154 3114 hsa-mir-1280 hsa-mir-1280 hsa-mir-1280 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in MDA Treated vs. MDA Un-treated 22076154 3115 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in MDA Treated vs. MDA Un-treated 22076154 3116 hsa-mir-99b hsa-mir-99b hsa-mir-99b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3117 hsa-mir-24-2 hsa-mir-24 hsa-mir-24 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3118 hsa-mir-24-1 hsa-mir-24 hsa-mir-24 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3119 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3120 hsa-mir-210 hsa-mir-210 hsa-mir-210 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3121 hsa-mir-93 hsa-mir-93 hsa-mir-93 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3122 hsa-mir-99a hsa-mir-99a hsa-mir-99a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3123 hsa-mir-342 hsa-mir-342 hsa-mir-342 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3124 hsa-mir-886 hsa-mir-886 hsa-mir-886 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3125 hsa-mir-125a hsa-mir-125a hsa-mir-125a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in MDA Treated vs. MDA Un-treated 22076154 3126 hsa-mir-378 hsa-mir-378 hsa-mir-378 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3127 hsa-mir-125b-1 hsa-mir-125b hsa-mir-125b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3128 hsa-mir-125b-2 hsa-mir-125b hsa-mir-125b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3129 hsa-mir-155 hsa-mir-155 hsa-mir-155 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3130 hsa-mir-424 hsa-mir-424 hsa-mir-424 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3131 hsa-mir-23a hsa-mir-23a hsa-mir-23a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3132 hsa-mir-1275 hsa-mir-1275 hsa-mir-1275 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3133 hsa-mir-193a hsa-mir-193a hsa-mir-193a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3134 hsa-mir-432 hsa-mir-432 hsa-mir-432 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human up-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3135 hsa-let-7c hsa-let-7c hsa-let-7c Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3136 hsa-let-7g hsa-let-7g hsa-let-7g Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3137 hsa-mir-193b hsa-mir-193b hsa-mir-193b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3138 hsa-mir-15a hsa-mir-15a hsa-mir-15a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3139 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3140 hsa-let-7i hsa-let-7i hsa-let-7i Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3141 hsa-mir-181a-1 hsa-mir-181a hsa-mir-181a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3142 hsa-mir-181a-2 hsa-mir-181a hsa-mir-181a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3143 hsa-mir-30a hsa-mir-30a hsa-mir-30a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3144 hsa-mir-181b-1 hsa-mir-181b hsa-mir-181b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3145 hsa-mir-181b-2 hsa-mir-181b hsa-mir-181b Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3146 hsa-let-7f-1 hsa-let-7f hsa-let-7f Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3147 hsa-let-7f-2 hsa-let-7f hsa-let-7f Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3148 hsa-mir-210 hsa-mir-210 hsa-mir-210 Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3149 hsa-mir-10a hsa-mir-10a hsa-mir-10a Breast cancer 5-aza-2'-deoxycytidine 5-aza-2'-deoxycytidine (DAC) treatment six breast cancer cell lines (MDA-MB231, MCF-7, HS578T, BT549, T47D and SKBR3) and a breast epithelial cell line (HB2) as a control. Human down-regulated in SKBR3 P1 vs. SKBR3 Un-treated 22076154 3150 hsa-mir-221 hsa-mir-221 hsa-mir-221 Glioma temozolomide temozolomide treatment glioma cell Human Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. 22075712 3151 hsa-mir-222 hsa-mir-222 hsa-mir-222 Glioma temozolomide temozolomide treatment glioma cell Human Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. 22075712 3152 hsa-mir-3163 hsa-mir-3163 hsa-mir-3163 Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3153 hsa-mir-539 hsa-mir-539 hsa-mir-539 Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3154 hsa-mir-1305 hsa-mir-1305 hsa-mir-1305 Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3155 hsa-mir-1260 hsa-mir-1260 hsa-mir-1260 Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3156 hsa-let-7a-2 hsa-let-7a hsa-let-7a Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3157 hsa-let-7a-1 hsa-let-7a hsa-let-7a Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3158 hsa-let-7a-3 hsa-let-7a hsa-let-7a Glioblastoma temozolomide temozolomide treatment glioblastoma patients Human Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02). 22074483 3159 hsa-mir-29 hsa-mir-29 hsa-mir-29 Influenza Influenza A Influenza A infection A549 human lung epithelial cells Human Epigenetic Changes Mediated by miR29 Activate Cyclooxygenase-2 and Interferon-Nj1 Production during Viral Infection. 22072783 3160 hsa-mir-885 miR-885-3p miR-885-3p squamous cell carcinoma cisplatin cisplatin treatment squamous cell carcinoma cell Human miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Altogether, our results support the notion that miR-885-3p might contribute in regulation of cell viability, apoptosis and/or autophagy in squamous cell carcinoma cells upon cisplatin exposure. 22071691 3161 hsa-mir-215 hsa-mir-215 hsa-mir-215 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3162 hsa-mir-125b hsa-mir-125b hsa-mir-125b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3163 hsa-mir-335 hsa-mir-335 hsa-mir-335 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3164 hsa-mir-193b hsa-mir-193b hsa-mir-193b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3165 hsa-mir-126 hsa-mir-126 hsa-mir-126 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3166 hsa-mir-1-1 hsa-mir-1 hsa-mir-1 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3167 hsa-mir-1-2 hsa-mir-1 hsa-mir-1 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3168 hsa-mir-125a hsa-mir-125a-5p hsa-mir-125a-5p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3169 hsa-mir-19a hsa-mir-19a hsa-mir-19a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3170 hsa-mir-16-1 hsa-mir-16 hsa-mir-16 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3171 hsa-mir-16-2 hsa-mir-16 hsa-mir-16 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3172 hsa-mir-122 hsa-mir-122 hsa-mir-122 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3173 hsa-mir-218 hsa-mir-218 hsa-mir-218 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3174 hsa-mir-100 hsa-mir-100 hsa-mir-100 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3175 hsa-mir-146a hsa-mir-146a hsa-mir-146a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3176 hsa-mir-10b hsa-mir-10b hsa-mir-10b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3177 hsa-mir-143 hsa-mir-143 hsa-mir-143 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3178 hsa-mir-150 hsa-mir-150 hsa-mir-150 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3179 hsa-let-7g hsa-let-7g hsa-let-7g acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3180 hsa-mir-193a hsa-mir-193a-5p hsa-mir-193a-5p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3181 hsa-mir-96 hsa-mir-96 hsa-mir-96 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3182 hsa-mir-183 hsa-mir-183 hsa-mir-183 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3183 hsa-mir-181b hsa-mir-181b hsa-mir-181b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3184 hsa-mir-146b hsa-mir-146b-5p hsa-mir-146b-5p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3185 hsa-mir-9-1 hsa-mir-9 hsa-mir-9 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3186 hsa-mir-9-2 hsa-mir-9 hsa-mir-9 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3187 hsa-mir-9-3 hsa-mir-9 hsa-mir-9 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3188 hsa-mir-21 hsa-mir-21 hsa-mir-21 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3189 hsa-mir-27a hsa-mir-27a hsa-mir-27a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3190 hsa-mir-98 hsa-mir-98 hsa-mir-98 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3191 hsa-let-7d hsa-let-7d hsa-let-7d acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3192 hsa-mir-148a hsa-mir-148a hsa-mir-148a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3193 hsa-mir-155 hsa-mir-155 hsa-mir-155 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3194 hsa-mir-7 hsa-mir-7 hsa-mir-7 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3195 hsa-mir-30c hsa-mir-30c hsa-mir-30c acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3196 hsa-mir-363 hsa-mir-363 hsa-mir-363 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3197 hsa-mir-181d hsa-mir-181d hsa-mir-181d acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3198 hsa-mir-196a hsa-mir-196a hsa-mir-196a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3199 hsa-mir-18a hsa-mir-18a hsa-mir-18a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3200 hsa-mir-184 hsa-mir-184 hsa-mir-184 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3201 hsa-mir-29a hsa-mir-29a hsa-mir-29a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3202 hsa-mir-200c hsa-mir-200c hsa-mir-200c acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3203 hsa-mir-10a hsa-mir-10a hsa-mir-10a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3204 hsa-mir-144 hsa-mir-144 hsa-mir-144 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3205 hsa-mir-203 hsa-mir-203 hsa-mir-203 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3206 hsa-let-7a-1 hsa-let-7a hsa-let-7a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3207 hsa-let-7a-2 hsa-let-7a hsa-let-7a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3208 hsa-let-7a-3 hsa-let-7a hsa-let-7a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3209 hsa-mir-140 hsa-mir-140-5p hsa-mir-140-5p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3210 hsa-mir-132 hsa-mir-132 hsa-mir-132 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3211 hsa-mir-23b hsa-mir-23b hsa-mir-23b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3212 hsa-mir-148b hsa-mir-148b hsa-mir-148b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3213 hsa-mir-124 hsa-mir-124 hsa-mir-124 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3214 hsa-mir-32 hsa-mir-32 hsa-mir-32 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3215 hsa-mir-128a hsa-mir-128a hsa-mir-128a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3216 hsa-mir-20b hsa-mir-20b hsa-mir-20b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3217 hsa-mir-214 hsa-mir-214 hsa-mir-214 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3218 hsa-let-7f hsa-let-7f hsa-let-7f acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3219 hsa-mir-133b hsa-mir-133b hsa-mir-133b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3220 hsa-mir-17 hsa-mir-17 hsa-mir-17 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3221 hsa-mir-199a hsa-mir-199a-3p hsa-mir-199a-3p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3222 hsa-mir-181c hsa-mir-181c hsa-mir-181c acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3223 hsa-mir-378 hsa-mir-378 hsa-mir-378 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3224 hsa-mir-181a hsa-mir-181a hsa-mir-181a acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3225 hsa-mir-27b hsa-mir-27b hsa-mir-27b acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3226 hsa-mir-191 hsa-mir-191 hsa-mir-191 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3227 hsa-mir-34c hsa-mir-34c-5p hsa-mir-34c-5p acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3228 hsa-mir-149 hsa-mir-149 hsa-mir-149 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3229 hsa-mir-212 hsa-mir-212 hsa-mir-212 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3230 hsa-mir-372 hsa-mir-372 hsa-mir-372 acute promyelocytic leukemia arsenic trioxide Then the NB4 cell (2105/ml) was cultured in the absence or presence of 2 njM concentrations of ATO (arsenic trioxide) for 48 h. Human APL cell line NB4 Human upregulated. 22072212 3231 hsa-mir-433 hsa-mir-433 hsa-mir-433 Ovarian cancer paclitaxel paclitaxel treatment epithelial ovarian cancer cell Human MAD2 protein expression levels were downregulated in pre-miR-433 transfected A2780 cells. Secondly, Pre-miR-433 suppressed the activity of a reporter construct containing the 3'-UTR of MAD2. Thirdly, blocking miR-433 binding to the MAD2 3'UTR protected MAD2 from miR-433 induced protein downregulation. Importantly, reduced MAD2 protein expression in pre-miR-433 transfected A2780 cells rendered these cells less sensitive to paclitaxel. In conclusion, loss of MAD2 protein expression results in increased resistance to paclitaxel in EOC cells. 22069160 3232 hsa-mir-638 hsa-mir-638 hsa-mir-638 Cell Transformation benzo(a)pyrene (BaP) benzo(a)pyrene (BaP) treatment human bronchial epithelial cells Human Aberrant Expression of miR-638 Contributes to Benzo(a)pyrene-induced Human Cell Transformation. 22048643 3233 hsa-mir-122 hsa-mir-122 hsa-mir-122 acute liver injury acetaminophen acetaminophen treatment serum Human Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients 22045675 3234 hsa-mir-192 hsa-mir-192 hsa-mir-192 acute liver injury acetaminophen acetaminophen treatment serum Human Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients 22045675 3235 hsa-mir-200c hsa-mir-200c hsa-mir-200c non-small-cell lung cancer erlotinib erlotinib treatment NSCLC cell line Human Ectopic expression of mir-200c alters expression of EMT proteins, sensitivity to erlotinib, and migration in lung cells. 22045191 3236 hsa-mir-15b hsa-mir-15b hsa-mir-15b anal carcinoma human papilloma virus (HPV) human papilloma virus (HPV) infection cervical cell line Human The expression of miR-15b was shown to be highly correlated with that of five selected E2F-induced genes (CCNA2, CCNB1, CCNB2, MSH6 and MCM7). A knockdown of HPV16 E7 resulted in decreased levels of miR-15b in Ca Ski cells.Conclusion:MiR-15b expression correlates with E2F-regulated genes in anal carcinoma and appears to be part of the E2F-regulatory network. 22045185 3237 hsa-mir-155 hsa-mir-155 hsa-mir-155 Innate immunity nitric oxide nitric oxide production N9 microglia cells Human The miR-155 knockdown by anti-miRNA oligonucleotides up-regulated SOCS-1 mRNA and protein levels and significantly decreased the production of nitric oxide and the expression of inflammatory cytokines and inducible nitric oxide synthase. 22043967 3238 hsa-mir-506 hsa-mir-506 hsa-mir-506 Colon cancer hydroxycamptothecin hydroxycamptothecin treatment colon cancer cells Human MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. 22036718 3239 hsa-mir-195a hsa-mir-195a hsa-mir-195a Carcinoma, Hepatocellular Benzothiazole Benzothiazole treatment Hepatocellular carcinoma (HCC) cell Human Benzothiazole based compounds exhibited effective cytotoxicity at 4 njM concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation. 22035408 3240 hsa-mir-101-1 hsa-mir-101 hsa-mir-101 Carcinoma, Hepatocellular Benzothiazole Benzothiazole treatment Hepatocellular carcinoma (HCC) cell Human Benzothiazole based compounds exhibited effective cytotoxicity at 4 njM concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation. 22035408 3241 hsa-mir-21 hsa-mir-21 hsa-mir-21 radiation-induced histomorphological changes irradiation irradiation treatment mouse hippocampal cells and brain tissue Human MiR-21 is Continually Elevated Long-Term in the Brain after Exposure to Ionizing Radiation.radiation stimulated miR-21 expression in mouse hippocampal cells and upregulation of EGFR, which is similar to that in human hepatocytes, as we reported previously. Interestingly, the miR-21 levels not only were higher in the brains from irradiated mice than in those from nonirradiated mice but also gradually increased within 1 year after irradiation, although there was no significant difference in the miR-21 levels in mice irradiated mice with low- or high-LET-radiation. The high expression of miR-21 in the brain was also associated with high expression of EGFR in all irradiated mice examined; thus our data strongly support that EGFR and miR-21 are in a positive regulatory loop, because it is known that radiation stimulates miR-21 through the EGFR/Stat3 pathway and miR-21 activates the EGFR pathway. 22034847 3242 hsa-mir-200b hsa-mir-200b hsa-mir-200b Endometrial cancer cisplatin cisplatin treatment endometrial cancer cell line HEC-1A Human Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2ǁ gene and negatively regulated the expression of endogenous AP-2ǁ proteins. SNP rs1045385 A>C variation enhanced AP-2ǁ expression by disrupting the binding of the miR-200b/200c/429 family to the 3' UTR of AP-2ǁ. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2ǁ with mutant 3' UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/429 and low levels of AP-2ǁ protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2ǁ has no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance by repressing AP-2ǁ expression in endometrial cancer cells. The SNP (rs1045385) A>C variation decreased the binding of miR-200b/200c/429 to the 3' UTR of AP-2ǁ, which upregulated AP-2ǁ protein expression and increased cisplatin sensitivity. Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment. 22194984 3243 hsa-mir-200c hsa-mir-200c hsa-mir-200c Endometrial cancer cisplatin cisplatin treatment endometrial cancer cell line HEC-1A Human Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2ǁ gene and negatively regulated the expression of endogenous AP-2ǁ proteins. SNP rs1045385 A>C variation enhanced AP-2ǁ expression by disrupting the binding of the miR-200b/200c/429 family to the 3' UTR of AP-2ǁ. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2ǁ with mutant 3' UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/429 and low levels of AP-2ǁ protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2ǁ has no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance by repressing AP-2ǁ expression in endometrial cancer cells. The SNP (rs1045385) A>C variation decreased the binding of miR-200b/200c/429 to the 3' UTR of AP-2ǁ, which upregulated AP-2ǁ protein expression and increased cisplatin sensitivity. Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment. 22194984 3244 hsa-mir-429 hsa-mir-429 hsa-mir-429 Endometrial cancer cisplatin cisplatin treatment endometrial cancer cell line HEC-1A Human Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2ǁ gene and negatively regulated the expression of endogenous AP-2ǁ proteins. SNP rs1045385 A>C variation enhanced AP-2ǁ expression by disrupting the binding of the miR-200b/200c/429 family to the 3' UTR of AP-2ǁ. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2ǁ with mutant 3' UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/429 and low levels of AP-2ǁ protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2ǁ has no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance by repressing AP-2ǁ expression in endometrial cancer cells. The SNP (rs1045385) A>C variation decreased the binding of miR-200b/200c/429 to the 3' UTR of AP-2ǁ, which upregulated AP-2ǁ protein expression and increased cisplatin sensitivity. Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment. 22194984 3245 nta-mir171d nta-miR171d nta-miR171d cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3246 nta-mir2111 nta-miR2111 nta-miR2111 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3247 nta-mir160c nta-miR160c nta-miR160c cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3248 nta-mirn32 nta-miRn32 nta-miRn32 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3249 nta-mirn64 nta-miRn64 nta-miRn64 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3250 nta-mir399a nta-miR399a nta-miR399a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3251 nta-mir168 nta-miR168* nta-miR168* cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3252 nta-mirn28 nta-miRn28 nta-miRn28 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3253 nta-mir166a nta-miR166a* nta-miR166a* cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3254 nta-mirn6 nta-miRn6 nta-miRn6 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3255 nta-mirn66 nta-miRn66 nta-miRn66 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3256 nta-mirn52 nta-miRn52 nta-miRn52 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3257 nta-mir398 nta-miR398 nta-miR398 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3258 nta-mirn24 nta-miRn24 nta-miRn24 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3259 nta-mirn51 nta-miRn51 nta-miRn51 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3260 nta-mirn39 nta-miRn39 nta-miRn39 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3261 nta-mir393b nta-miR393b* nta-miR393b* cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3262 nta-mirn18 nta-miRn18 nta-miRn18 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3263 nta-mir1384b nta-miR1384b nta-miR1384b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3264 nta-mirn36a nta-miRn36a nta-miRn36a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3265 nta-mir171a nta-miR171a* nta-miR171a* cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3266 nta-mir3627a nta-miR3627a nta-miR3627a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3267 nta-mir169b nta-miR169b nta-miR169b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3268 nta-mir479 nta-miR479 nta-miR479 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3269 nta-mir160a nta-miR160a nta-miR160a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3270 nta-mir160b nta-miR160b nta-miR160b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3271 nta-mirn1a nta-miRn1a nta-miRn1a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3272 nta-mir171b nta-miR171b nta-miR171b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3273 nta-mirn56 nta-miRn56 nta-miRn56 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco up-regulated 22194852 3274 nta-mir156a nta-miR156a nta-miR156a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3275 nta-mir156e nta-miR156e nta-miR156e cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3276 nta-mir156f nta-miR156f nta-miR156f cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3277 nta-mir156b nta-miR156b nta-miR156b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3278 nta-mir156c nta-miR156c nta-miR156c cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3279 nta-mir156d nta-miR156d nta-miR156d cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3280 nta-mir159 nta-miR159 nta-miR159 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3281 nta-mir827 nta-miR827 nta-miR827 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3282 nta-mir172e nta-miR172e nta-miR172e cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3283 nta-mirn47 nta-miRn47 nta-miRn47 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3284 nta-mirn60a nta-miRn60a nta-miRn60a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3285 nta-mirn31 nta-miRn31 nta-miRn31 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3286 nta-mirn11b nta-miRn11b nta-miRn11b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3287 nta-mirn11c nta-miRn11c nta-miRn11c cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3288 nta-mirn35 nta-miRn35 nta-miRn35 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3289 nta-mirn70 nta-miRn70 nta-miRn70 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3290 nta-mir166c nta-miR166c nta-miR166c cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3291 nta-mir395b nta-miR395b nta-miR395b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3292 nta-mirn49 nta-miRn49 nta-miRn49 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3293 nta-mir164a nta-miR164a nta-miR164a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3294 nta-mirn73 nta-miRn73 nta-miRn73 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3295 nta-mir394a nta-miR394a nta-miR394a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3296 nta-mirn19 nta-miRn19 nta-miRn19 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3297 nta-mirn27a nta-miRn27a nta-miRn27a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3298 nta-mirn3 nta-miRn3 nta-miRn3 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3299 nta-mirn58a nta-miRn58a nta-miRn58a cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3300 nta-mirn74 nta-miRn74 nta-miRn74 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3301 nta-mirn44 nta-miRn44 nta-miRn44 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3302 nta-mir477b nta-miR477b nta-miR477b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3303 nta-mirn12 nta-miRn12 nta-miRn12 cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3304 nta-mir397b nta-miR397b nta-miR397b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3305 nta-mir4367b nta-miR4367b nta-miR4367b cultivating measure for flue-cured tobacco topping topping treatment Flue-Cured Tobacco (Nicotiana tabacum) Roots. Tobacco down-regulated 22194852 3306 gga-mir-15b gga-miR-15b gga-miR-15b lymphoma susceptibility Marek's disease virus Marek's disease virus infection chickens Chicken Chicken miRNA gga-miR-15b, which is reduced in infected susceptible chickens and splenic tumors, controls the expression of ATF2 (activating transcription factor 2). ATF2 is significantly increased in the same group. 22178800 3307 hsa-mir-146a hsa-mir-146a hsa-mir-146a Prostatic Neoplasms castration castration treatment prostate cancer cell Human MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. 22161865 3308 ghr-MIR156a ghr-miR156a ghr-miR156a salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3309 ghr-MIR156d ghr-miR156d ghr-miR156d salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3310 ghr-MIR156e ghr-miR156e ghr-miR156e salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3311 ghr-MIR169 ghr-miR169 ghr-miR169 salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3312 ghr-MIR535a ghr-miR535a ghr-miR535a salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3313 ghr-MIR535b ghr-miR535b ghr-miR535b salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3314 ghr-MIR827b ghr-miR827b ghr-miR827b salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3315 ghr-MIR167a ghr-miR167a ghr-miR167a salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3316 ghr-MIR397a ghr-miR397a ghr-miR397a salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3317 ghr-MIR397b ghr-miR397b ghr-miR397b salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3318 ghr-MIR399a ghr-miR399a ghr-miR399a salt adaptation salt salt stress treatment cotton Cotton Under salt stress treatment, miR156a/d/e, miR169, miR535a/b and miR827b were dramatically down-regulated in SN-011 (salt-tolerant cotton cultivar), while miR167a, miR397a/b and miR399a were up-regulated. Only miR159 was found to be down-regulated in LM-6 (salt-sensitive cultivar) under salt stress. 22160515 3319 hsa-mir-30a hsa-mir-30a hsa-mir-30a Ovarian cancer cis-dichloro-diamine platinum (cis-DDP) or Taxol cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment HeLa, MCF-7, HepG2 Human MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. 22157765 3320 hsa-mir-30a hsa-mir-30a hsa-mir-30a Breast cancer cis-dichloro-diamine platinum (cis-DDP) or Taxol cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment HeLa, MCF-7, HepG2 Human MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. 22157765 3321 hsa-mir-30a hsa-mir-30a hsa-mir-30a Liver cancer cis-dichloro-diamine platinum (cis-DDP) or Taxol cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment HeLa, MCF-7, HepG2 Human MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. 22157765 3322 hsa-mir-30b hsa-mir-30b hsa-mir-30b Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3323 hsa-mir-30c hsa-mir-30c hsa-mir-30c Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3324 hsa-mir-221 hsa-mir-221 hsa-mir-221 Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3325 hsa-mir-222 hsa-mir-222 hsa-mir-222 Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3326 hsa-mir-103 hsa-mir-103 hsa-mir-103 Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3327 hsa-mir-203 hsa-mir-203 hsa-mir-203 Lung cancer gefitinib gefitinib treatment TKI-resistant NSCLC (non-small-cell lung cancer) cell Human Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC). 22157681 3328 hsa-let-7f-1 hsa-let-7f hsa-let-7f Breast Neoplasms letrozole letrozole treatment MCF-7 Human Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. 22407818 3329 hsa-let-7f-2 hsa-let-7f hsa-let-7f Breast Neoplasms letrozole letrozole treatment MCF-7 Human Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. 22407818 3330 hsa-mir-27a hsa-mir-27a hsa-mir-27a Breast Neoplasms Betulinic acid Betulinic acid treatment MDA-MB-231 cells Human Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10.BA induced cell cycle arrest in the G2/M phase and increased Myt-1 mRNA (a microRNA-27a target gene), which causes inhibition in G2/M by phosphorylation of cdc2. 22407812 3331 hsa-mir-21 hsa-mir-21 hsa-mir-21 Albuminuria arsenic arsenic content Urinary Human miR-21 was associated with microalbuminuria (p=0.02). Urinary arsenic and lead levels had a negative association with both miR-21 and miR-221. 22405870 3332 hsa-mir-21 hsa-mir-21 hsa-mir-21 Albuminuria lead lead content Urinary Human miR-21 was associated with microalbuminuria (p=0.02). Urinary arsenic and lead levels had a negative association with both miR-21 and miR-221. 22405870 3333 hsa-mir-15b hsa-mir-15b hsa-mir-15b Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3334 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3335 hsa-mir-638 hsa-mir-638 hsa-mir-638 Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3336 hsa-mir-663 hsa-mir-663 hsa-mir-663 Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3337 hsa-mir-1915 hsa-mir-1915 hsa-mir-1915 Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3338 hsa-let-7a-1 hsa-let-7a hsa-let-7a Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3339 hsa-let-7a-2 hsa-let-7a hsa-let-7a Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3340 hsa-let-7a-3 hsa-let-7a hsa-let-7a Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3341 hsa-let-7b hsa-let-7b hsa-let-7b Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3342 hsa-let-7c hsa-let-7c hsa-let-7c Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3343 hsa-let-7d hsa-let-7d hsa-let-7d Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3344 hsa-let-7e hsa-let-7e hsa-let-7e Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3345 hsa-let-7f-1 hsa-let-7f hsa-let-7f Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3346 hsa-let-7f-2 hsa-let-7f hsa-let-7f Breast Neoplasms E2 E2 treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3347 hsa-mir-15b hsa-mir-15b hsa-mir-15b Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3348 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3349 hsa-mir-638 hsa-mir-638 hsa-mir-638 Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3350 hsa-mir-663 hsa-mir-663 hsa-mir-663 Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3351 hsa-mir-1915 hsa-mir-1915 hsa-mir-1915 Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3352 hsa-let-7a-1 hsa-let-7a hsa-let-7a Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3353 hsa-let-7a-2 hsa-let-7a hsa-let-7a Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3354 hsa-let-7a-3 hsa-let-7a hsa-let-7a Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3355 hsa-let-7b hsa-let-7b hsa-let-7b Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3356 hsa-let-7c hsa-let-7c hsa-let-7c Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3357 hsa-let-7d hsa-let-7d hsa-let-7d Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3358 hsa-let-7e hsa-let-7e hsa-let-7e Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3359 hsa-let-7f-1 hsa-let-7f hsa-let-7f Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3360 hsa-let-7f-2 hsa-let-7f hsa-let-7f Breast Neoplasms BPA BPA treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3361 hsa-mir-15b hsa-mir-15b hsa-mir-15b Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3362 hsa-mir-27b hsa-mir-27b hsa-mir-27b Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3363 hsa-mir-638 hsa-mir-638 hsa-mir-638 Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3364 hsa-mir-663 hsa-mir-663 hsa-mir-663 Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3365 hsa-mir-1915 hsa-mir-1915 hsa-mir-1915 Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3366 hsa-let-7a-1 hsa-let-7a hsa-let-7a Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3367 hsa-let-7a-2 hsa-let-7a hsa-let-7a Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3368 hsa-let-7a-3 hsa-let-7a hsa-let-7a Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3369 hsa-let-7b hsa-let-7b hsa-let-7b Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3370 hsa-let-7c hsa-let-7c hsa-let-7c Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3371 hsa-let-7d hsa-let-7d hsa-let-7d Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3372 hsa-let-7e hsa-let-7e hsa-let-7e Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3373 hsa-let-7f-1 hsa-let-7f hsa-let-7f Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3374 hsa-let-7f-2 hsa-let-7f hsa-let-7f Breast Neoplasms DDT DDT treatment MCF-7 Human Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT 22403704 3375 hsa-mir-34a hsa-mir-34a hsa-mir-34a Myocardial Infarction H2O2 H2O2 induce bone marrow-derived mononuclear cells Human IGF-1 significantly inhibited H(2)O(2)-induced miR-34a expression, and miR-34a overexpression abolished the anti-apoptotic effect of IGF-1. 22403243 3376 mmu-mir-122 mmu-mir-122 mmu-mir-122 Inflammatory quercetin Laboratory mice were fed for six weeks with control or quercetin enriched high fat diets liver Mouse hepatic miR-122 and miR-125b concentrations were increased by dietary quercetin supplementation and may therefore contribute to the gene-regulatory activity of quercetin in vivo. 22402395 3377 mmu-mir-125b-1 mmu-mir-125b mmu-mir-125b Inflammatory quercetin Laboratory mice were fed for six weeks with control or quercetin enriched high fat diets liver Mouse hepatic miR-122 and miR-125b concentrations were increased by dietary quercetin supplementation and may therefore contribute to the gene-regulatory activity of quercetin in vivo. 22402395 3378 mmu-mir-125b-2 mmu-mir-125b mmu-mir-125b Inflammatory quercetin Laboratory mice were fed for six weeks with control or quercetin enriched high fat diets liver Mouse hepatic miR-122 and miR-125b concentrations were increased by dietary quercetin supplementation and may therefore contribute to the gene-regulatory activity of quercetin in vivo. 22402395 3379 rno-mir-140 rno-mir-140 rno-mir-140 Regulation in growth food Prepubertal rats were fed ad libitum or were subjected to 40% food restriction for 10 days followed by a renewal of the regular food supply epiphyseal growth plate Rat Chondrocyte-specific miR-140-3p showed the highest expression in the mature EGP, and it was one of the few miRNAs that were significantly reduced following nutrition restriction.Nutrition restriction induced an increase in the level of the miR-140-3p target, NAD+-dependent SIRT1. 22402365 3380 hsa-mir-375 hsa-mir-375 hsa-mir-375 Breast Neoplasms neoadjuvant chemotherapy neoadjuvant chemotherapy (NCT) followed by surgical tumor resection blood Human Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients. 22400902 3381 hsa-mir-122 hsa-mir-122 hsa-mir-122 Breast Neoplasms neoadjuvant chemotherapy neoadjuvant chemotherapy (NCT) followed by surgical tumor resection blood Human Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients. 22400902 3382 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b non-small cell lung cancer Necitumumab Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3383 hsa-mir-29b-2 hsa-mir-29b hsa-mir-29b non-small cell lung cancer Necitumumab Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3384 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b non-small cell lung cancer cisplatin Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3385 hsa-mir-29b-2 hsa-mir-29b hsa-mir-29b non-small cell lung cancer cisplatin Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3386 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b non-small cell lung cancer gemcitabine Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3387 hsa-mir-29b-2 hsa-mir-29b hsa-mir-29b non-small cell lung cancer gemcitabine Necitumumab in combination with cisplatin/gemcitabine A549 cell Human increased 22399498 3388 hsa-mir-126 hsa-mir-126 hsa-mir-126 metastatic colorectal cancer capecitabine and oxaliplatin capecitabine and oxaliplatin treatment primary tumours Human The median miRNA-126 expression level was significantly higher in patients responding to XELOX (capecitabine and oxaliplatin). 22397399 3389 mmu-mir-29b-1 mmu-mir-29b mmu-mir-29b Pulmonary Fibrosis Bleomycin Bleomycin induce lung Mouse miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice. 22395530 3390 mmu-mir-29b-2 mmu-mir-29b mmu-mir-29b Pulmonary Fibrosis Bleomycin Bleomycin induce lung Mouse miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice. 22395530 3391 diet high-fat diet skeletal muscle Mouse up-regulated in the high-fat diet-fed mice. 22395471 3392 hsa-mir-30a hsa-mir-30a hsa-mir-30a Leukemia, Myeloid, Chronic-Phase imatinib imatinib treatment human chronic myeloid leukemia cells Human Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.imatinib markedly inhibits expression of miR-30a in human chronic myeloid leukemia cells. miR-30a is a potent inhibitor of autophagy by downregulating Beclin 1 and ATG5 expression. miR-30a mimic or knockdown of autophagy genes (ATGs) such as Beclin 1 and ATG5 by shRNA enhances imatinib-induced cytotoxicity and promotes mitochondria-dependent intrinsic apoptosis. In contrast, knockdown of miR-30a by antagomir-30a increases the expression of Beclin 1 and ATG5, and inhibits imatinib-induced cytotoxicity. 22395361 3393 mmu-mir-29b-1 mmu-mir-29b mmu-mir-29b liver injury Estrogen Estrogen induce liver Mouse Estrogen-induced miRNA-29 expression has a protective role of in carbon tetrachloride-induced mouse liver injury. 22393047 3394 mmu-mir-29b-2 mmu-mir-29b mmu-mir-29b liver injury Estrogen Estrogen induce liver Mouse Estrogen-induced miRNA-29 expression has a protective role of in carbon tetrachloride-induced mouse liver injury. 22393047 3395 mmu-mir-29a mmu-mir-29a mmu-mir-29a liver injury Estrogen Estrogen induce liver Mouse Estrogen-induced miRNA-29 expression has a protective role of in carbon tetrachloride-induced mouse liver injury. 22393047 3396 hsa-mir-520h hsa-mir-520h hsa-mir-520h Lung Neoplasms Resveratrol Resveratrol treatment lung cancer cells Human MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. 22410781 3397 hsa-mir-16-1 hsa-mir-16 hsa-mir-16 cellular DNA damage response Polycyclic aromatic hydrocarbons Polycyclic aromatic hydrocarbons PAH-contaminated soils HepG2 cells exposed to soil PAH Human Discrepancies between mRNA and protein levels of Wip1 in response to soil extracts, in parallel with increased microRNA (miR)-16 levels, suggest a role of miR-16 in the regulation of DNA damage signaling in response to PAHs. 22409540 3398 hsa-mir-16-2 hsa-mir-16 hsa-mir-16 cellular DNA damage response Polycyclic aromatic hydrocarbons Polycyclic aromatic hydrocarbons PAH-contaminated soils HepG2 cells exposed to soil PAH Human Discrepancies between mRNA and protein levels of Wip1 in response to soil extracts, in parallel with increased microRNA (miR)-16 levels, suggest a role of miR-16 in the regulation of DNA damage signaling in response to PAHs. 22409540 3399 hsa-mir-210 hsa-mir-210 hsa-mir-210 Carcinoma, Hepatocellular radioation radioation treatment SMMC-7721, HepG2 and HuH7 cells Human Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. 22387901 3400 hsa-mir-193 hsa-mir-193 hsa-mir-193 proliferation of mesenchymal stem cells irradiation (Low-level laser irradiation mesenchymal stem cells Human miR-193 plays a critical part in MSC proliferation in response to LLLI(Low-level laser irradiation) stimulation, which is potentially amenable to therapeutic manipulation for clinical application. 22384930 3401 hsa-mir-26a-1 hsa-mir-26a hsa-mir-26a Breast Neoplasms Trastuzumab Trastuzumab treatment HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days Human Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. 22384020 3402 hsa-mir-26a-2 hsa-mir-26a hsa-mir-26a Breast Neoplasms Trastuzumab Trastuzumab treatment HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days Human Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. 22384020 3403 hsa-mir-30b hsa-mir-30b hsa-mir-30b Breast Neoplasms Trastuzumab Trastuzumab treatment HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days Human Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. 22384020 3404 hsa-mir-21 hsa-mir-21 hsa-mir-21 Colon Neoplasms 5-FU 5-FU treatment DLD-1 and KM12C cell lines Human In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells. 22382630 3405 hsa-mir-19b-1 hsa-mir-19b hsa-mir-19b Colon Neoplasms 5-FU 5-FU treatment DLD-1 and KM12C cell lines Human In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells. 22382630 3406 hsa-mir-19b-2 hsa-mir-19b hsa-mir-19b Colon Neoplasms 5-FU 5-FU treatment DLD-1 and KM12C cell lines Human In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells. 22382630 3407 hsa-mir-181a-2 hsa-mir-181a-2* hsa-mir-181a-2* n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3408 hsa-mir-181b hsa-mir-181b hsa-mir-181b n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3409 hsa-mir-181a-1 hsa-mir-181a hsa-mir-181a n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3410 hsa-mir-338 hsa-mir-338-3p hsa-mir-338-3p n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3411 hsa-mir-1225 hsa-mir-1225-5p hsa-mir-1225-5p n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3412 hsa-mir-26b hsa-mir-26b hsa-mir-26b n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3413 hsa-mir-132 hsa-mir-132 hsa-mir-132 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3414 hsa-mir-15a hsa-mir-15a hsa-mir-15a n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3415 hsa-mir-939 hsa-mir-939 hsa-mir-939 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3416 hsa-mir-7-1 hsa-mir-7 hsa-mir-7 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3417 hsa-mir-140 hsa-mir-140-5p hsa-mir-140-5p n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3418 hsa-mir-21 hsa-mir-21* hsa-mir-21* n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3419 hsa-mir-940 hsa-mir-940 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was upregulated after excersise. 22376254 3420 hsa-mir-125b-1 hsa-mir-125b hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3421 hsa-mir-125b-2 hsa-mir-125b hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3422 hsa-let-7e hsa-let-7e hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3423 hsa-mir-451 hsa-mir-451 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3424 hsa-mir-320a hsa-mir-320a hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3425 hsa-mir-151 hsa-mir-151-5p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3426 hsa-mir-486 hsa-mir-486-5p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3427 hsa-mir-31 hsa-mir-31 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3428 hsa-mir-125a hsa-mir-125a-5p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3429 hsa-mir-99b hsa-mir-99b hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3430 hsa-mir-652 hsa-mir-652 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3431 hsa-mir-151 hsa-mir-151-3p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3432 hsa-mir-130a hsa-mir-130a hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3433 hsa-mir-126 hsa-mir-126 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3434 hsa-mir-199b hsa-mir-199b-3p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3435 hsa-mir-23b hsa-mir-23b hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3436 hsa-mir-221 hsa-mir-221 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3437 hsa-mir-199a-1 hsa-mir-199a-5p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3438 hsa-mir-199a-2 hsa-mir-199a-5p hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3439 hsa-mir-584 hsa-mir-584 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3440 hsa-mir-145 hsa-mir-145 hsa-mir-940 n/a exercise Twelve young men performed brief bouts of heavy exercise peripheral blood mononuclear cells Human The miRNA was downregulated after excersise. 22376254 3441 hsa-mir-205 hsa-mir-205 hsa-mir-205 Nasopharyngeal Neoplasms radioation radioation treatment CNE-2R Human MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. 22374676 3442 hsa-mir-92a-1 hsa-mir-92a hsa-mir-92a Prostatic cancer Isoflavone Isoflavone treatment prostatic cancer cell Human Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression. 22412975 3443 hsa-mir-92a-2 hsa-mir-92a hsa-mir-92a Prostatic cancer Isoflavone Isoflavone treatment prostatic cancer cell Human Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression. 22412975 3444 hsa-mir-210 hsa-mir-210 hsa-mir-210 Breast cancer Trastuzumab Trastuzumab treatment MicroRNA expression levels also were compared in trastuzumab-sensitive and trastuzumab-resistant breast cancer cells derived from BT474 cells and in an independent set of preoperative plasma samples (n = 39) and postoperative plasma samples (n = 30) from 43 breast cancer patients who did not receive any treatment. Human Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. 22370716 3445 hsa-mir-34c hsa-mir-34c hsa-mir-34c Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. miR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation. 22370637 3446 hsa-mir-135a-1 hsa-mir-135a hsa-mir-135a Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3447 hsa-mir-135a-2 hsa-mir-135a hsa-mir-135a Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3448 hsa-mir-135b hsa-mir-135b hsa-mir-135b Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3449 hsa-mir-520a hsa-mir-520a hsa-mir-520a Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3450 hsa-mir-520b hsa-mir-520b hsa-mir-520b Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3451 hsa-mir-520c hsa-mir-520c hsa-mir-520c Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3452 hsa-mir-520d hsa-mir-520d hsa-mir-520d Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3453 hsa-mir-520e hsa-mir-520e hsa-mir-520e Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3454 hsa-mir-124-1 hsa-mir-124 hsa-mir-124 Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3455 hsa-mir-17 hsa-mir-17 hsa-mir-17 Non-Small-Cell Lung cancer paclitaxel paclitaxel treatment non-small cell lung carcinoma A549 cell line Human The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. 22370637 3456 hsa-let-7e hsa-let-7e hsa-let-7e Human health risks ionizing radiation acute or chronic low doses of 10 cGy or a moderate dose of 400 cGy of (137)Cs ǃ-rays human cells Human The expression of miRNA let-7e, a negative regulator of RAS oncogene, and the c-MYC miRNA cluster were upregulated after 10 cGy chronic dose but were downregulated after 3 h of acute 10 cGy. 22367372 3457 hsa-mir-21 hsa-mir-21 hsa-mir-21 Human health risks ionizing radiation acute or chronic low doses of 10 cGy or a moderate dose of 400 cGy of (137)Cs ǃ-rays human cells Human The miR-21 was upregulated in chronic or acute low dose and moderate dose treated cells and its target genes hPDCD4, hPTEN, hSPRY2, and hTPM1 were found to be downregulated. 22367372 3458 hsa-mir-206 hsa-mir-206 hsa-mir-206 Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3459 hsa-mir-516b-1 hsa-mir-516b hsa-mir-516b Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3460 hsa-mir-516b-2 hsa-mir-516b hsa-mir-516b Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3461 hsa-mir-550-1 hsa-mir-550 hsa-mir-550 Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3462 hsa-mir-550-2 hsa-mir-550 hsa-mir-550 Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3463 hsa-mir-671 hsa-mir-671 hsa-mir-671 Prolactinoma bromocriptine bromocriptine treatment Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery Human miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. 22366961 3464 hsa-mir-34a hsa-mir-34a hsa-mir-34a EMT Hypoxia Hypoxia induce HK-2 cells Human Hypoxia-Induced Down-Regulation of microRNA-34a Promotes EMT by Targeting the Notch Signaling Pathway in Tubular Epithelial Cells. 22363487 3465 hsa-mir-21 hsa-mir-21 hsa-mir-21 Esophageal Neoplasms Curcumin Curcumin treatment esophageal cancer cell lines Human Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA. 22363450 3466 hsa-mir-34a hsa-mir-34a hsa-mir-34a Esophageal Neoplasms Curcumin Curcumin treatment esophageal cancer cell lines Human Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA. 22363450 3467 hsa-let-7a-1 hsa-let-7a hsa-let-7a Esophageal Neoplasms Curcumin Curcumin treatment esophageal cancer cell lines Human Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA. 22363450 3468 hsa-let-7a-2 hsa-let-7a hsa-let-7a Esophageal Neoplasms Curcumin Curcumin treatment esophageal cancer cell lines Human Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA. 22363450 3469 hsa-mir-21 hsa-mir-21 hsa-mir-21 Glioblastoma Ursolic Acid 5 to 20 njmol/L of UA suppressed proliferation and induced apoptosis of U251 cells in dose- and time-dependent manners. human glioma cell line U251 Human Ursolic Acid Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cell Lines U251 by Suppressing TGF-ǂ1/miR-21 /PDCD4 Pathway. 22353043 3470 hsa-let-7i hsa-let-7i* hsa-let-7i* DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3471 hsa-mir-7-1 hsa-mir-7-1* hsa-mir-7-1* DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3472 hsa-mir-27a hsa-mir-27a hsa-mir-27a DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3473 hsa-mir-144 hsa-mir-144 hsa-mir-144 DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3474 hsa-mir-200a hsa-mir-200a hsa-mir-200a DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3475 hsa-mir-598 hsa-mir-598 hsa-mir-598 DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3476 hsa-mir-650 hsa-mir-650 hsa-mir-650 DNA-damage response Ionizing radiation Ionizing radiation treatment human peripheral blood lymphocytes (PBL) Human let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650 are deregulated by the combined action of radiation and MMG (modeled microgravity). 22347458 3477 hsa-mir-15b hsa-mir-15b hsa-mir-15b radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H1 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3478 hsa-mir-302b hsa-mir-302b hsa-mir-302b radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H1 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3479 hsa-mir-1973 hsa-mir-1973 hsa-mir-1973 radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H1 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3480 hsa-mir-720 hsa-mir-720 hsa-mir-720 radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H1 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3481 hsa-mir-20a hsa-mir-20a hsa-mir-20a radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H1 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3482 hsa-mir-1973 hsa-mir-1973 hsa-mir-1973 radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H9 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3483 hsa-mir-92a-1 hsa-mir-92a hsa-mir-92a radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H9 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3484 hsa-mir-92a-2 hsa-mir-92a hsa-mir-92a radiation response Ionizing radiation Ionizing radiation exposure human embryonic stem cells (hESC) Human upregulated in H9 hESC at 2 hr post 1 Gy of X-ray exposures 22347422 3485 hsa-mir-449a hsa-mir-449a hsa-mir-449a Ovarian cancer adriamycin adriamycin treatment ovarian cancer cells and serous ovarian cancer tissues Human The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin. 22340095 3486 hsa-mir-449b hsa-mir-449b hsa-mir-449b Ovarian cancer adriamycin adriamycin treatment ovarian cancer cells and serous ovarian cancer tissues Human The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin. 22340095 3487 hsa-mir-34c hsa-mir-34c hsa-mir-34c Ovarian cancer adriamycin adriamycin treatment ovarian cancer cells and serous ovarian cancer tissues Human The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin. 22340095 3488 hsa-mir-34b hsa-mir-34b hsa-mir-34b Ovarian cancer adriamycin adriamycin treatment ovarian cancer cells and serous ovarian cancer tissues Human The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin. 22340095 3489 hsa-mir-21 hsa-mir-21 hsa-mir-21 Glioma radiation radiation treatment SHG-44(R) cells (Radioresistant cell line) and SHG-44 cells Human miR-21 was up-regulated 1.49-fold in SHG-44(R) cells (Radioresistant cell line) relative to the SHG-44 cells. 22335906 3490 rno-mir-29a rno-mir-29a rno-mir-29a germ cell death estradiol benzoate (EB) estradiol benzoate (EB) exposure Rat Neonatal exposure to EB induced adult germ cell apoptosis together with a dose-dependent increase in miR-29a, miR-29b, and miR-29c expression. 22334722 3491 rno-mir-29b-1 rno-mir-29b rno-mir-29b germ cell death estradiol benzoate (EB) estradiol benzoate (EB) exposure Rat Neonatal exposure to EB induced adult germ cell apoptosis together with a dose-dependent increase in miR-29a, miR-29b, and miR-29c expression. 22334722 3492 rno-mir-29c rno-mir-29c rno-mir-29c germ cell death estradiol benzoate (EB) estradiol benzoate (EB) exposure Rat Neonatal exposure to EB induced adult germ cell apoptosis together with a dose-dependent increase in miR-29a, miR-29b, and miR-29c expression. 22334722 3493 hsa-mir-29a hsa-mir-29a hsa-mir-29a Breast cancer progestin 6h of progestin treatment breast cancer cell Human Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, the authors demonstrate that PR itself is regulated by a progestin-upregulated miRNA, miR-513a-5p, providing a novel mechanism for tight control of PR protein expression. 22330642 3494 hsa-mir-29b-1 hsa-mir-29b hsa-mir-29b Breast cancer progestin 6h of progestin treatment breast cancer cell Human Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, the authors demonstrate that PR itself is regulated by a progestin-upregulated miRNA, miR-513a-5p, providing a novel mechanism for tight control of PR protein expression. 22330642 3495 hsa-mir-29c hsa-mir-29c hsa-mir-29c Breast cancer progestin 6h of progestin treatment breast cancer cell Human Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, the authors demonstrate that PR itself is regulated by a progestin-upregulated miRNA, miR-513a-5p, providing a novel mechanism for tight control of PR protein expression. 22330642 3496 hsa-mir-513a-1 hsa-mir-513a hsa-mir-513a Breast cancer progestin 6h of progestin treatment breast cancer cell Human Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, the authors demonstrate that PR itself is regulated by a progestin-upregulated miRNA, miR-513a-5p, providing a novel mechanism for tight control of PR protein expression. 22330642 3497 hsa-mir-513a-2 hsa-mir-513a hsa-mir-513a Breast cancer progestin 6h of progestin treatment breast cancer cell Human Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, the authors demonstrate that PR itself is regulated by a progestin-upregulated miRNA, miR-513a-5p, providing a novel mechanism for tight control of PR protein expression. 22330642 3498 rno-mir-126 rno-mir-126 rno-mir-126 Angiogenesis increasing Swimming T1 consisted of 60min/day swimming, 5/week/10week with 5% body overload. T2 the same protocol of T1 until 8 week, in the 9 week trained 2/day and 10 week trained 3/day. heart muscle Rat Swimming Training in Rats Increases Cardiac MicroRNA-126 Expression and Angiogenesis. 22330028 3499 hsa-mir-22 hsa-mir-22 hsa-mir-22 Colon cancer vitamin D vitamin D metabolites 1,25(OH)(2)D(3) SW480-ADH and HCT116 cells Human MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells.miR-22 is induced by 1,25(OH)(2)D(3) in a time-, dose- and VDR-dependent manner. 22328083 3500 hsa-mir-155 hsa-mir-155 hsa-mir-155 Inflammation Glucocorticoids Glucocorticoids treatment RAW264.7 cells Human Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155 22326887 3501 hsa-mir-10b hsa-mir-10b hsa-mir-10b Colorectal Cancer 5-FU 5-FU treatment colorectal cancer cells Human MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells. 22322955 3502 hsa-mir-21 hsa-mir-21 hsa-mir-21 Colon cancer 5-FU 5-FU treatment HCT116 Human microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. 22322462 3503 hsa-mir-21 hsa-mir-21 hsa-mir-21 Colon cancer metformin metformin treatment Human microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. 22322462 3504 hsa-mir-122 hsa-mir-122 hsa-mir-122 Liver cancer 5-FU 5-FU treatment BEL-7402/5-FU cells Human MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. 22312705 3505 hsa-mir-146b hsa-mir-146b hsa-mir-146b Listerial infection Listerial Listerial infection Caco-2 cells Human miR- 146b, miR-16, let-7a1, miR-145 and miR-155 were significantly deregulated following listerial infection. 22312311 3506 hsa-mir-16-1 hsa-mir-16 hsa-mir-16 Listerial infection Listerial Listerial infection Caco-2 cells Human miR- 146b, miR-16, let-7a1, miR-145 and miR-155 were significantly deregulated following listerial infection. 22312311 3507 hsa-let-7a-1 hsa-let-7a hsa-let-7a Listerial infection Listerial Listerial infection Caco-2 cells Human miR- 146b, miR-16, let-7a1, miR-145 and miR-155 were significantly deregulated following listerial infection. 22312311 3508 hsa-mir-145 hsa-mir-145 hsa-mir-145 Listerial infection Listerial Listerial infection Caco-2 cells Human miR- 146b, miR-16, let-7a1, miR-145 and miR-155 were significantly deregulated following listerial infection. 22312311 3509 hsa-mir-155 hsa-mir-155 hsa-mir-155 Listerial infection Listerial Listerial infection Caco-2 cells Human miR- 146b, miR-16, let-7a1, miR-145 and miR-155 were significantly deregulated following listerial infection. 22312311 3510 mmu-mir-217 mmu-mir-217 mmu-mir-217 fat accumulation in hepatocytes ethanol ethanol treatment mouse AML-12 hepatocytes Mouse MiR-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. 22308024 3511 hsa-mir-205 hsa-mir-205 hsa-mir-205 Nasopharyngeal cancer radiation radiation treatment radio-resistant NPC cell line, CNE-2R Human MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. 22306986 3512 hsa-mir-16-1 hsa-mir-16 hsa-mir-16 Thyroid Cell Growth thyrotropin thyrotropin treatment Thyroid Cell Human overexpression of miR-16 and miR-195 suppressed cell cycle progression and DNA synthesis that was induced by TSH 22301781 3513 hsa-mir-16-2 hsa-mir-16 hsa-mir-16 Thyroid Cell Growth thyrotropin thyrotropin treatment Thyroid Cell Human overexpression of miR-16 and miR-195 suppressed cell cycle progression and DNA synthesis that was induced by TSH 22301781 3514 hsa-mir-195 hsa-mir-195 hsa-mir-195 Thyroid Cell Growth thyrotropin thyrotropin treatment Thyroid Cell Human overexpression of miR-16 and miR-195 suppressed cell cycle progression and DNA synthesis that was induced by TSH 22301781 3515 mmu-let-7g mmu-let-7g mmu-let-7g myocardial injury doxorubicin Rats were treated with doxorubicin at increasing doses (0mg/kg, 6mg/kg, 12mg/kg, 18mg/kg). myocardial cells Mouse Let-7g is involved in doxorubicin induced myocardial injury. 22301161 3516 hsa-mir-99a hsa-mir-99a hsa-mir-99a epithelial to mesenchymal plasticity TGF-ǂ TGF-ǂtreatment normal murine mammary gland cells Human MIR-99a and MIR-99b modulate TGF-ǂ induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. 22299047 3517 hsa-mir-99b hsa-mir-99b hsa-mir-99b epithelial to mesenchymal plasticity TGF-ǂ TGF-ǂtreatment normal murine mammary gland cells Human MIR-99a and MIR-99b modulate TGF-ǂ induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. 22299047 3518 dre-mir-725-1 dre-mir-725 dre-mir-725 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3519 dre-mir-725-2 dre-mir-725 dre-mir-725 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3520 dre-mir-153a dre-mir-153a dre-mir-153a developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3521 dre-mir-30d dre-mir-30d dre-mir-30d developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3522 dre-mir-100-1 dre-mir-100 dre-mir-100 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3523 dre-mir-100-2 dre-mir-100 dre-mir-100 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3524 dre-mir-738 dre-mir-738 dre-mir-738 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3525 dre-mir-732 dre-mir-732 dre-mir-732 developmental disorder susceptibility Ethanol Ethanol exposure Zebrafish embryos were exposed to 1% and 1.5% of ethanol from 4 hours post-fertilization (hpf) to 24hpf. Zebrafish Ethanol exposure induces up-regulation of specific microRNAs in zebrafish embryos. 22298809 3526 mmu-mir-34a mmu-mir-34a mmu-mir-34a carcinogenesis N-ethyl-N-nitrosourea N-ethyl-N-nitrosourea exposure spleen Mouse Increased expression of miR-34a in mouse spleen one day after exposure to N-ethyl-N-nitrosourea. 22297810 3527 rno-mir-186 rno-mir-186 rno-mir-186 stress response Stress Exposure to two weeks of mild restraint stress cerebellum Rat Stress altered the expression of Prlr, miR-186 in hippocampus and prefrontal cortex. 22291890 3528 hsa-mir-10b hsa-mir-10b hsa-mir-10b Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3529 hsa-mir-17 hsa-mir-17 hsa-mir-17 Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3530 hsa-mir-21 hsa-mir-21 hsa-mir-21 Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3531 hsa-mir-9-1 hsa-mir-9 hsa-mir-9 Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3532 hsa-mir-9-2 hsa-mir-9 hsa-mir-9 Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3533 hsa-mir-9-3 hsa-mir-9 hsa-mir-9 Breast cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3534 hsa-mir-10b hsa-mir-10b hsa-mir-10b Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3535 hsa-mir-17 hsa-mir-17 hsa-mir-17 Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3536 hsa-mir-21 hsa-mir-21 hsa-mir-21 Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3537 hsa-mir-9-1 hsa-mir-9 hsa-mir-9 Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3538 hsa-mir-9-2 hsa-mir-9 hsa-mir-9 Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3539 hsa-mir-9-3 hsa-mir-9 hsa-mir-9 Colon cancer sulindac sulfide sulindac sulfide treatment MDA-MB-231 breast and HCT116 colon tumor cells Human response to sulindac sulfide treatment 22286762 3540 hsa-mir-181a hsa-mir-181a hsa-mir-181a Leukemia daunorubicin daunorubicin treatment Leukemia cell Human miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. 22285729 3541 hsa-mir-155 hsa-mir-155 hsa-mir-155 Lymphoma Epstein-Barr virus Epstein-Barr virus infection lymphoma cell Human Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. 22268450 3542 hsa-mir-125b-1 hsa-mir-125b hsa-mir-125b Cancer Camptothecin (CPT) Camptothecin (CPT) treatment cancer cell Human CPT induced apoptosis in cancer cells by miR-125b mediated mitochondrial pathways via targeting to the 3?eUTR regions of Bak1, Mcl1 and p53. 22252650 3543 hsa-mir-125b-2 hsa-mir-125b hsa-mir-125b Cancer Camptothecin (CPT) Camptothecin (CPT) treatment cancer cell Human CPT induced apoptosis in cancer cells by miR-125b mediated mitochondrial pathways via targeting to the 3?eUTR regions of Bak1, Mcl1 and p53. 22252650 3544 hsa-mir-21 hsa-mir-21 hsa-mir-21 oral squamous cell carcinoma cisplatin cisplatin treatment oral squamous cell carcinoma (OSCC) cells Human miR-21 inhibitor sensitizes human OSCC(oral squamous cell carcinoma) cells to cisplatin. 22249446 3545 mmu-mir-132 mmu-mir-132 mmu-mir-132 cognitive deficits Stress stress treatment hippocampal Mouse Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. 22246100 3546 hsa-mir-26a-1 hsa-mir-26a hsa-mir-26a Pancreatic Neoplasms Metformin metformin treatment Sw1990 cells and Panc-1 cells Human Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect. 22245693 3547 hsa-mir-26a-2 hsa-mir-26a hsa-mir-26a Pancreatic Neoplasms Metformin metformin treatment Sw1990 cells and Panc-1 cells Human Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect. 22245693 3548 hsa-mir-192 hsa-mir-192 hsa-mir-192 Pancreatic Neoplasms Metformin metformin treatment Sw1990 cells and Panc-1 cells Human Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner 22245693 3549 hsa-let-7c hsa-let-7c hsa-let-7c Pancreatic Neoplasms Metformin metformin treatment Sw1990 cells and Panc-1 cells Human Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner 22245693 3550 hsa-mir-212 hsa-mir-212 hsa-mir-212 chronic myeloid leukemia imatinib imatinib treatment K-562 cells Human ABCG2 protein was 7.2-fold elevated after long-term treatment with 0.3 njmol/l imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. 22241070 3551 hsa-mir-328 hsa-mir-328 hsa-mir-328 chronic myeloid leukemia imatinib imatinib treatment K-562 cells Human ABCG2 protein was 7.2-fold elevated after long-term treatment with 0.3 njmol/l imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. 22241070 3552 hsa-mir-21 hsa-mir-21 hsa-mir-21 Non-Small-Cell Lung cancer platinum platinum treatment A549 cell Human Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell. 22237007 3553 zma-MIR171h zma-MIR171h zma-MIR171h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3554 zma-MIR171k zma-MIR171k zma-MIR171k plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3555 zma-MIR162 zma-MIR162 zma-MIR162 plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3556 zma-MIR172e zma-MIR172e zma-MIR172e plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3557 zma-MIR394a zma-MIR394a zma-MIR394a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3558 zma-MIR394b zma-MIR394b zma-MIR394b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3559 zma-MIR167j zma-MIR167j zma-MIR167j plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3560 zma-MIR167e zma-MIR167e zma-MIR167e plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3561 zma-MIR167f zma-MIR167f zma-MIR167f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize up-regulated 22235323 3562 zma-MIR169a zma-MIR169a zma-MIR169a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3563 zma-MIR169c zma-MIR169c zma-MIR169c plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3564 zma-MIR169r zma-MIR169r zma-MIR169r plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3565 zma-MIR398b zma-MIR398b zma-MIR398b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3566 zma-MIR398a zma-MIR398a zma-MIR398a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3567 zma-MIR169m zma-MIR169m zma-MIR169m plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3568 zma-MIR169n zma-MIR169n zma-MIR169n plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3569 zma-MIR169q zma-MIR169q zma-MIR169q plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3570 zma-MIR169f zma-MIR169f zma-MIR169f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3571 zma-MIR169h zma-MIR169h zma-MIR169h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3572 zma-MIR528a zma-MIR528a zma-MIR528a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3573 zma-MIR528b zma-MIR528b zma-MIR528b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3574 zma-MIR169g zma-MIR169g zma-MIR169g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3575 zma-MIR164f zma-MIR164f zma-MIR164f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3576 zma-MIR397b zma-MIR397b zma-MIR397b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3577 zma-MIR397a zma-MIR397a zma-MIR397a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3578 zma-MIR408 zma-MIR408 zma-MIR408 plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3579 zma-MIR408b zma-MIR408b zma-MIR408b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3580 zma-MIR164h zma-MIR164h zma-MIR164h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation shoot Maize down-regulated 22235323 3581 zma-MIR156j zma-MIR156j zma-MIR156j plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3582 zma-MIR171g zma-MIR171g zma-MIR171g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3583 zma-MIR159c zma-MIR159c zma-MIR159c plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3584 zma-MIR159d zma-MIR159d zma-MIR159d plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3585 zma-MIR167a zma-MIR167a zma-MIR167a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3586 zma-MIR167c zma-MIR167c zma-MIR167c plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3587 zma-MIR167d zma-MIR167d zma-MIR167d plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3588 zma-MIR167b zma-MIR167b zma-MIR167b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3589 zma-MIR162 zma-MIR162 zma-MIR162 plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3590 zma-MIR393b zma-MIR393b zma-MIR393b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3591 zma-MIR164e zma-MIR164e zma-MIR164e plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3592 zma-MIR164f zma-MIR164f zma-MIR164f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3593 zma-MIR167g zma-MIR167g zma-MIR167g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3594 zma-MIR167i zma-MIR167i zma-MIR167i plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3595 zma-MIR167h zma-MIR167h zma-MIR167h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize up-regulated 22235323 3596 zma-MIR169p zma-MIR169p zma-MIR169p plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3597 zma-MIR169g zma-MIR169g zma-MIR169g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3598 zma-MIR397b zma-MIR397b zma-MIR397b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3599 zma-MIR169c zma-MIR169c zma-MIR169c plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3600 zma-MIR169r zma-MIR169r zma-MIR169r plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3601 zma-MIR408 zma-MIR408 zma-MIR408 plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3602 zma-MIR408b zma-MIR408b zma-MIR408b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3603 zma-MIR169a zma-MIR169a zma-MIR169a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3604 zma-MIR169i zma-MIR169i zma-MIR169i plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3605 zma-MIR169j zma-MIR169j zma-MIR169j plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3606 zma-MIR169k zma-MIR169k zma-MIR169k plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3607 zma-MIR164h zma-MIR164h zma-MIR164h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3608 zma-MIR169b zma-MIR169b zma-MIR169b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3609 zma-MIR396e zma-MIR396e zma-MIR396e plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3610 zma-MIR396f zma-MIR396f zma-MIR396f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3611 zma-MIR827 zma-MIR827 zma-MIR827 plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3612 zma-MIR399a zma-MIR399a zma-MIR399a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3613 zma-MIR399c zma-MIR399c zma-MIR399c plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3614 zma-MIR399h zma-MIR399h zma-MIR399h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3615 zma-MIR395o zma-MIR395o zma-MIR395o plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3616 zma-MIR395b zma-MIR395b zma-MIR395b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3617 zma-MIR395d zma-MIR395d zma-MIR395d plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3618 zma-MIR395e zma-MIR395e zma-MIR395e plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3619 zma-MIR395f zma-MIR395f zma-MIR395f plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3620 zma-MIR395g zma-MIR395g zma-MIR395g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3621 zma-MIR395h zma-MIR395h zma-MIR395h plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3622 zma-MIR395i zma-MIR395i zma-MIR395i plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3623 zma-MIR395j zma-MIR395j zma-MIR395j plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3624 zma-MIR395n zma-MIR395n zma-MIR395n plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3625 zma-MIR395p zma-MIR395p zma-MIR395p plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3626 zma-MIR395a zma-MIR395a zma-MIR395a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3627 zma-MIR528b zma-MIR528b zma-MIR528b plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3628 zma-MIR528a zma-MIR528a zma-MIR528a plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3629 zma-MIR399g zma-MIR399g zma-MIR399g plant adaptive responses to nutrient deprivation nitrogen nitrogen limitation root Maize down-regulated 22235323 3630 hsa-mir-122 hsa-mir-122 hsa-mir-122 Lymphoma doxorubicin doxorubicin treatment T-cell lymphoma cell line Human miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. 22235305 3631 hsa-mir-122 hsa-mir-122 hsa-mir-122 Lymphoma bortezomib bortezomib treatment T-cell lymphoma cell line Human miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. 22235305 3632 mmu-mir-21 mmu-mir-21 mmu-mir-21 pulmonary vascular remodeling hypoxia chronic hypoxia exposure distal small arteries in the lungs of hypoxia exposed mice Mouse miR-21 regulates chronic hypoxia induced pulmonary vascular remodeling. 22227207 3633 mmu-mir-29b-1 mmu-mir-29b mmu-mir-29b cardiovascular diseases diet high-fat diet aorta Mouse microRNA-29b expression was increased in the aorta of mice fed with a high-fat diet 22226905 3634 mmu-mir-29b-2 mmu-mir-29b mmu-mir-29b cardiovascular diseases diet high-fat diet aorta Mouse microRNA-29b expression was increased in the aorta of mice fed with a high-fat diet 22226905 3635 mmu-mir-29b-3 mmu-mir-29b mmu-mir-29b cardiovascular diseases diet high-fat diet aorta Mouse microRNA-29b expression was increased in the aorta of mice fed with a high-fat diet 22226905 3636 hsa-mir-199a-1 has-mir-199a has-mir-199a Colon cancer Oltipraz Oltipraz treatment HCT116 cells Human M2 with pyrrolopyrazine structure and its 7-ethyl congenor have the ability to prevent the induction of HIF-1ǁ, which may result from the inhibition of HIF-1ǁ de novo synthesis, as mediated by the induction of miR-199a-5p and miR-20a. 22223846 3637 hsa-mir-20a hsa-mir-20a hsa-mir-20a Colon cancer Oltipraz Oltipraz treatment HCT116 cells Human M2 with pyrrolopyrazine structure and its 7-ethyl congenor have the ability to prevent the induction of HIF-1ǁ, which may result from the inhibition of HIF-1ǁ de novo synthesis, as mediated by the induction of miR-199a-5p and miR-20a. 22223846 3638 hsa-mir-199a-2 hsa-mir-199a hsa-mir-199a Colon cancer Oltipraz Oltipraz treatment HCT116 cells Human M2 with pyrrolopyrazine structure and its 7-ethyl congenor have the ability to prevent the induction of HIF-1ǁ, which may result from the inhibition of HIF-1ǁ de novo synthesis, as mediated by the induction of miR-199a-5p and miR-20a. 22223846 3639 mmu-mir-483 mmu-mir-483 mmu-mir-483 Diabetes Mellitus, Type 2 nutrition suboptimal nutrition adipose tissue Mouse Increased miR-483-3p expression in vivo, programmed by early-life nutrition, limits storage of lipids in adipose tissue, causing lipotoxicity and insulin resistance and thus increasing susceptibility to metabolic disease. 22223106 3640 rno-mir-21 rno-mir-21 rno-mir-21 microvascular rarefaction prevention Swimming Swimming training Soleus Rat ET in SHR-Ts reduced miRNA-16 and -21 levels and elevated vascular endothelial growth factor and Bcl-2 levels. 22215713 3641 rno-mir-16 rno-mir-16 rno-mir-16 microvascular rarefaction prevention Swimming Swimming training Soleus Rat ET in SHR-Ts reduced miRNA-16 and -21 levels and elevated vascular endothelial growth factor and Bcl-2 levels. 22215713 3642 rno-mir-126 rno-mir-126 rno-mir-126 microvascular rarefaction prevention Swimming Swimming training Soleus Rat miRNA-126 levels were reduced in SHRs with an increase of 51% in phosphoinositol-3 kinase regulatory subunit 2 expression but normalized in SHR-Ts. 22215713 3643 hsa-mir-125b-1 hsa-mir-125b hsa-mir-125b melanoma 5-Aza 5-Aza treatment melanoma cell lines and in normal human melanocytes Human Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM. 22213330 3644 hsa-mir-27b hsa-mir-27b hsa-mir-27b melanoma 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) treatment melanoma cell lines and in normal human melanocytes Human Treatment with 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) reduced the miR-27b expression in three out of four melanoma cell lines. 22213330 3645 hsa-mir-125b-2 hsa-mir-125b hsa-mir-125b melanoma 5-Aza 5-Aza treatment melanoma cell lines and in normal human melanocytes Human Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM. 22213330 3646 zma-MIR528a zma-MIR528a zma-MIR528a plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3647 zma-MIR528b zma-MIR528b zma-MIR528b plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3648 zma-MIR528a zma-MIR528a* zma-MIR528a* plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3649 zma-MIR528b zma-MIR528b* zma-MIR528b* plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3650 zma-MIR169i zma-MIR169i zma-MIR169i plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3651 zma-MIR169j zma-MIR169j zma-MIR169j plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3652 zma-MIR169k zma-MIR169k zma-MIR169k plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3653 zma-MIR169i zma-MIR169i* zma-MIR169i* plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3654 zma-MIR169j zma-MIR169j* zma-MIR169j* plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3655 zma-MIR169k zma-MIR169k* zma-MIR169k* plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3656 zma-MIR166j zma-MIR166j zma-MIR166j plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3657 zma-MIR166k zma-MIR166k zma-MIR166k plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3658 zma-MIR166n zma-MIR166n zma-MIR166n plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3659 zma-MIR408b zma-MIR408b zma-MIR408b plant response to nutrients nitrate nitrate-supplied and nitrate-depleted roots root Maize The repression of the transcription of miR528a/b, miR528a*/b*, miR169i/j/k, miR169i*/j*/k*, miR166j/k/n and miR408/b upon nitrate shortage could represent a crucial step integrating nitrate signals into developmental changes in maize roots. 22211437 3660 hsa-mir-181a hsa-mir-181a hsa-mir-181a Leukaemia Ara-C Ara-C treatment Ara-C-resistant cell line HL-60/Ara-C compared with its parental cell line HL-60 Human miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. 22209977 3661 hsa-mir-203 hsa-mir-203 hsa-mir-203 Breast cancer Cisplatin cisplatin treatment MCF-7 Human Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. 22207897 3662 mdv1-mir-M9 mdv1-mir-M9 mdv1-mir-M9 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3663 mdv1-mir-M4 mdv1-mir-M4 mdv1-mir-M4 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3664 mdv1-mir-M31 mdv1-mir-M31 mdv1-mir-M31 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3665 mdv1-mir-M11 mdv1-mir-M11 mdv1-mir-M11 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3666 mdv1-mir-M2 mdv1-mir-M2 mdv1-mir-M2 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3667 mdv1-mir-M3 mdv1-mir-M3 mdv1-mir-M3 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3668 mdv1-mir-M12 mdv1-mir-M12 mdv1-mir-M12 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3669 mdv1-mir-M5 mdv1-mir-M5 mdv1-mir-M5 T lymphoma Marek's disease virus Marek's disease virus infection n/a Chicken The kinetic expression analysis of the cluster mdv1-mir-M9~M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. 22442112 3670 mmu-mir-27a mmu-mir-27a mmu-mir-27a MCMV infection Mouse Cytomegalovirus Mouse Cytomegalovirus infection MCMV infected cells Mouse The authors found that 3 mouse miRNAs showed an altered expression due to MCMV infection. Down-regulation of miR-27a, as previously described, could be confirmed. In addition, miR-26a was down-regulated and an up-regulation of miR-7a dependent on viral protein expression could be observed. 22442111 3671 mmu-mir-26a-1 mmu-mir-26a mmu-mir-26a MCMV infection Mouse Cytomegalovirus Mouse Cytomegalovirus infection MCMV infected cells Mouse The authors found that 3 mouse miRNAs showed an altered expression due to MCMV infection. Down-regulation of miR-27a, as previously described, could be confirmed. In addition, miR-26a was down-regulated and an up-regulation of miR-7a dependent on viral protein expression could be observed. 22442111 3672 mmu-mir-26a-2 mmu-mir-26a mmu-mir-26a MCMV infection Mouse Cytomegalovirus Mouse Cytomegalovirus infection MCMV infected cells Mouse The authors found that 3 mouse miRNAs showed an altered expression due to MCMV infection. Down-regulation of miR-27a, as previously described, could be confirmed. In addition, miR-26a was down-regulated and an up-regulation of miR-7a dependent on viral protein expression could be observed. 22442111 3673 mmu-let-7a-1 mmu-let-7a mmu-let-7a MCMV infection Mouse Cytomegalovirus Mouse Cytomegalovirus infection MCMV infected cells Mouse The authors found that 3 mouse miRNAs showed an altered expression due to MCMV infection. Down-regulation of miR-27a, as previously described, could be confirmed. In addition, miR-26a was down-regulated and an up-regulation of miR-7a dependent on viral protein expression could be observed. 22442111 3674 mmu-let-7a-2 mmu-let-7a mmu-let-7a MCMV infection Mouse Cytomegalovirus Mouse Cytomegalovirus infection MCMV infected cells Mouse The authors found that 3 mouse miRNAs showed an altered expression due to MCMV infection. Down-regulation of miR-27a, as previously described, could be confirmed. In addition, miR-26a was down-regulated and an up-regulation of miR-7a dependent on viral protein expression could be observed. 22442111 3675 mmu-mir-30a mmu-mir-30a mmu-mir-30a cardiac defect alcohol Wild-type FVB and cardiac-specific overexpression of alcohol dehydrogenase mice were placed on a 4% nutrition-balanced alcohol diet for 8 weeks. Myocard Mouse ADH (Acetaldehyde) accentuated or unmasked alcohol-induced downregulation of Bcl-2, Bcl-xL and MiR-30a. 22441020 3676 cre-MIR1144a miR1144a.1 miR1144a.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3677 cre-MIR1144b miR1144b miR1144b responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3678 cre-MIR1147 miR1147.1 miR1147.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3679 cre-MIR1148 miR1148.2 miR1148.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3680 cre-MIR1149 miR1149.1 miR1149.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3681 cre-MIR1149 miR1149.2 miR1149.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3682 cre-MIR1150 miR1150.3 miR1150.3 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3683 cre-MIR1153 miR1153.1 miR1153.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3684 cre-MIR1153 miR1153.2* miR1153.2* responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3685 cre-MIR1155 miR1155 miR1155 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3686 cre-MIR1156 miR1156.1 miR1156.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3687 cre-MIR1156 miR1156.2 miR1156.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3688 cre-MIR1158 miR1158 miR1158 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3689 cre-MIR1159 miR1159.2 miR1159.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3690 cre-MIR1160 miR1160.2 miR1160.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3691 cre-MIR1160 miR1160.3 miR1160.3 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3692 cre-MIR1164 miR1164 miR1164 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3693 cre-MIR1166 miR1166.1 miR1166.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3694 cre-MIR1172 miR1172.1 miR1172.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3695 cre-MIR1172 miR1172.2 miR1172.2 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3696 cre-MIR906 miR906-3p miR906-3p responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3697 cre-MIR909 miR909.1 miR909.1 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3698 cre-MIR910 miR910 miR910 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3699 cre-MIR912 miR912 miR912 responses to sulfur-deprivation sulfur sulfur-replete and sulfur-deprived conditions n/a Chlamydomonas reinhardtii responsive to sulfur-deprivation 22439676 3700 hsa-mir-193a hsa-mir-193a hsa-mir-193a Prostatic cancer XMRV XMRV infection Two prostate cell lines (LNCaP and DU145) and two primary cells Human miR-193a-3p and miRPlus-E1245 observed to be specific to XMRV infection in all 4 cell types (Two prostate cell lines (LNCaP and DU145) and two primary cells). 22438885 3701 hsa-mir-34a hsa-mir-34a hsa-mir-34a lung cancer Delta-tocotrienol Delta-tocotrienol treatment lung cancer cells Human Delta-tocotrienol suppresses Notch-1 pathway by up-regulating miR-34a in non-small cell lung cancer cells. 22438124 3702 mmu-mir-34a mmu-mir-34a mmu-mir-34a neuronal death seizure prolonged seizures CA3 and CA1 hippocampal subfields Mouse MicroRNA-34a upregulation during seizure-induced neuronal death. 22436728 3703 hsa-mir-24 hsa-mir-24 hsa-mir-24 DNA damage response etoposide etoposide treatment CD8(+) T cells Human Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death. 22435726 3704 hsa-mir-504 hsa-mir-504 hsa-mir-504 Lymphoma ionizing ionizing treatment U937 Human ionizing radiation could alter the expression of miR-503 and its target gene CD40, and may be very important to shed light on a possible mechanism regarding regulation of immune responses to irradiation. 22429276 3705 ath-MIR156a ath-miR156a ath-miR156a delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3706 ath-MIR156b ath-miR156b ath-miR156b delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3707 ath-MIR156c ath-miR156c ath-miR156c delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3708 ath-MIR156d ath-miR156d ath-miR156d delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3709 ath-MIR156e ath-miR156e ath-miR156e delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3710 ath-MIR156f ath-miR156f ath-miR156f delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3711 ath-MIR156g ath-miR156g ath-miR156g delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3712 ath-MIR156h ath-miR156h ath-miR156h delayed flowering temperature ambient temperature leaf Arabidopsis thaliana Overexpression of miR156 led to more delayed flowering at a lower ambient temperature 22427344 3713 mmu-mir-203 mmu-mir-203 mmu-mir-203 cellular response to caloric restriction Caloric Caloric restriction breast tissue Mouse microRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. 22421148 3714 dre-mir-122 dre-mir-122 dre-mir-122 V. harveyi infection V. harveyi V. harveyi infection Zebrafish Zebrafish The results indicated that miR-122 and miR-194 were higher in PBS-injected zebrafish compared with TH2-3 zebrafish or wild-type (WT) zebrafish after V. harveyi infection. 22419229 3715 dre-mir-194a dre-mir-194a dre-mir-194a V. harveyi infection V. harveyi V. harveyi infection Zebrafish Zebrafish The results indicated that miR-122 and miR-194 were higher in PBS-injected zebrafish compared with TH2-3 zebrafish or wild-type (WT) zebrafish after V. harveyi infection. 22419229 3716 dre-mir-194b dre-mir-194b dre-mir-194b V. harveyi infection V. harveyi V. harveyi infection Zebrafish Zebrafish The results indicated that miR-122 and miR-194 were higher in PBS-injected zebrafish compared with TH2-3 zebrafish or wild-type (WT) zebrafish after V. harveyi infection. 22419229 3717 dre-mir-122 dre-mir-122 dre-mir-122 V. harveyi infection lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment liver Zebrafish Overexpression of miRNAs (miR-122, miR-192, and miR-194a) was seen in zebrafish liver (ZFL) cells after lipopolysaccharide (LPS) treatment and in untreated fish. 22419229 3718 dre-mir-194a dre-mir-194a dre-mir-194a V. harveyi infection lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment liver Zebrafish Overexpression of miRNAs (miR-122, miR-192, and miR-194a) was seen in zebrafish liver (ZFL) cells after lipopolysaccharide (LPS) treatment and in untreated fish. 22419229 3719 dre-mir-192 dre-mir-192 dre-mir-192 V. harveyi infection lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment liver Zebrafish Overexpression of miRNAs (miR-122, miR-192, and miR-194a) was seen in zebrafish liver (ZFL) cells after lipopolysaccharide (LPS) treatment and in untreated fish. 22419229 3720 rno-mir-125a rno-mir-125a rno-mir-125a Short bowel syndrome bowel resection or transection Rats underwent either 80% massive small bowel resection or transection and were harvested after 48 hours Rat Upregulation of Proapoptotic MicroRNA mir-125a After Massive Small Bowel Resection in Rats. 22418008 3721 hsa-mir-27a hsa-mir-27a hsa-mir-27a macrophage inflammatory response lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment RAW264.7 macrophage cells Human Downregulation of miR-27a* and miR-532-5p and Upregulation of miR-146a and miR-155 in LPS-induced RAW264.7 Macrophage Cells. 22415194 3722 hsa-mir-532 hsa-mir-532 hsa-mir-532 macrophage inflammatory response lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment RAW264.7 macrophage cells Human Downregulation of miR-27a* and miR-532-5p and Upregulation of miR-146a and miR-155 in LPS-induced RAW264.7 Macrophage Cells. 22415194 3723 hsa-mir-146a hsa-mir-146a hsa-mir-146a macrophage inflammatory response lipopolysaccharide (LPS) lipopolysaccharide (LPS) treatment RAW264.7 macrophage cells Human Downregulation of miR-27a* and miR-532-5p and Upregulation of miR-146a and miR-155 in LPS-induced RAW264.7 Macrophage Cells. 22415194 3724 hsa-mir-9-1 hsa-mir-9 hsa-mir-9 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3725 hsa-mir-9-2 hsa-mir-9 hsa-mir-9 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3726 hsa-mir-9-3 hsa-mir-9 hsa-mir-9 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3727 hsa-mir-21 hsa-mir-21 hsa-mir-21 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3728 hsa-mir-135-1 hsa-mir-153 hsa-mir-153 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3729 hsa-mir-135-2 hsa-mir-153 hsa-mir-153 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3730 hsa-mir-335 hsa-mir-335 hsa-mir-335 neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3731 hsa-mir-140 hsa-mir-140-3p hsa-mir-140-3p neural stem cell maturation Ethanol Gestational day 12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures were exposed to EtOH, nicotine, and mecamylamine, a noncompetitive nAChR antagonist, individually or in combination, for short (24 hour) and long (5 day) periods, to mimic exposure during the in vivo period of neurogenesis. mouse fetal murine cerebral cortical-derived neurosphere cultures Human EtOH suppressed the expression of known EtOH-sensitive miRNAs ( (miR-9, miR-21, miR-153, and miR-335)) and miR-140-3p (a nicotine-sensitive miRNA), while nicotine at concentrations attained by cigarette smokers induced a dose-related increase in these miRNAs. Nicotine's effect was blocked by EtOH and by mecamylamine. 22458409 3732 hsa-mir-130a hsa-mir-130a hsa-mir-130a Ovarian cancer Cisplatin cisplatin treatment Cisplatin resistant ovarian cancer cell lines Human The over expression of miR-130a is associated with cisplatin resistance of ovarian cancer. Inhibiting miR-130a expression may help reverse the cisplatin resistance of ovarian cancer. 22455133 3733 hsa-mir-375 hsa-mir-375 hsa-mir-375 n/a IL-13 IL-13 stimulation human esophageal squamous and bronchial columnar epithelial cells Human MiR-375 is downregulated in epithelial cells after IL-13 stimulation and regulates an IL-13-induced epithelial transcriptome. 22453679 3734 hsa-let-7c hsa-let-7c hsa-let-7c H1N1 Influenza H1N1 H1N1 infection human lung epithelial cells (A549) Human Cellular MicroRNA let-7c Inhibits M1 Protein Expression of the H1N1 Influenza A Virus in Infected Human Lung Epithelial Cells. 22452878 3735 hsa-mir-20a hsa-mir-20a hsa-mir-20a Hypertension hypoxia Hypoxia induce pulmonary arterial smooth muscle cells Human AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. 22450430 3736 hsa-mir-15a hsa-mir-15a hsa-mir-15a Leukemia curcumin Curcumin treatment K562 and HL-60 cells Human Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. 22449094 3737 hsa-mir-16-1 hsa-mir-16 hsa-mir-16 Leukemia curcumin Curcumin treatment K562 and HL-60 cells Human Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. 22449094 3738 hsa-mir-16-2 hsa-mir-16 hsa-mir-16 Leukemia curcumin Curcumin treatment K562 and HL-60 cells Human Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. 22449094 3739 hsa-mir-93 hsa-mir-93 hsa-mir-93 Ovarian cancer cisplatin cisplatin treatment ovarian cancer cells Human Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. 22465665 3740 hsa-mir-145 hsa-mir-145 hsa-mir-145 DNA demethylation in skin keratinocytes decitabine decitabine treatment skin keratinocytes Human 96% of keratinocytes show expression of the endogenous Oct4 protein and the OCT4 repressor mir-145. 22486352 3741 hsa-mir-145 hsa-mir-145 hsa-mir-145 DNA demethylation in skin keratinocytes doxorubicin doxorubicin treatment skin keratinocytes Human Treatment with doxorubicin, another cancer drug, induces expression of mir-145 only in cells that already express OCT4, suggesting that Oct4 regulates its own repressor. 22486352 3742 hsa-mir-145 hsa-mir-145 hsa-mir-145 DNA demethylation in skin keratinocytes decitabine and doxorubicin co-treatment skin keratinocytes Human Co-treatment with decitabine and doxorubicin results first in increased OCT4 and mir-145, then a decrease in both, suggesting that OCT4 and mir-145 regulate each other. 22486352 3743 sly-MIR172b sly-MIR172b sly-MIR172b early flowering phenotype 5-Azacytidine (AzaC) AzaC treatment Solanum up-regulated in the AzaC-treated plants;miRNA172, could play a role on the early flowering phenotype 22484918 3744 sly-MIR172a sly-MIR172a sly-MIR172a early flowering phenotype 5-Azacytidine (AzaC) AzaC treatment Solanum up-regulated in the AzaC-treated plants;miRNA172, could play a role on the early flowering phenotype 22484918 3745 hsa-mir-17 hsa-mir-17 hsa-mir-17 acute lymphocytic leukemia glucocorticoid glucocorticoid treatment ALL cell line Human Down-regulation of miR17 plays an important role in glucocorticoid-induced cell death suggesting that targeting miR17 may improve the current ALL combination therapy. 22475310 3746 hsa-mir-199a-1 hsa-mir-199a hsa-mir-199a Ovarian cancer cisplatin cisplatin treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3747 hsa-mir-199a-2 hsa-mir-199a hsa-mir-199a Ovarian cancer cisplatin cisplatin treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3748 hsa-mir-199a-1 hsa-mir-199a hsa-mir-199a Ovarian cancer pacitaxel pacitaxel treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3749 hsa-mir-199a-2 hsa-mir-199a hsa-mir-199a Ovarian cancer pacitaxel pacitaxel treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3750 hsa-mir-199a-1 hsa-mir-199a hsa-mir-199a Ovarian cancer adriamycin adriamycin treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3751 hsa-mir-199a-2 hsa-mir-199a hsa-mir-199a Ovarian cancer adriamycin adriamycin treatment ovarian cancer stem cells Human MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.MiR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel and adriamycin, and reduced mRNA expression of the multi-drug resistance gene ABCG2, compared to miR-199a mutant transfected and untransfected cells. 22498306 3752 hsa-mir-106b hsa-mir-106b hsa-mir-106b Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3753 hsa-mir-92a-1 hsa-mir-92a hsa-mir-92a Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3754 hsa-mir-92a-2 hsa-mir-92a hsa-mir-92a Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3755 hsa-mir-92b hsa-mir-92b hsa-mir-92b Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3756 hsa-mir-93 hsa-mir-93 hsa-mir-93 Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3757 hsa-mir-7-1 hsa-mir-7 hsa-mir-7 Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3758 hsa-mir-34a hsa-mir-34a hsa-mir-34a Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3759 hsa-mir-99a hsa-mir-99a hsa-mir-99a Neuroblastoma 4-HPR and EGCG Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) SK-N-BE2 and IMR-32 cells Human Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells) 22498172 3760 hsa-mir-149 hsa-mir-149 hsa-mir-149 HTLV-1 pathogenesis HTLV-1 HTLV-1 infection T cell Human miR-149 and miR-873 were found to be capable of directly targeting p300 and p/CAF, chromatin remodeling factors known to play critical role in HTLV-1 pathogenesis. 22496815 3761 hsa-mir-873 hsa-mir-873 hsa-mir-873 HTLV-1 pathogenesis HTLV-1 HTLV-1 infection T cell Human miR-149 and miR-873 were found to be capable of directly targeting p300 and p/CAF, chromatin remodeling factors known to play critical role in HTLV-1 pathogenesis. 22496815 3762 mmu-mir-222 mmu-miR-222 mmu-miR-222 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3763 mmu-mir-342 mmu-miR-342-3p mmu-miR-342-3p Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3764 mmu-mir-142 mmu-miR-142-3p mmu-miR-142-3p Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3765 mmu-mir-142 mmu-miR-142-5p mmu-miR-142-5p Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3766 mmu-mir-21 mmu-miR-21 mmu-miR-21 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3767 mmu-mir-146a mmu-miR-146a mmu-miR-146a Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3768 mmu-mir-146b mmu-miR-146b mmu-miR-146b Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3769 mmu-mir-379 mmu-miR-379 mmu-miR-379 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse up-regulation 22496873 3770 mmu-mir-200b mmu-miR-200b mmu-miR-200b Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3771 mmu-mir-200c mmu-miR-200c mmu-miR-200c Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3772 mmu-mir-204 mmu-miR-204 mmu-miR-204 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3773 mmu-mir-30a mmu-miR-30a* mmu-miR-30a* Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3774 mmu-mir-193 mmu-miR-193 mmu-miR-193 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3775 mmu-mir-378 mmu-miR-378 mmu-miR-378 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3776 mmu-mir-30e mmu-miR-30e* mmu-miR-30e* Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3777 mmu-mir-122 mmu-miR-122 mmu-miR-122 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3778 mmu-mir-133b mmu-miR-133b mmu-miR-133b Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3779 mmu-mir-1a-1 mmu-miR-1a mmu-miR-1a Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3780 mmu-mir-1a-2 mmu-miR-1a mmu-miR-1a Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3781 mmu-mir-1b mmu-miR-1b mmu-miR-1b Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3782 mmu-mir-192 mmu-miR-192 mmu-miR-192 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3783 mmu-mir-203 mmu-miR-203 mmu-miR-203 Obesity Diet Long-Term High-Fat Diet-Induced Obesity in Mice. white adipose tissue Mouse down-regulation 22496873 3784 hsa-mir-34a hsa-mir-34a hsa-mir-34a indefinite proliferation Epstein-Barr virus Epstein-Barr virus (EBV) infection primary human B cells Human The Epstein-Barr virus induced tumor suppressor miR-34a is growth promoting in EBV-infected B cells. 22496226 3785 hsa-mir-181a-1 hsa-mir-181a hsa-mir-181a cell apoptosis Cisplatin cisplatin treatment HK-2 cells Human MicroRNA-181a expression significantly down-regulated in cells transfected with microRNA-181a inhibitor, compared with that in untransfectd cells (21.19 € 2.01 vs. 38.87 € 1.97, P < 0.05). Cell apoptosis induced by DDP significantly decreased in cells transfected with MicroRNA-181a inhibitor. Compared with DDP treated cells alone, Bcl-2 expression strikingly was up-regulated and Bax expression was down-regulated in cells transfected with microRNA-181a inhibitor. 22490414 3786 hsa-mir-181a-2 hsa-mir-181a hsa-mir-181a cell apoptosis Cisplatin cisplatin treatment HK-2 cells Human MicroRNA-181a expression significantly down-regulated in cells transfected with microRNA-181a inhibitor, compared with that in untransfectd cells (21.19 € 2.01 vs. 38.87 € 1.97, P < 0.05). Cell apoptosis induced by DDP significantly decreased in cells transfected with MicroRNA-181a inhibitor. Compared with DDP treated cells alone, Bcl-2 expression strikingly was up-regulated and Bax expression was down-regulated in cells transfected with microRNA-181a inhibitor. 22490414 3787 hsa-mir-126 hsa-mir-126 hsa-mir-126 Non-Small-Cell Lung cancer adriamycin adriamycin treatment A549 cells Human miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. 22510476 3788 hsa-mir-126 hsa-mir-126 hsa-mir-126 Non-Small-Cell Lung cancer vincristine vincristine treatment A549 cells Human miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. 22510476 3789 hsa-mir-22 hsa-mir-22 hsa-mir-22 Retinoblastoma curcumin Curcumin treatment Y79 RB cells Human upregulated. Transfected miR-22 Y79 cells inhibited the cell proliferation and reduced the migration 22510010 3790 hsa-mir-375 hsa-mir-375 hsa-mir-375 Breast cancer tamoxifen tamoxifen treatment MCF-7 breast cancer cells Human Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. 22508479 3791 hsa-mir-127 hsa-mir-127 hsa-mir-127 Osteosarcoma 4-phenylbutyrate 4-phenylbutyrate treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3792 hsa-mir-411 hsa-mir-411 hsa-mir-411 Osteosarcoma 4-phenylbutyrate 4-phenylbutyrate treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3793 hsa-mir-431 hsa-mir-431 hsa-mir-431 Osteosarcoma 4-phenylbutyrate 4-phenylbutyrate treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3794 hsa-mir-432 hsa-mir-432 hsa-mir-432 Osteosarcoma 4-phenylbutyrate 4-phenylbutyrate treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3795 hsa-mir-127 hsa-mir-127 hsa-mir-127 Osteosarcoma 5-Azacytidine 5-Azacytidine treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3796 hsa-mir-411 hsa-mir-411 hsa-mir-411 Osteosarcoma 5-Azacytidine 5-Azacytidine treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3797 hsa-mir-431 hsa-mir-431 hsa-mir-431 Osteosarcoma 5-Azacytidine 5-Azacytidine treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3798 hsa-mir-432 hsa-mir-432 hsa-mir-432 Osteosarcoma 5-Azacytidine 5-Azacytidine treatment Osteosarcoma cell Human Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma. 22957032 3799 hsa-mir-944 hsa-mir-944 hsa-mir-944 Bladder Neoplasms cisplatin cisplatin treatment bladder cancer cell Human Three miRNAs were associated with both response (to chemotherapy) and survival (886-3p, 923, 944). 22954303 3800 hsa-mir-138-1 hsa-mir-138 hsa-mir-138 Bladder Neoplasms cisplatin cisplatin treatment bladder cancer cell Human Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. 22954303 3801 hsa-mir-138-2 hsa-mir-138 hsa-mir-138 Bladder Neoplasms cisplatin cisplatin treatment bladder cancer cell Human Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. 22954303 3802 hsa-mir-27a hsa-mir-27a hsa-mir-27a Bladder Neoplasms cisplatin cisplatin treatment bladder cancer cell Human Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. 22954303 3803 hsa-mir-642 hsa-mir-642 hsa-mir-642 Bladder Neoplasms cisplatin cisplatin treatment bladder cancer cell Human Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. 22954303 3804 rno-mir-182 rno-mir-182 rno-mir-182 Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3805 rno-mir-199a rno-mir-199a rno-mir-199a Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3806 rno-mir-203a rno-mir-203a rno-mir-203a Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3807 rno-mir-203b rno-mir-203b rno-mir-203b Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3808 rno-mir-211 rno-mir-211 rno-mir-211 Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3809 rno-mir-222 rno-mir-222 rno-mir-222 Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3810 rno-mir-29b-1 rno-mir-29b rno-mir-29b Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3811 rno-mir-29b-2 rno-mir-29b rno-mir-29b Sepsis aPC aPC treatment liver Rat highly expressed during sepsis and restored to basal levels after aPC treatment. 22940033 3812 hsa-mir-214 hsa-mir-214 hsa-mir-214 non-small cell lung cancer radiation radiation treatment non-small cell lung cancer cell Human miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. 22929890 3813 hsa-mir-151 hsa-mir-151 hsa-mir-151 Prostatic cancer Genistein Genistein treatment PC3 and DU145 cells Human Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151. 22928040 3814 dre-mir-451 dre-mir-451 dre-mir-451 disrupt embryonic development 2,3,7,8-tetrachlorodibenzo-p-dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure embryos Zebrafish significant changes in expression of miR-451, 23a, 23b, 24 and 27e at 60hpf. 22921993 3815 dre-mir-23a dre-mir-23a dre-mir-23a disrupt embryonic development 2,3,7,8-tetrachlorodibenzo-p-dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure embryos Zebrafish significant changes in expression of miR-451, 23a, 23b, 24 and 27e at 60hpf. 22921993 3816 dre-mir-23b dre-mir-23b dre-mir-23b disrupt embryonic development 2,3,7,8-tetrachlorodibenzo-p-dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure embryos Zebrafish significant changes in expression of miR-451, 23a, 23b, 24 and 27e at 60hpf. 22921993 3817 dre-mir-24 dre-mir-24 dre-mir-24 disrupt embryonic development 2,3,7,8-tetrachlorodibenzo-p-dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure embryos Zebrafish significant changes in expression of miR-451, 23a, 23b, 24 and 27e at 60hpf. 22921993 3818 dre-mir-27e dre-mir-27e dre-mir-27e disrupt embryonic development 2,3,7,8-tetrachlorodibenzo-p-dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure embryos Zebrafish significant changes in expression of miR-451, 23a, 23b, 24 and 27e at 60hpf. 22921993 3819 hsa-mir-132 hsa-mir-132 hsa-mir-132 Prostatic cancer Luteolin (3',4',5,7-tetrahydroxyflavone) Luteolin (3',4',5,7-tetrahydroxyflavone) treatment PC12 cell Human Luteolin Induces microRNA-132 Expression and Modulates Neurite Outgrowth in PC12 Cells. 22916239 3820 hsa-mir-122 hsa-mir-122 hsa-mir-122 Prostatic cancer castration castration treatment Kupffer cells Human miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment for castration-resistant prostate cancer. 22914437 3821 rno-mir-342 rno-mir-342 rno-mir-342 Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3822 rno-mir-335 rno-mir-335 rno-mir-335 Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3823 rno-mir-150 rno-mir-150 rno-mir-150 Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3824 rno-mir-126 rno-mir-126* rno-mir-126* Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3825 rno-mir-151 rno-mir-151* rno-mir-151* Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3826 rno-mir-21 rno-mir-21 rno-mir-21 Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3827 rno-mir-34a rno-mir-34a rno-mir-34a Bronchopulmonary dysplasia hyperoxia hyperoxia exposure neonatal rat lungs Rat down-regulation of five miRNAs, miR-342, miR-335, miR-150, miR-126* and miR-151* and up-regulation of two miRNAs, miR-21 and miR-34a. 22911455 3828 miR168 miR168 miR168 virus infection virus virus infection grapevines leads grapevine miRNA168 and miRNA3623 likely regulate grapevine's defense response 22903235 3829 miR3623 miR3623 miR3623 virus infection virus virus infection grapevines leads grapevine miRNA168 and miRNA3623 likely regulate grapevine's defense response 22903235 3830 miR319 miR319 miR319 virus infection virus virus infection grapevines leads grapevine miRNA319 and miRNA395 modulate the expression of genes that are involved in nutrient metabolisms while miRNA396 plays a role in the regulation of cell division and cell cycle. 22903235 3831 miR395 miR395 miR395 virus infection virus virus infection grapevines leads grapevine miRNA319 and miRNA395 modulate the expression of genes that are involved in nutrient metabolisms while miRNA396 plays a role in the regulation of cell division and cell cycle. 22903235 3832 miR169 miR169 miR169 virus infection virus virus infection grapevines leads grapevine The abiotic stress-induced miR169 and mi398 were negatively regulated by virus infection in grapevines. 22903235 3833 miR398 miR398 miR398 virus infection virus virus infection grapevines leads grapevine The abiotic stress-induced miR169 and mi398 were negatively regulated by virus infection in grapevines. 22903235 3834 hsa-mir-199a hsa-mir-199a-5p hsa-mir-199a-5p Colorectal cancer deoxycholic acid deoxycholic acid treatment human primary colonic epithelial cells Human miR-199a-5p was expressed at a low level in human primary colonic epithelial cells treated with deoxycholic acid compared with control, and miR-199a-5p was significantly down-regulated in colorectal cancer tissues.CAC1 was a direct miR-199a-5p target.The high miR-199a-5p expression and low CAC1 protein expression reverse the tumor cell drug resistance. 22903020 3835 hsa-mir-34a hsa-mir-34a hsa-mir-34a Non-alcoholic Fatty Liver Disease Ursodeoxycholic Acid Ursodeoxycholic Acid treatment liver Rat miR-34a/SIRT1/p53 is Suppressed by Ursodeoxycholic Acid in Rat Liver and Activated by Disease Severity in Human Non-alcoholic Fatty Liver Disease. 22902550 3836 hsa-mir-141 hsa-mir-141 hsa-mir-141 Ovarian cancer platinum platinum treatment epithelial ovarian cancer Human Some genes involved in EMT, such as BMP and activin membrane-bound inhibitor (BAMBI), and mir-141 resulted in association with overall or progression free survival. 22897840 3837 hsa-mir-204 hsa-mir-204 hsa-mir-204 Neuroblastoma cisplatin cisplatin treatment neuroblastoma cells Human MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. 22892391 3838 hsa-mir-199a hsa-mir-199a hsa-mir-199a Hepatocellular carcinoma Cisplatin cisplatin treatment hcc cell Human Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. 22713463 3839 hsa-mir-31 hsa-mir-31 hsa-mir-31 oesophageal adenocarcinoma radiation radiation treatment oesophageal adenocarcinoma cell Human MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. 22706599 3840 rat-mir-31 rat-mir-31 rat-mir-31 esophageal cancer zinc zinc deficiency esophagus Rat Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. 22689922 3841 rat-mir-21 rat-mir-21 rat-mir-21 esophageal cancer zinc zinc deficiency esophagus Rat Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. 22689922 3842 hsa-mir-21 hsa-mir-21 hsa-mir-21 Breast cancer omega-3 polyunsaturated fatty acid omega-3 polyunsaturated fatty acid treatment MDA-MB-231 and MCF-7 Human miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. 22678116 3843 hsa-mir-34a hsa-mir-34a hsa-mir-34a squamous cell carcinoma cis-diamminedichloroplatinum cis-diamminedichloroplatinum treatment cell line RPMI2650CR Human miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. 22624980 3844 hsa-mir-21 hsa-mir-21 hsa-mir-21 Breast cancer 17beta-estradiol (E2) 17beta-estradiol (E2) treatment MDA-MB-231 (ER-) breast cancer cells Human Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells. 22618231 3845 rno-mir-34a rno-mir-34a rno-mir-34a Breast cancer 3,6-dihydroxyflavone 3,6-dihydroxyflavone treatment breast cancer cells Rat MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. 22616882 3846 hsa-mir-27b hsa-mir-27b hsa-mir-27b Cryptosporidium parvum infection Cryptosporidium parvum Cryptosporidium parvum infection Human miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. 22615562 3847 hsa-mir-130a hsa-mir-130a hsa-mir-130a Ovarian cancer cisplatin cisplatin treatment ovarian cancer cells Human Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. 22614869 3848 hsa-mir-181a hsa-mir-181a hsa-mir-181a chronic lymphocytic leukemia fludarabine fludarabine treatment chronic lymphocytic leukemia cell Human miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. 22610076 3849 hsa-mir-181b hsa-mir-181b hsa-mir-181b chronic lymphocytic leukemia fludarabine fludarabine treatment chronic lymphocytic leukemia cell Human miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. 22610076 3850 hsa-mir-34b hsa-mir-34b hsa-mir-34b non small cell lung cancer radiation radiation treatment NSCLC cell lines A549 Human Overexpression of miR-34b significantly reduced cell survival at lower than 4 Gy radiation doses. 22593438 3851 hsa-mir-182 hsa-mir-182 hsa-mir-182 Leukemia, lymphoblastic glucocorticoid glucocorticoid treatment cell lines Human Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. 22582938 3852 hsa-mir-21 hsa-mir-21 hsa-mir-21 Glioblastoma temozolomide temozolomide treatment glioblastoma U251 stem cells Human MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. 22528454 3853 hsa-let-7a-1 hsa-let-7a hsa-let-7a Carcinoma, Hepatocellular 1, 3, 4-tri-O-galloyl-6-O-caffeoyl-β-D-glucopyranose (BJA32515) BJA32515 treatment HepG(2) cancer cells Human This miRNA was up-regulated in HepG2 cells treated with BJA32515. 22027761 3854 hsa-mir-520a hsa-mir-520a hsa-mir-520a colorectal cancer saracatinib saracatinib treatment colorectal cancer cell lines Human A 3' untranslated region (UTR) mutation was also shown to be associated with increased sensitivity to saracatinib and have a reduced affinity for miR-520a and miR-525a. 22553375 3855 hsa-mir-525a hsa-mir-525a hsa-mir-525a colorectal cancer saracatinib saracatinib treatment colorectal cancer cell lines Human A 3' untranslated region (UTR) mutation was also shown to be associated with increased sensitivity to saracatinib and have a reduced affinity for miR-520a and miR-525a. 22553375 3856 hsa-mir-10a hsa-mir-10a hsa-mir-10a host defense and immunoregulation retinoic acid retinoic acid treatment helper T cells Human TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. 22544395 3857 hsa-mir-10a hsa-mir-10a hsa-mir-10a host defense and immunoregulation TGF-beta TGF-beta treatment helper T cells Human TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. 22544395